<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) - Buzzetti, E - 2017 | Cochrane Library</title> <meta content="Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) - Buzzetti, E - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011646.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) - Buzzetti, E - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011646.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011646.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease)" name="citation_title"/> <meta content="Elena Buzzetti" name="citation_author"/> <meta content="Royal Free Hospital and the UCL Institute of Liver and Digestive Health" name="citation_author_institution"/> <meta content="Maria Kalafateli" name="citation_author"/> <meta content="Royal Free Hospital and the UCL Institute of Liver and Digestive Health" name="citation_author_institution"/> <meta content="Douglas Thorburn" name="citation_author"/> <meta content="Royal Free Hospital and the UCL Institute of Liver and Digestive Health" name="citation_author_institution"/> <meta content="Brian R Davidson" name="citation_author"/> <meta content="Royal Free Campus, UCL Medical School" name="citation_author_institution"/> <meta content="Maja Thiele" name="citation_author"/> <meta content="Odense University Hospital" name="citation_author_institution"/> <meta content="Lise Lotte Gluud" name="citation_author"/> <meta content="Copenhagen University Hospital Hvidovre" name="citation_author_institution"/> <meta content="Cinzia Del Giovane" name="citation_author"/> <meta content="University of Modena and Reggio Emilia" name="citation_author_institution"/> <meta content="Gro Askgaard" name="citation_author"/> <meta content="Rigshospitalet" name="citation_author_institution"/> <meta content="Aleksander Krag" name="citation_author"/> <meta content="Odense University Hospital" name="citation_author_institution"/> <meta content="Emmanuel Tsochatzis" name="citation_author"/> <meta content="Royal Free Hospital and the UCL Institute of Liver and Digestive Health" name="citation_author_institution"/> <meta content="Kurinchi Selvan Gurusamy" name="citation_author"/> <meta content="Royal Free Campus, UCL Medical School" name="citation_author_institution"/> <meta content="k.gurusamy@ucl.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD011646.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/03/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011646.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011646.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011646.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011646.pub2&amp;doi=10.1002/14651858.CD011646.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="IregKd2C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011646\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011646\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011646.pub2",title:"Pharmacological interventions for alcoholic liver disease (alcohol\\u2010related liver disease)",firstPublishedDate:"Mar 31, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011646.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011646.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011646.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011646.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011646.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011646.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011646.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011646.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011646.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011646.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4219 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011646.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-sec-0145"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-sec-0065"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-sec-0136"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-sec-0150"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/table_n/CD011646StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/table_n/CD011646StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0002">Elena Buzzetti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0003">Maria Kalafateli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0004">Douglas Thorburn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0005">Brian R Davidson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0006">Maja Thiele</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0007">Lise Lotte Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0008">Cinzia Del Giovane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0009">Gro Askgaard</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0010">Aleksander Krag</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0011">Emmanuel Tsochatzis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information#CD011646-cr-0012"><i class="icon corresponding-author fa fa-envelope"></i>Kurinchi Selvan Gurusamy</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information/en#CD011646-sec-0185">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 March 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011646.pub2">https://doi.org/10.1002/14651858.CD011646.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011646-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011646-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011646-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011646-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011646-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011646-abs-0001" lang="en"> <section id="CD011646-sec-0001"> <h3 class="title" id="CD011646-sec-0001">Background</h3> <p>Alcohol‐related liver disease is due to excessive alcohol consumption. It includes a spectrum of liver diseases such as alcohol‐related fatty liver, alcoholic hepatitis, and alcoholic cirrhosis. Mortality associated with alcoholic hepatitis is high. The optimal pharmacological treatment of alcoholic hepatitis and other alcohol‐related liver disease remains controversial. </p> </section> <section id="CD011646-sec-0002"> <h3 class="title" id="CD011646-sec-0002">Objectives</h3> <p>To assess the comparative benefits and harms of different pharmacological interventions in the management of alcohol‐related liver disease through a network meta‐analysis and to generate rankings of the available pharmacological interventions according to their safety and efficacy in order to identify potential treatments. However, even in the subgroup of participants when the potential effect modifiers appeared reasonably similar across comparisons, there was evidence of inconsistency by one or more methods of assessment of inconsistency. Therefore, we did not report the results of the network meta‐analysis and reported the comparative benefits and harms of different interventions using standard Cochrane methodology. </p> </section> <section id="CD011646-sec-0003"> <h3 class="title" id="CD011646-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform and randomised controlled trials registers until February 2017 to identify randomised clinical trials on pharmacological treatments for alcohol‐related liver diseases. </p> </section> <section id="CD011646-sec-0004"> <h3 class="title" id="CD011646-sec-0004">Selection criteria</h3> <p>Randomised clinical trials (irrespective of language, blinding, or publication status) including participants with alcohol‐related liver disease. We excluded trials that included participants who had previously undergone liver transplantation and those with co‐existing chronic viral diseases. We considered any of the various pharmacological interventions compared with each other or with placebo or no intervention. </p> </section> <section id="CD011646-sec-0005"> <h3 class="title" id="CD011646-sec-0005">Data collection and analysis</h3> <p>Two review authors independently identified trials and independently extracted data. We calculated the odds ratio (OR) and rate ratio with 95% confidence intervals (CIs) using both fixed‐effect and random‐effects models based on available‐participant analysis with Review Manager. We assessed risk of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis, and assessed the quality of the evidence using GRADE. </p> </section> <section id="CD011646-sec-0006"> <h3 class="title" id="CD011646-sec-0006">Main results</h3> <p>We identified a total of 81 randomised clinical trials. All the trials were at high risk of bias, and the overall quality of the evidence was low or very low for all outcomes. </p> <p><b>Alcoholic hepatitis</b> </p> <p>Fifty randomised clinical trials included 4484 participants with alcoholic hepatitis. The period of follow‐up ranged from one to 12 months. Because of concerns about transitivity assumption, we did not perform the network meta‐analysis. None of the active interventions showed any improvement in any of the clinical outcomes reported in the trials, which includes mortality (at various time points), cirrhosis, decompensated cirrhosis, liver transplantation. None of the trials reported health‐related quality of life or incidence of hepatocellular carcinoma. </p> <p><i>Severe alcoholic hepatitis</i> </p> <p>Of the trials on alcoholic hepatitis, 19 trials (2545 participants) included exclusively participants with severe alcoholic hepatitis (Maddrey Discriminat Function &gt; 32). The period of follow‐up ranged from one to 12 months. There was no alteration in the conclusions when only people with severe alcoholic hepatitis were included in the analysis. </p> <p><b>Source of funding:</b> Eleven trials were funded by parties with vested interest in the results. Sixteen trials were funded by parties without vested interest in the results. The source of funding was not reported in 23 trials. </p> <p><b>Other alcohol‐related liver diseases</b> </p> <p>Thirty‐one randomised clinical trials included 3695 participants with other alcohol‐related liver diseases (with a wide spectrum of alcohol‐related liver diseases). The period of follow‐up ranged from one to 48 months. The mortality at maximal follow‐up was lower in the propylthiouracil group versus the no intervention group (OR 0.45, 95% CI 0.26 to 0.78; 423 participants; 2 trials; low‐quality evidence). However, this result is based on two small trials at high risk of bias and further confirmation in larger trials of low risk of bias is necessary to recommend propylthiouracil routinely in people with other alcohol‐related liver diseases. The mortality at maximal follow‐up was higher in the ursodeoxycholic acid group versus the no intervention group (OR 2.09, 95% CI 1.12 to 3.90; 226 participants; 1 trial; low‐quality evidence). </p> <p><b>Source of funding:</b> Twelve trials were funded by parties with vested interest in the results. Three trials were funded by parties without vested interest in the results. The source of funding was not reported in 16 trials. </p> </section> <section id="CD011646-sec-0007"> <h3 class="title" id="CD011646-sec-0007">Authors' conclusions</h3> <p>Because of very low‐quality evidence, there is uncertainty in the effectiveness of any pharmacological intervention versus no intervention in people with alcoholic hepatitis or severe alcoholic hepatitis. Based on low‐quality evidence, propylthiouracil may decrease mortality in people with other alcohol‐related liver diseases. However, these results must be confirmed by adequately powered trials with low risk of bias before propylthiouracil can be considered effective. </p> <p>Future randomised clinical trials should be conducted with approximately 200 participants in each group and follow‐up of one to two years in order to compare the benefits and harms of different treatments in people with alcoholic hepatitis. Randomised clinical trials should include health‐related quality of life and report serious adverse events separately from adverse events. Future randomised clinical trials should have a low risk of bias and low risk of random errors. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011646-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011646-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011646-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011646-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011646-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011646-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011646-abs-0004" lang="en"> <h3>Medical treatment of alcohol‐related liver disease</h3> <p><b>Background</b> </p> <p>Alcohol‐related liver disease or alcoholic liver disease is liver disease related to excessive alcohol consumption. It includes a spectrum of liver diseases that includes alcoholic steatosis (simple fatty liver or simple steatosis or accumulation of fat in liver cells), alcoholic hepatitis (inflammation of liver cells), and alcoholic cirrhosis (destruction of liver cells and replacement with scar tissue). This can cause major health problems such as excessive tiredness, and liver failure leading to vomiting blood, confusion, and death. A number of medical treatments have been used to treat alcohol‐related liver disease. The best way to treat alcohol‐related liver disease is not clear. We sought to resolve this issue by searching for existing studies on the topic. We included all randomised clinical trials whose results were reported until February 2017. We included only studies in which participants had not undergone liver transplantation previously and those who did not have liver disease due to other causes such as viral infections. Apart from using standard Cochrane methods which allow comparison of only two treatments at a time (direct comparison), we planned to use an advanced method which allows comparison of the many different treatments that are individually compared in the trials (network meta‐analysis). However, because of the nature of the information available, we could not determine whether the network meta‐analysis results were reliable. Therefore, we used standard Cochrane methodology. </p> <p><b>Study characteristics</b> </p> <p>We identified 81 trials which were eligible for our review. We have presented the results for people with differing spectrum of alcohol‐related liver disease separately. </p> <p><b>Key results</b> </p> <p><b><i>Alcoholic hepatitis</i> </b> </p> <p>Fifty randomised clinical trials included 4484 participants with alcoholic hepatitis. The period of follow‐up ranged from one to 12 months. Because of the nature of the information available, we used methods similar to Cochrane methodology. None of the active interventions showed any improvement in any of the clinical outcomes reported in the trials, which includes deaths (at various time points), cirrhosis, liver failure or liver transplantation. None of the trials reported health‐related quality of life or incidence of primary liver cancer. </p> <p><i>Severe alcoholic hepatitis</i> </p> <p>Of the trials on alcoholic hepatitis, 19 trials (2545 participants) included exclusively participants with severe alcoholic hepatitis. The period of follow‐up ranged from one to 12 months. There was no alteration in the conclusions when only people with severe alcoholic hepatitis were included in the analysis. </p> <p><b>Source of funding:</b> Eleven trials were funded by parties with vested interest in the results. Sixteen trials were funded by parties without vested interest in the results. The source of funding was not reported in 23 trials. </p> <p><b><i>Other alcohol‐related liver diseases</i> </b> </p> <p>Thirty‐one randomised clinical trials included 3695 participants with other alcohol‐related liver diseases (with a wide spectrum of alcohol‐related liver diseases). The period of follow‐up ranged from one to 48 months. The risk of deaths was lower in the propylthiouracil group than in the no intervention group and higher in the ursodeoxycholic acid group than in the no intervention group. However, these results are based on trials with methodological deficiencies that make the results unreliable. As a result, trials of low risk of bias of sufficient sample size are required before propylthiouracil can be recommended routinely. There was no evidence of improvement in any of the remaining clinical outcomes by any of the interventions compared with no intervention. </p> <p><b>Source of funding:</b> Twelve trials were funded by parties with vested interest in the results. Three trials were funded by parties without vested interest in the results. The source of funding was not reported in 16 trials. </p> <p><b>Quality of the evidence</b> </p> <p>The overall quality of the evidence was very low and all the trials were at unclear or high risk of bias, which means that there is possibility of making wrong conclusions overestimating benefits or underestimating harms of one treatment or the other because of the way that the studies were conducted. Further high‐quality randomised clinical trials are necessary. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011646-sec-0145" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011646-sec-0145"></div> <h3 class="title" id="CD011646-sec-0146">Implications for practice</h3> <section id="CD011646-sec-0146"> <p>Because of very low‐quality evidence, there is uncertainty in the effectiveness of any pharmacological intervention versus no intervention in people with alcoholic hepatitis or severe alcoholic hepatitis. Based on low‐quality evidence, propylthiouracil may decrease mortality in people with other alcohol‐related liver diseases. However, these have to be confirmed by adequately powered trials with low risk of bias before propylthiouracil can be considered effective. </p> </section> <h3 class="title" id="CD011646-sec-0147">Implications for research</h3> <section id="CD011646-sec-0147"> <p>Large randomised clinical trials should be conducted with approximately 200 participants in each group to compare the benefits and harms of different interventions in people with alcoholic hepatitis. The interventions compared should include no intervention (placebo) as the one of the trial groups. They may also include glucocorticosteroids, pentoxifylline, and combinations involving these drugs such as granulocyte stimulation factor (GSF) plus pentoxifylline, pentoxifylline plus metadoxine, or glucocorticosteroids as one of the intervention groups as these combinations appear to decrease mortality based on network meta‐analysis. Such trials should follow up participants for at least one to two years and should include health‐related quality of life and report serious adverse events separately from adverse events. The trials should be designed and reported using guidance from SPIRIT statement (<a href="./references#CD011646-bbs2-0115" title="ChanAW , TetzlaffJM , AltmanDG , LaupacisA , GotzschePC , Krleza‐JericK , et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine2013;158(3):200‐7. ">Chan 2013</a>) and CONSORT statements (<a href="./references#CD011646-bbs2-0167" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical Research Ed.)2010;340:c332. ">Schulz 2010</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011646-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011646-sec-0022"></div> <div class="table" id="CD011646-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Glucocorticosteroids compared with no intervention for alcoholic hepatitis (all severity)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Glucocorticosteroids compared with no intervention for alcoholic hepatitis (all severity)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with alcoholic hepatitis (all severity) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> glucocorticosteroids </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Glucocorticosteroids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>353 per 1000</b> <br/> (301 to 409) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.85</b> <br/> (0.67 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1147</b> <br/> (12 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>391 per 1000</b> <br/> (313 to 472) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.00</b> <br/> (0.71 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>672</b> <br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>390 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>467 per 1000</b> <br/> (385 to 552) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.37</b> <br/> (0.98 to 1.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>546</b> </p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded by one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded by one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded by one level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011646-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Pentoxifylline compared with no intervention for alcoholic hepatitis (all severity)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pentoxifylline compared with no intervention for alcoholic hepatitis (all severity)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with alcoholic hepatitis (all severity) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> pentoxifylline </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pentoxifylline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>331 per 1000</b> <br/> (271 to 396) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.77</b> <br/> (0.58 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>881</b> <br/> (6 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>431 per 1000</b> <br/> (342 to 528) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.18</b> <br/> (0.81 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>545</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>390 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>406 per 1000</b><br/> (327 to 491) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.07</b><br/> (0.76 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>545</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011646-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Colchicine compared with no intervention for alcoholic hepatitis (all severity)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Colchicine compared with no intervention for alcoholic hepatitis (all severity)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with alcoholic hepatitis (all severity) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> colchicine </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Colchicine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 3 to 4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>86 per 1000</b> <br/> (32 to 206) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.31</b> <br/> (0.47 to 3.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>139</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>185 per 1000</b><br/> (9 to 853) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 3.18</b><br/> (0.13 to 81.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011646-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Insulin plus glucagon compared with no intervention for alcoholic hepatitis (all severity)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Insulin plus glucagon compared with no intervention for alcoholic hepatitis (all severity)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with alcoholic hepatitis (all severity) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> insulin plus glucagon </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Insulin plus glucagon</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>423 per 1000</b> <br/> (307 to 550) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.14</b> <br/> (0.69 to 1.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>265</b> <br/> (5 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>623 per 1000</b> <br/> (371 to 821) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 2.57</b> <br/> (0.92 to 7.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011646-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Propylthiouracil compared with no intervention for alcoholic hepatitis (all severity)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Propylthiouracil compared with no intervention for alcoholic hepatitis (all severity)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with alcoholic hepatitis (all severity) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> propylthiouracil </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Propylthiouracil</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>427 per 1000</b> <br/> (243 to 636) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.16</b> <br/> (0.50 to 2.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>108</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011646-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Glucocorticosteroids compared with no intervention for severe alcoholic hepatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Glucocorticosteroids compared with no intervention for severe alcoholic hepatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with severe alcoholic hepatitis </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> glucocorticosteroids </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Glucocorticosteroids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 2 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>409 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>378 per 1000</b><br/> (304 to 456) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.88</b> <br/> (0.63 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>607</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>272 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>274 per 1000</b> <br/> (210 to 348) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.01</b> <br/> (0.71 to 1.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>607</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>390 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>467 per 1000</b> <br/> (385 to 552) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.37</b> <br/> (0.98 to 1.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>546</b> </p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011646-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Pentoxifylline compared with no intervention for severe alcoholic hepatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pentoxifylline compared with no intervention for severe alcoholic hepatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with severe alcoholic hepatitis </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> pentoxifylline </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pentoxifylline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>409 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>356 per 1000</b> <br/> (290 to 425) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.80</b> <br/> (0.59 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>726</b> <br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>272 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>306 per 1000</b> <br/> (232 to 394) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.18</b> <br/> (0.81 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>545</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>390 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>406 per 1000</b> <br/> (327 to 491) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.07</b> <br/> (0.76 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>545</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011646-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Anabolic steroids compared with no intervention for alcohol‐related disorders (others)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Anabolic steroids compared with no intervention for alcohol‐related disorders (others)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol‐related disorders (others) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> anabolic steroids </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anabolic steroids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 6 to 28 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>252 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>303 per 1000</b> <br/> (191 to 446) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.29</b> <br/> (0.70 to 2.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>248</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011646-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Antioxidants compared with no intervention for alcohol‐related disorders (others)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Antioxidants compared with no intervention for alcohol‐related disorders (others)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol‐related disorders (others) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> antioxidants </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antioxidants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>252 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>398 per 1000</b> <br/> (250 to 567) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.96</b> <br/> (0.99 to 3.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>255</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3,4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011646-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Colchicine compared with no intervention for alcohol‐related disorders (others)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Colchicine compared with no intervention for alcohol‐related disorders (others)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol‐related disorders (others) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> colchicine </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Colchicine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 41 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>252 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>272 per 1000</b><br/> (212 to 340) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.11</b><br/> (0.80 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>604</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011646-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Propylthiouracil compared with no intervention for alcohol‐related disorders (others)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Propylthiouracil compared with no intervention for alcohol‐related disorders (others)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol‐related disorders (others) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> propylthiouracil </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Propylthiouracil</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>252 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>132 per 1000</b><br/> (81 to 208) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.45</b><br/> (0.26 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>423</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011646-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011646-sec-0023"></div> <section id="CD011646-sec-0024"> <h3 class="title" id="CD011646-sec-0024">Description of the condition</h3> <p>Alcohol‐related liver disease or alcoholic liver disease is liver disease related to excessive alcohol consumption (<a href="./references#CD011646-bbs2-0112" title="British LiverTrust . Alcohol, 2014. www.britishlivertrust.org.uk/liver‐information/liver‐conditions/alcohol/ (accessed 23 October 2014). ">BLT 2014</a>; <a href="./references#CD011646-bbs2-0147" title="NCBI . Liver diseases, alcoholic, 2014. www.ncbi.nlm.nih.gov/mesh/68008108 (accessed 23 October 2014). ">NCBI 2014a</a>; <a href="./references#CD011646-bbs2-0151" title="NHS Choices. Alcohol‐related liver disease. www.nhs.uk/conditions/liver_disease_(alcoholic)/Pages/Introduction.aspx (accessed 23 October 2014). ">NHS 2014</a>). It includes a spectrum of liver diseases that includes alcoholic steatosis (simple fatty liver (simple steatosis)), overt alcoholic hepatitis, and alcoholic cirrhosis (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>; <a href="./references#CD011646-bbs2-0147" title="NCBI . Liver diseases, alcoholic, 2014. www.ncbi.nlm.nih.gov/mesh/68008108 (accessed 23 October 2014). ">NCBI 2014a</a>). Fatty liver, which indicates accumulation of fat in the liver parenchymal cells (<a href="./references#CD011646-bbs2-0148" title="NCBI . Fatty liver, 2014. www.ncbi.nlm.nih.gov/mesh/68005234 (accessed 23 October 2014). ">NCBI 2014b</a>), is usually the earliest manifestation of alcohol‐related liver disease and develops in about 90% to 95% of people who consume large quantities of alcohol (<a href="./references#CD011646-bbs2-0152" title="O'SheaRS , DasarathyS , McCulloughAJ , Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology2010;51(1):307‐28. ">O'Shea 2010</a>; <a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). About 10% to 40% of people with fatty liver develop liver fibrosis (<a href="./references#CD011646-bbs2-0152" title="O'SheaRS , DasarathyS , McCulloughAJ , Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology2010;51(1):307‐28. ">O'Shea 2010</a>; <a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). One fifth of people who develop liver fibrosis develop alcoholic liver cirrhosis (advanced liver fibrosis) (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). About 10% to 35% of people who consume large quantities of alcohol may also develop alcoholic hepatitis (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). Alcoholic hepatitis is characterised by liver parenchymal necrosis and inflammation (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>; <a href="./references#CD011646-bbs2-0149" title="NCBI . Hepatitis, alcoholic, 2014. www.ncbi.nlm.nih.gov/mesh/68006519 (accessed 23 October 2014). ">NCBI 2014c</a>), and presents clinically as jaundice and liver failure that usually occur after several decades of consumption of large quantities of alcohol (<a href="./references#CD011646-bbs2-0142" title="LuceyMR , MathurinP , MorganTR . Alcoholic hepatitis. New England Journal of Medicine2009;360(26):2758‐69. ">Lucey 2009</a>). About 18% of people with alcoholic hepatitis progress to cirrhosis (<a href="./references#CD011646-bbs2-0152" title="O'SheaRS , DasarathyS , McCulloughAJ , Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology2010;51(1):307‐28. ">O'Shea 2010</a>). A significant proportion of people may develop alcoholic cirrhosis without developing alcoholic hepatitis (<a href="./references#CD011646-bbs2-0152" title="O'SheaRS , DasarathyS , McCulloughAJ , Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology2010;51(1):307‐28. ">O'Shea 2010</a>). </p> <p>Alcohol increases the fats that reach the liver from the intestine, increases fatty acid synthesis (lipogenesis), and decreases the breakdown of fatty acids (by decreasing beta‐oxidation of fatty acids) resulting in accumulation of fat in liver cells (<a href="./references#CD011646-bbs2-0142" title="LuceyMR , MathurinP , MorganTR . Alcoholic hepatitis. New England Journal of Medicine2009;360(26):2758‐69. ">Lucey 2009</a>; <a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). The process of alcohol metabolism results in generation of reactive oxygen species, lipid peroxidation, mitochondrial glutathione depletion, and S‐adenosylmethionine depletion (<a href="./references#CD011646-bbs2-0142" title="LuceyMR , MathurinP , MorganTR . Alcoholic hepatitis. New England Journal of Medicine2009;360(26):2758‐69. ">Lucey 2009</a>; <a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). This sensitises liver cells to injury (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). Acetate, a breakdown product of alcohol, causes inflammation (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). In addition, alcohol increases gut permeability and translocation of bacteria from the bowel resulting in increased bacterial lipopolysaccharides, which in turn cause inflammation by activation of Kupffer cells (<a href="./references#CD011646-bbs2-0142" title="LuceyMR , MathurinP , MorganTR . Alcoholic hepatitis. New England Journal of Medicine2009;360(26):2758‐69. ">Lucey 2009</a>; <a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). Thus, alcohol can cause alcoholic hepatitis (<a href="./references#CD011646-bbs2-0142" title="LuceyMR , MathurinP , MorganTR . Alcoholic hepatitis. New England Journal of Medicine2009;360(26):2758‐69. ">Lucey 2009</a>; <a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). Alcohol may also inhibit proliferation of liver cells, thereby decreasing liver regeneration in response to injury (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). Acetaldehyde, another breakdown product of alcohol, activates hepatic stellate cells (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). Activation of Kupffer cells also promotes fibrogenesis by activating the hepatic stellate cells (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). In addition to activation of Kupffer cells, increased lipopolysaccharides due to translocation of bacteria from the bowel also promotes fibrogenesis directly by activating hepatic stellate cells (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). Natural killer cells destroy activated hepatic stellate cells and produce interferon‐gamma (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). Alcohol inhibits natural killer cells and so promotes fibrosis (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). </p> <p>The true prevalence of alcohol‐related liver disease is difficult to estimate. Overall, alcohol causes 38 deaths per 100,000 men and 28 deaths per 100,000 women every year in Europe due to liver cirrhosis, alcoholic hepatitis, alcohol‐related injuries, and cancers attributable to alcohol consumption (<a href="./references#CD011646-bbs2-0181" title="World Health Organization ‐ Regional Office for Europe. Status report on alcohol and health in 35 European countries 2013. www.euro.who.int/__data/assets/pdf_file/0017/190430/Status‐Report‐on‐Alcohol‐and‐Health‐in‐35‐European‐Countries.pdf?ua=1 (accessed 23 October 2014). ">WHO 2013</a>). Worldwide, of every 100 deaths, alcohol causes 5.9 deaths (7.6 deaths per 100 deaths in men and four deaths per 100 deaths in women) (<a href="./references#CD011646-bbs2-0182" title="World Health Organization. Global status report on alcohol and health 2014. http://apps.who.int/iris/bitstream/10665/112736/1/9789240692763_eng.pdf2014. ">WHO 2014</a>). About 30% of people with alcoholic hepatitis die within three months of hospital admission (<a href="./references#CD011646-bbs2-0180" title="WhitfieldK , RambaldiA , WetterslevJ , GluudC . Pentoxifylline for alcoholic hepatitis. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007339.pub2] ">Whitfield 2009</a>). Alcohol is the most common cause of liver cirrhosis in Europe (<a href="./references#CD011646-bbs2-0111" title="BlachierM , LeleuH , Peck‐RadosavljevicM , VallaDC , Roudot‐ThoravalF . The burden of liver disease in Europe ‐ a review of available epidemiological data, 2013. www.easl.eu/assets/application/files/54ae845caec619f_file.pdf (accessed 23 October 2014). ">Blachier 2013</a>). Cirrhosis has two phases ‐ an asymptomatic 'compensated cirrhosis' phase and a symptomatic 'decompensated cirrhosis' phase characterised by clinical symptoms such as upper gastrointestinal bleeding from varices, ascites, encephalopathy, jaundice, or renal failure (<a href="./references#CD011646-bbs2-0116" title="D'AmicoG , Garcia‐TsaoG , PagliaroL . Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. Journal of Hepatology2006;44(1):217‐31. ">D'Amico 2006</a>). The median survival after compensated liver disease can be more than 10 years, while that of decompensated liver disease is less than two years (<a href="./references#CD011646-bbs2-0116" title="D'AmicoG , Garcia‐TsaoG , PagliaroL . Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. Journal of Hepatology2006;44(1):217‐31. ">D'Amico 2006</a>). The only definitive treatment for decompensated liver cirrhosis is liver transplantation. Alcoholic cirrhosis is the second most common cause of liver transplantation in the USA (<a href="./references#CD011646-bbs2-0170" title="Scientific Registry of TransplantRecipients . OPTN/SRTR 2012 annual data report: liver, 2012. srtr.transplant.hrsa.gov/annual_reports/2012/pdf/03_liver_13.pdf (accessed 8 October 2014). ">SRTR 2012</a>). The median survival after liver transplantation is in excess of 10 years (<a href="./references#CD011646-bbs2-0125" title="DuffyJP , KaoK , KoCY , FarmerDG , McDiarmidSV , HongJC , et al. Long‐term patient outcome and quality of life after liver transplantation: analysis of 20‐year survivors. Annals of Surgery2010;252(4):652‐61. ">Duffy 2010</a>; <a href="./references#CD011646-bbs2-0170" title="Scientific Registry of TransplantRecipients . OPTN/SRTR 2012 annual data report: liver, 2012. srtr.transplant.hrsa.gov/annual_reports/2012/pdf/03_liver_13.pdf (accessed 8 October 2014). ">SRTR 2012</a>; <a href="./references#CD011646-bbs2-0165" title="SchoeningWN , BuescherN , RademacherS , AndreouA , KuehnS , NeuhausR , et al. Twenty‐year longitudinal follow‐up after orthotopic liver transplantation: a single‐center experience of 313 consecutive cases. American Journal of Transplantation2013;13(9):2384‐94. ">Schoening 2013</a>). There is also improvement in the health‐related quality of life of people with chronic liver disease after liver transplantation (<a href="./references#CD011646-bbs2-0184" title="YangLS , ShanLL , SaxenaA , MorrisDL . Liver transplantation: a systematic review of long‐term quality of life. Liver International2014;34(9):1298‐313. ">Yang 2014</a>). </p> </section> <section id="CD011646-sec-0025"> <h3 class="title" id="CD011646-sec-0025">Description of the intervention</h3> <p>Alcohol abstinence is the main form of preventing and limiting the damage due to alcohol‐related liver disease (<a href="./references#CD011646-bbs2-0152" title="O'SheaRS , DasarathyS , McCulloughAJ , Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology2010;51(1):307‐28. ">O'Shea 2010</a>; <a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). Disulfiram, frequently prescribed to promote alcohol abstinence, is not recommended in people with alcohol‐related liver disease because of its liver toxicity (<a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>). Various interventions have been used for the treatment of alcohol‐related liver disease. These include pharmacological interventions such as glucocorticosteroids, anabolic‐androgenic steroids, pentoxifylline, anti‐tumour necrosis factor (infliximab and etanercept), colchicine, S‐adenosylmethionine, N‐acetyl cysteine, propylthiouracil, vitamin E and other antioxidants, and milk thistle (silymarin or <i>Silybum marianum</i> extract); nutritional supplement, for example, protein and vitamin supplementation; and psychotherapy for alcohol abstinence (<a href="./references#CD011646-bbs2-0130" title="FerriM , AmatoL , DavoliM . Alcoholics Anonymous and other 12‐step programmes for alcohol dependence. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005032.pub2] ">Ferri 2006</a>; <a href="./references#CD011646-bbs2-0156" title="RambaldiA , GluudC . Anabolic‐androgenic steroids for alcoholic liver disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003045.pub2] ">Rambaldi 2006</a>; <a href="./references#CD011646-bbs2-0158" title="RambaldiA , GluudC . S‐adenosyl‐L‐methionine for alcoholic liver diseases. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD002235.pub3] ">Rambaldi 2015</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0142" title="LuceyMR , MathurinP , MorganTR . Alcoholic hepatitis. New England Journal of Medicine2009;360(26):2758‐69. ">Lucey 2009</a>; <a href="./references#CD011646-bbs2-0180" title="WhitfieldK , RambaldiA , WetterslevJ , GluudC . Pentoxifylline for alcoholic hepatitis. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007339.pub2] ">Whitfield 2009</a>; <a href="./references#CD011646-bbs2-0152" title="O'SheaRS , DasarathyS , McCulloughAJ , Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology2010;51(1):307‐28. ">O'Shea 2010</a>; <a href="./references#CD011646-bbs2-0129" title="FedeG , GermaniG , GluudC , GurusamyKS , BurroughsAK . Propylthiouracil for alcoholic liver disease. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002800.pub3] ">Fede 2011</a>; <a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>). Glucocorticoids may be combined with other treatments (<a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0152" title="O'SheaRS , DasarathyS , McCulloughAJ , Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology2010;51(1):307‐28. ">O'Shea 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>). </p> </section> <section id="CD011646-sec-0026"> <h3 class="title" id="CD011646-sec-0026">How the intervention might work</h3> <p>Glucocorticosteroids, pentoxifylline, and anti‐tumour necrosis factor are aimed at decreasing the inflammation (<a href="./references#CD011646-bbs2-0142" title="LuceyMR , MathurinP , MorganTR . Alcoholic hepatitis. New England Journal of Medicine2009;360(26):2758‐69. ">Lucey 2009</a>; <a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>). In addition to its action on tumour necrosis factor (TNF) (and hence its effect on inflammation), pentoxifylline might prevent hepatorenal syndrome by maintaining kidney function (<a href="./references#CD011646-bbs2-0142" title="LuceyMR , MathurinP , MorganTR . Alcoholic hepatitis. New England Journal of Medicine2009;360(26):2758‐69. ">Lucey 2009</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>). S‐adenosylmethionine (SAMe), N‐acetyl cysteine (NAC), propylthiouracil, Vitamin E and other antioxidants, and milk thistle (silymarin) are aimed at decreasing the oxidative damage to liver cells (<a href="./references#CD011646-bbs2-0135" title="HicksM , WongLS , DayRO . Antioxidant activity of propylthiouracil. Biochemical Pharmacology1992;43(3):439‐44. ">Hicks 1992</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0142" title="LuceyMR , MathurinP , MorganTR . Alcoholic hepatitis. New England Journal of Medicine2009;360(26):2758‐69. ">Lucey 2009</a>; <a href="./references#CD011646-bbs2-0109" title="AbenavoliL , CapassoR , MilicN , CapassoF . Milk thistle in liver diseases: past, present, future. Phytotherapy Research2010;24(10):1423‐32. ">Abenavoli 2010</a>; <a href="./references#CD011646-bbs2-0131" title="GaoB , BatallerR . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology2011;141(5):1572‐85. ">Gao 2011</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0110" title="AnsteeQM , DayCP . S‐adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. Journal of Hepatology2012;57(5):1097‐109. ">Anstee 2012</a>). Anabolic‐androgenic steroids have been evaluated in alcohol‐related liver disease because of their anabolic (muscle building) effect (<a href="./references#CD011646-bbs2-0142" title="LuceyMR , MathurinP , MorganTR . Alcoholic hepatitis. New England Journal of Medicine2009;360(26):2758‐69. ">Lucey 2009</a>), and direct effects on liver metabolism (<a href="./references#CD011646-bbs2-0132" title="GluudC . Testosterone and alcoholic cirrhosis. Epidemiologic, pathophysiologic and therapeutic studies in men. Danish Medical Bulletin1988;35(6):564‐75. ">Gluud 1988</a>). Colchicine has been evaluated in alcohol‐related liver disease because of its anti‐inflammatory and anti‐fibrogenic properties (<a href="./references#CD011646-bbs2-0152" title="O'SheaRS , DasarathyS , McCulloughAJ , Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology2010;51(1):307‐28. ">O'Shea 2010</a>). </p> </section> <section id="CD011646-sec-0027"> <h3 class="title" id="CD011646-sec-0027">Why it is important to do this review</h3> <p>We included only pharmacological therapies used in the treatment of alcoholic liver disease with the aim of reducing liver injury. The current guidelines on management of alcohol‐related liver disease by the European Association for the Study of Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) are similar in terms of recommending glucocorticoids for severe alcoholic hepatitis unless there are contraindications, in which case pentoxifylline is recommended (<a href="./references#CD011646-bbs2-0152" title="O'SheaRS , DasarathyS , McCulloughAJ , Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology2010;51(1):307‐28. ">O'Shea 2010</a>; <a href="./references#CD011646-bbs2-0126" title="European Association for Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. Journal of Hepatology2012;57(2):399‐420. ">EASL 2012</a>). EASL guidelines also suggest that N‐acetyl cysteine may be useful in people with severe alcoholic fatty liver disease receiving corticosteroids (<a href="./references#CD011646-bbs2-0126" title="European Association for Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. Journal of Hepatology2012;57(2):399‐420. ">EASL 2012</a>). The role of the other pharmacological agents, the benefit of combination therapies, and the relative ranking of these different interventions is not clear from these guidelines. Network meta‐analyses allow combination of the direct evidence and indirect evidence, and allow ranking of different interventions in terms of the different outcomes (<a href="./references#CD011646-bbs2-0161" title="SalantiG , AdesAE , IoannidisJP . Graphical methods and numerical summaries for presenting results from multiple‐treatment meta‐analysis: an overview and tutorial. Journal of Clinical Epidemiology2011;64(2):163‐71. ">Salanti 2011</a>; <a href="./references#CD011646-bbs2-0162" title="SalantiG . Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods2012;3(2):80‐97. ">Salanti 2012</a>). This systematic review and attempted network meta‐analysis aimed to provide the best level of evidence for the role of different pharmacological interventions in the treatment of people with alcohol‐related liver disease. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011646-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011646-sec-0028"></div> <p>To assess the comparative benefits and harms of different pharmacological interventions in the management of alcohol‐related liver disease through a network meta‐analysis and to generate rankings of the available pharmacological interventions according to their safety and efficacy in order to identify potential treatments. However, even in the subgroup of participants when the potential effect modifiers appeared reasonably similar across comparisons, there was evidence of inconsistency by one or more methods of assessment of inconsistency. Therefore, we assessed the comparative benefits and harms of different interventions using standard Cochrane methodology. However, we have presented the methods of the network meta‐analysis for one of the subgroups where the potential effect modifiers appeared reasonably similar across comparisons; the data used for network meta‐analysis and the results in <a href="./appendices#CD011646-sec-0151">Appendix 1</a>; <a href="./appendices#CD011646-sec-0165">Appendix 2</a>; <a href="./appendices#CD011646-sec-0166">Appendix 3</a>; <a href="./appendices#CD011646-sec-0178">Appendix 4</a>; <a href="./appendices#CD011646-sec-0179">Appendix 5</a>; <a href="./appendices#CD011646-sec-0180">Appendix 6</a>. Once new data appear allowing the conduct of a network meta‐analysis which is reliable, we will perform a revised analysis, and then, we will move it back into the Methods section and Results section of the Cochrane review. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011646-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011646-sec-0029"></div> <section id="CD011646-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011646-sec-0031"> <h4 class="title">Types of studies</h4> <p>We considered only randomised clinical trials for this meta‐analysis irrespective of language, publication status, or date of publication. We excluded studies of other design because of the risk of bias in such studies. We are all aware that such exclusions make us focus much more on potential benefits and not fully assess the risks of serious adverse events as well as risks of adverse events. </p> </section> <section id="CD011646-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included randomised clinical trials involving participants with alcohol‐related liver disease irrespective of the method of diagnosis of the disease and severity of alcohol‐related liver disease. We excluded randomised clinical trials in which participants had undergone liver transplantation previously. We also excluded randomised clinical trials in which participants had other causes of chronic liver disease such as hepatitis C virus, hepatitis B virus, and hepatitis delta virus infections along with alcohol‐related liver disease, or non‐alcohol‐related liver disease. </p> </section> <section id="CD011646-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included any of the following pharmacological interventions that are possible treatments for alcohol‐related liver disease (i.e. alcoholic fatty liver, alcoholic hepatitis, alcoholic cirrhosis), and which can be compared with each other either alone or in combination or with placebo or no intervention. </p> <p>The interventions that we considered a priori included:</p> <p> <ul id="CD011646-list-0001"> <li> <p>glucocorticosteroids;</p> </li> <li> <p>anabolic‐androgenic steroids;</p> </li> <li> <p>pentoxifylline;</p> </li> <li> <p>anti‐tumour necrosis factor (infliximab and etanercept);</p> </li> <li> <p>colchicine;</p> </li> <li> <p>S‐adenosylmethionine;</p> </li> <li> <p>N‐acetyl cysteine;</p> </li> <li> <p>propylthiouracil;</p> </li> <li> <p>antioxidants (including vitamin E);</p> </li> <li> <p>milk thistle (silymarin).</p> </li> </ul> </p> <p>We included anti‐tumour necrosis factor (anti‐TNF), granulocyte stimulation factor (GSF), rifaximin, and ursodeoxycholic acid (UDCA), used either alone or in a combination of the above interventions after searching the references. We have reported the findings for these interventions in the <a href="./full#CD011646-sec-0065">Results</a> and <a href="#CD011646-sec-0136">Discussion</a> sections of the review. </p> <p>In this systematic review, we included only pharmacological interventions where the target of treatment is the liver, i.e. we did not include nutritional, psychotherapy, and other supportive therapy required to manage complications such as infections, portal hypertension, or alcohol withdrawal syndrome, or therapies targeted at promoting alcohol abstinence or decreasing alcohol dependence. </p> </section> <section id="CD011646-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>We assessed the comparative benefits and harms (and report the relative ranking) of available pharmacological interventions aimed at reducing liver injury with alcohol‐related liver disease for the following outcomes. </p> <section id="CD011646-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011646-list-0002"> <li> <p>Mortality at maximal follow‐up.</p> </li> <li> <p>Early mortality (up to three months).</p> </li> <li> <p>Adverse events. Depending on the availability of data, we planned to classify adverse events as serious or non‐serious. We defined a non‐serious adverse event as any untoward medical occurrence not necessarily having a causal relationship with the intervention but resulting in a dose reduction or discontinuation of treatment (any time after commencement of treatment) (<a href="./references#CD011646-bbs2-0138" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, Pennsylvania: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>). We defined a serious adverse event as any event that would increase mortality; is life‐threatening; requires hospitalisation; results in persistent or significant disability; is a congenital anomaly/birth defect; or any important medical event that might jeopardise the person or require intervention to prevent it (<a href="./references#CD011646-bbs2-0138" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, Pennsylvania: Barnett International/PAREXEL, 1997. ">ICH‐GCP 1997</a>). We used the definition used by study authors for non‐serious and serious adverse events: </p> <ul id="CD011646-list-0003"> <li> <p>proportion of participants with serious adverse events;</p> </li> <li> <p>number of serious adverse events.</p> </li> </ul> </li> </ul> <ul id="CD011646-list-0004"> <li> <p>Health‐related quality of life as defined in the included trials using a validated scale such as EQ‐5D or 36‐item Short Form (SF‐36) (<a href="./references#CD011646-bbs2-0128" title="EuroQol . About EQ‐5D. www.euroqol.org/about‐eq‐5d.html (accessed 8 October 2014). ">EuroQol 2014</a>; <a href="./references#CD011646-bbs2-0177" title="WareJE . SF‐36® health survey update, 2014. www.sf‐36.org/tools/sf36.shtml (accessed 8 October 2014). ">Ware 2014</a>): </p> <ul id="CD011646-list-0005"> <li> <p>short term (up to one year);</p> </li> <li> <p>medium term (one to five years);</p> </li> <li> <p>long term (beyond five years).</p> </li> </ul> </li> </ul> </p> <p>We planned to consider long‐term health‐related quality of life more important than short‐term or medium‐term health‐related quality of life, although short‐term and medium‐term health‐related quality of life are also important primary outcomes. </p> </section> <section id="CD011646-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011646-list-0006"> <li> <p>Liver transplantation (maximal follow‐up):</p> <ul id="CD011646-list-0007"> <li> <p>proportion of participants with liver transplantation;</p> </li> <li> <p>time to liver transplantation.</p> </li> </ul> </li> <li> <p>Decompensated liver disease (maximal follow‐up):</p> <ul id="CD011646-list-0008"> <li> <p>proportion of participants with decompensated liver disease;</p> </li> <li> <p>time to liver decompensation.</p> </li> </ul> </li> </ul> </p> <p>We had to calculate the decompensated liver disease rate rather than proportion since it was not always clear whether these episodes of decompensation occurred in the same participant or different participants. </p> <p> <ul id="CD011646-list-0009"> <li> <p>Cirrhosis (maximal follow‐up) (in participants without cirrhosis):</p> <ul id="CD011646-list-0010"> <li> <p>proportion of participants with cirrhosis;</p> </li> <li> <p>time to cirrhosis.</p> </li> </ul> </li> <li> <p>Proportion of participants with hepatocellular carcinoma (maximal follow‐up).</p> </li> <li> <p>Any adverse events:</p> <ul id="CD011646-list-0011"> <li> <p>proportion of participants with any type of adverse event;</p> </li> <li> <p>number of any type of adverse event.</p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD011646-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011646-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and Science Citation Index Expanded (<a href="./references#CD011646-bbs2-0160" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591‐603. ">Royle 2003</a>) from inception to February 2017 for randomised clinical trials comparing two or more of the above interventions (including placebo or no intervention) without applying any language restrictions. We searched for all possible comparisons formed by the interventions of interest. To identify further ongoing or completed trials, we also searched the World Health Organization International Clinical Trials Registry Platform search portal (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>), which searches various trial registers, including <a href="http://www.isrctn.com/" target="_blank">ISRCTN</a> and <a href="http://www.clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a>. <a href="./appendices#CD011646-sec-0181">Appendix 7</a> shows the search strategies that we used. </p> </section> <section id="CD011646-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched the references of the identified trials and the existing Cochrane reviews on alcohol‐related liver disease to identify additional trials for inclusion. </p> </section> </section> <section id="CD011646-sec-0040"> <h3 class="title" id="CD011646-sec-0040">Data collection and analysis</h3> <section id="CD011646-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (EB and MK) independently identified trials for inclusion by screening the titles and abstracts. We sought full‐text articles for any references that at least one of the review authors identified for potential inclusion. We selected trials for inclusion based on the full‐text articles, or, if no full text existed, then the abstracts of the trial. We listed the excluded full‐text references with reasons for their exclusion in the 'Characteristics of excluded trials' table. We also listed any ongoing trials identified primarily through the search of the clinical trial registers for further follow‐up. We resolved discrepancies through discussion and by arbitration with KG, DT, and ET. </p> </section> <section id="CD011646-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (EB and MK) independently extracted the following data.</p> <p> <ul id="CD011646-list-0012"> <li> <p>Outcome data (for each outcome and for each intervention group whenever applicable):</p> <ul id="CD011646-list-0013"> <li> <p>number of participants randomised;</p> </li> <li> <p>number of participants included for the analysis;</p> </li> <li> <p>number of participants with events for binary outcome, mean and standard deviation for continuous outcomes, number of events for count outcomes, and the number of participants with events and the mean follow‐up period for time‐to‐event outcomes; </p> </li> <li> <p>definition of outcomes or scale used if appropriate.</p> </li> </ul> </li> <li> <p>Data on potential effect modifiers:</p> <ul id="CD011646-list-0014"> <li> <p>participant characteristics such as age, sex, co‐morbidities, and proportion of participants with severe alcoholic hepatitis; </p> </li> <li> <p>details of the intervention and control (including dose, frequency, and duration);</p> </li> <li> <p>risk of bias (assessment of risk of bias in included trials).</p> </li> </ul> </li> <li> <p>Other data:</p> <ul id="CD011646-list-0015"> <li> <p>year and language of publication;</p> </li> <li> <p>country in which the participants were recruited;</p> </li> <li> <p>year(s) in which the trial was conducted;</p> </li> <li> <p>inclusion and exclusion criteria;</p> </li> <li> <p>follow‐up time points of the outcome.</p> </li> </ul> </li> </ul> </p> <p>Data were not available separately for different severities of alcoholic hepatitis. Therefore, the subgroup analysis of severe alcoholic hepatitis was based on a study level. We sought unclear or missing information by contacting the trial authors. If there was any doubt whether trials shared the same participants, completely or partially (by identifying common authors and centres), we attempted to contact the trial authors to clarify whether the trial report was duplicated. We resolved any differences in opinion through discussion. </p> </section> <section id="CD011646-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We followed the guidance given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011646-bbs2-0136" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Cochrane, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and described in the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD011646-bbs2-0133" title="GluudC , NikolovaD , KlingenbergSL . Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 10. Art. No.: LIVER. ">Gluud 2016</a>) to assess the risk of bias in included studies. Specifically, we assessed the risk of bias in included trials for the following domains using the methods below (<a href="./references#CD011646-bbs2-0166" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>; <a href="./references#CD011646-bbs2-0146" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. ">Moher 1998</a>; <a href="./references#CD011646-bbs2-0140" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a>; <a href="./references#CD011646-bbs2-0183" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601‐5. ">Wood 2008</a>; <a href="./references#CD011646-bbs2-0163" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment2012;16(35):1‐82. ">Savović 2012a</a>; <a href="./references#CD011646-bbs2-0164" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savović 2012b</a>; <a href="./references#CD011646-bbs2-0143" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). </p> <section id="CD011646-sec-0044"> <h5 class="title">Allocation sequence generation</h5> <p> <ul id="CD011646-list-0016"> <li> <p>Low risk of bias: the study authors performed sequence generation using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if an independent person not otherwise involved in the study performed them. </p> </li> <li> <p>Unclear risk of bias: the study authors did not specify the method of sequence generation.</p> </li> <li> <p>High risk of bias: the sequence generation method was not random. We planned to only include such studies for assessment of harms. </p> </li> </ul> </p> </section> <section id="CD011646-sec-0045"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD011646-list-0017"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. A central and independent randomisation unit controlled allocation. The investigators were unaware of the allocation sequence (e.g. if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Unclear risk of bias: the study authors did not describe the method used to conceal the allocation so the intervention allocations may have been foreseen before, or during, enrolment. </p> </li> <li> <p>High risk of bias: it is likely that the investigators who assigned the participants knew the allocation sequence. We planned to only include such studies for assessment of harms. </p> </li> </ul> </p> </section> <section id="CD011646-sec-0046"> <h5 class="title">Blinding of participants and personnel</h5> <p> <ul id="CD011646-list-0018"> <li> <p>Low risk of bias: any of the following: no blinding or incomplete blinding, but the review authors judged that the outcome was not likely to be influenced by lack of blinding; or blinding of participants and key study personnel ensured, and it was unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information to permit judgement of 'low risk' or 'high risk'; or the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: any of the following: no blinding or incomplete blinding, and the outcome was likely to be influenced by lack of blinding; or blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD011646-sec-0047"> <h5 class="title">Blinded outcome assessment</h5> <p> <ul id="CD011646-list-0019"> <li> <p>Low risk of bias: any of the following: no blinding of outcome assessment, but the review authors judged that the outcome measurement was not likely to be influenced by lack of blinding; or blinding of outcome assessment ensured, and unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information to permit judgement of 'low risk' or 'high risk'; or the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: any of the following: no blinding of outcome assessment, and the outcome measurement was likely to be influenced by lack of blinding; or blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD011646-sec-0048"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD011646-list-0020"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The study used sufficient methods, such as multiple imputation, to handle missing data. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD011646-sec-0049"> <h5 class="title">Selective outcome reporting</h5> <p> <ul id="CD011646-list-0021"> <li> <p>Low risk of bias: the trial reported the following predefined outcomes: (e.g. at least one of the long‐term outcomes related to the disease process, namely, mortality, decompensated liver disease, or requirement for transplantation along with treatment‐related adverse events). If the original trial protocol was available, the outcomes should have been those called for in that protocol. If the trial protocol was obtained from a trial registry (e.g. <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>), the outcomes sought should have been those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. If the trial protocol was registered after the trial was begun, those outcomes were not considered to be reliable. </p> </li> <li> <p>Unclear risk of bias: not all predefined, or clinically relevant and reasonably expected, outcomes were reported fully, or it was unclear whether data on these outcomes were recorded or not. </p> </li> <li> <p>High risk of bias: one or more predefined or clinically relevant and reasonably expected outcomes were not reported, despite the fact that data on these outcomes should have been available and even recorded. </p> </li> </ul> </p> </section> <section id="CD011646-sec-0050"> <h5 class="title">For‐profit bias</h5> <p> <ul id="CD011646-list-0022"> <li> <p>Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for‐profit support that could manipulate the trial design, conductance, or results of the trial. </p> </li> <li> <p>Uncertain risk of bias: the trial may or may not have been free of for‐profit bias as no information on clinical trial support or sponsorship was provided. </p> </li> <li> <p>High risk of bias: the trial was sponsored by industry or received other type of for‐profit support. </p> </li> </ul> </p> </section> <section id="CD011646-sec-0051"> <h5 class="title">Other bias</h5> <p> <ul id="CD011646-list-0023"> <li> <p>Low risk of bias: the trial appeared to be free of other components (e.g. inappropriate control or dose or administration of control, baseline differences, early stopping) that could put it at risk of bias. </p> </li> <li> <p>Uncertain risk of bias: the trial may or may not have been free of other components that could put it at risk of bias. </p> </li> <li> <p>High risk of bias: there were other factors in the trial that could put it at risk of bias (e.g. baseline differences, early stopping). </p> </li> </ul> </p> <p>We considered a trial at low risk of bias if we assessed the trial to be at low risk of bias across all domains. Otherwise, we considered trials to be at high risk of bias. </p> </section> </section> <section id="CD011646-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous variables (e.g. short‐term and medium‐term mortality or liver transplantation, proportion of participants with adverse events, decompensated liver disease, cirrhosis, or hepatocellular carcinoma), we calculated the odds ratio (OR) with 95% confidence intervals (CIs). For continuous variables (e.g. health‐related quality of life reported on the same scale), we planned to calculate the mean difference (MD) with 95% CI. We planned to use standardised mean difference (SMD) values with 95% CI for health‐related quality of life if included trials used different scales. For count outcomes (e.g. number of adverse events), we calculated the rate ratio with 95% CI. For time‐to‐event data (e.g. mortality at maximal follow‐up or requirement for liver transplantation, time to liver decompensation, and time to cirrhosis), we planned to use the hazard ratio (HR) with 95% confidence intervals. However, because of the nature of the data available, we calculated the odds ratio with 95% CI for these outcomes also. We also calculated Trial Sequential Analysis‐adjusted CI to control random errors (<a href="./references#CD011646-bbs2-0172" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011:1‐115. ">Thorlund 2011</a>). </p> </section> <section id="CD011646-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis were people with alcohol‐related liver disease according to the intervention group to which they were randomly assigned. </p> <section id="CD011646-sec-0054"> <h5 class="title">Cluster‐randomised clinical trials</h5> <p>As expected, we did find cluster‐randomised clinical trials. However, had we found any such trials, we planned to include them provided that the effect estimate adjusted for cluster correlation is available. </p> </section> <section id="CD011646-sec-0055"> <h5 class="title">Cross‐over randomised clinical trials</h5> <p>We included the outcomes after the period of first intervention since alcohol‐related liver disease is a chronic unstable disease and the treatments could potentially have a residual effect. On the other hand, alcoholic hepatitis is an acute illness and the intervention given initially can influence the outcome of the patients with alcoholic disease. </p> </section> <section id="CD011646-sec-0056"> <h5 class="title">Trials with multiple intervention groups</h5> <p>We collected data for all trial intervention groups that met the inclusion criteria. The codes for analysis, that we used, accounts for the correlation between the effect sizes from studies with more than two groups. </p> </section> </section> <section id="CD011646-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>We performed an intention‐to‐treat analysis whenever possible (<a href="./references#CD011646-bbs2-0150" title="NewellDJ . Intention‐to‐treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology1992;21(5):837‐41. ">Newell 1992</a>). Otherwise, we used the data that were available to us (e.g. a trial might have reported only per‐protocol analysis results). As such per‐protocol analyses may be biased, we planned to conduct best‐worst case scenario analyses (good outcome in intervention group and bad outcome in control group) and worst‐best case scenario analyses (bad outcome in intervention group and good outcome in control group) as sensitivity analyses whenever possible. However, we did not perform these analyses because of lack of sufficient information. </p> <p>For continuous outcomes, we planned to impute the standard deviation from P values according to guidance given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011646-bbs2-0136" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Cochrane, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If the data were likely to be normally distributed, we planned to use the median for meta‐analysis when the mean was not available. If it was not possible to calculate the standard deviation from the P value or the confidence intervals, we planned to impute the standard deviation using the largest standard deviation in other trials for that outcome. This form of imputation may decrease the weight of the study for calculation of mean differences and may bias the effect estimate to no effect for calculation of standardised mean differences (<a href="./references#CD011646-bbs2-0136" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Cochrane, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD011646-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity by carefully examining the characteristics and design of included trials. Different study designs and risk of bias may contribute to methodological heterogeneity. We used the I<sup>2</sup> test and Chi<sup>2</sup> test for heterogeneity, and overlapping of CIs to assess heterogeneity. </p> </section> <section id="CD011646-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>We used visual asymmetry on a funnel plot to explore reporting bias in the presence of at least 10 trials that could be included for a comparison (<a href="./references#CD011646-bbs2-0127" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315(7109):629‐34. ">Egger 1997</a>; <a href="./references#CD011646-bbs2-0144" title="MacaskillP , WalterSD , IrwigL . A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine2001;20(4):641‐54. ">Macaskill 2001</a>). In the presence of heterogeneity that could be explained by subgroup analysis, we planned to produce a funnel plot for each subgroup in the presence of an adequate number of trials (at least 10 trials). We used the linear regression approach described by <a href="./references#CD011646-bbs2-0127" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315(7109):629‐34. ">Egger 1997</a> to determine funnel plot asymmetry. </p> <p>We also considered selective reporting as evidence of reporting bias.</p> </section> <section id="CD011646-sec-0060"> <h4 class="title">Data synthesis</h4> <p>We performed the meta‐analyses according to the recommendations of Cochrane (<a href="./references#CD011646-bbs2-0136" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Cochrane, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), using the software package Review Manager 5 (<a href="./references#CD011646-bbs2-0159" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used a random‐effects model (<a href="./references#CD011646-bbs2-0119" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>) and a fixed‐effect model (<a href="./references#CD011646-bbs2-0118" title="DeMetsDL . Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341‐50. ">DeMets 1987</a>). In the case of a discrepancy between the two models, we reported the more conservative results; otherwise, we reported only the results from the fixed‐effect model. </p> <p>We performed the direct comparisons using the same codes and the same technical details.</p> <section id="CD011646-sec-0061"> <h5 class="title">Calculation of required information size and Trial Sequential Analysis</h5> <p>For calculation of the required information size, see <a href="./appendices#CD011646-sec-0182">Appendix 8</a>. We performed Trial Sequential Analysis to control the risk of random errors (<a href="./references#CD011646-bbs2-0178" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. ">Wetterslev 2008</a>; <a href="./references#CD011646-bbs2-0172" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. Available from www.ctu.dk/tsa2011:1‐115. ">Thorlund 2011</a>; <a href="./references#CD011646-bbs2-0174" title="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen. TSA version 0.9. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, 2011. ">TSA 2011</a>; <a href="./references#CD011646-bbs2-0179" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta‐analysis. BMC Medical Research Methodology2017;17(1):39. ">Wetterslev 2017</a>) when there were at least two trials included for the comparisons involving an active intervention versus no intervention for the following outcomes: mortality at maximal follow‐up, serious adverse events (proportion), and health‐related quality of life. These are outcomes that determine whether an intervention should be used. We used an alpha error as per guidance of <a href="./references#CD011646-bbs2-0139" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology2014;14(1):120. ">Jakobsen 2014</a>, power of 90% (beta error of 10%), a relative risk reduction of 20%, a control group proportion observed in the trials, and the diversity observed in the meta‐analysis. </p> </section> </section> <section id="CD011646-sec-0062"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to assess the differences in the effect estimates between the following subgroups. </p> <p> <ul id="CD011646-list-0024"> <li> <p>Trials with low risk of bias compared to trials with high risk of bias.</p> </li> <li> <p>Biopsy‐confirmed alcohol‐related liver disease.</p> </li> <li> <p>Different severity of alcoholic hepatitis.</p> </li> <li> <p>Different regimens of pharmacological interventions. For example, different doses and different durations. </p> </li> </ul> </p> <p>We planned to use the Chi<sup>2</sup> test for subgroup differences to identify subgroup differences. </p> </section> <section id="CD011646-sec-0063"> <h4 class="title">Sensitivity analysis</h4> <p>If a trial reported only per‐protocol analysis results, we planned to re‐analyse the results using the best‐worst scenario and worst‐best case scenario analyses as sensitivity analyses whenever possible. </p> <section id="CD011646-sec-0064"> <h5 class="title">Presentation of results</h5> <p>We presented the results in a 'Summary of findings' table format, downgrading the quality of the evidence for risk of bias, inconsistency, indirectness, imprecision, and publication bias using GRADE (<a href="./references#CD011646-bbs2-0134" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. ">Guyatt 2011</a>). We presented the 'Summary of findings' tables for primary outcomes comparing active interventions versus no interventions when there were at least two trials for at least one of the primary outcomes. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011646-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011646-sec-0065"></div> <section id="CD011646-sec-0066"> <h3 class="title">Description of studies</h3> <section id="CD011646-sec-0067"> <h4 class="title">Results of the search</h4> <p>We identified 11,178 references through electronic searches of CENTRAL (Wiley) (n = 1406), MEDLINE (OvidSP) (n = 5901), Embase (OvidSP) (n = 1830), Science Citation Index expanded (n = 1942), ClinicalTrials.gov (n = 51) and WHO Trials register (n = 48). After removing duplicate references, there were 8021 references. We excluded 7866 clearly irrelevant references through reading titles and abstracts. We identified two references by reference searching. We retrieved a total of 157 full text references for further assessment in detail. We excluded 29 references (27 trials) for the reasons stated in the <a href="./references#CD011646-sec-0193" title="">Characteristics of excluded studies</a>. Thus, we included a total of 81 trials described in 128 references (<a href="./references#CD011646-sec-0192" title="">Characteristics of included studies</a>). The reference flow is shown in <a href="#CD011646-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD011646-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011646-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011646-sec-0068"> <h4 class="title">Included studies</h4> <p>Of the 81 trials included in the review, 50 trials were conducted exclusively in people with acute alcoholic hepatitis (<a href="./references#CD011646-bbs2-0029" title="HelmanRA , TemkoMH , NyeSW , FallonHJ . Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine1971;74:311‐21. ">Helman 1971</a>; <a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0011" title="CampraJL , HamlinEMJr , KirshbaumRJ , OlivierM , RedekerAG , ReynoldsTB . Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Annals of Internal Medicine1973;79(5):625‐31. ">Campra 1973</a>; <a href="./references#CD011646-bbs2-0061" title="ResnickRH , BoitnottJ , IberFL , MakopourH , CerdaJJ . Preliminary observations of d‐penicillamine therapy in acute alcoholic liver disease. Digestion1974;11:257‐65. ">Resnick 1974</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0066" title="ShumakerJB , ResnickRH , GalambosJT . A controlled trial of 6‐methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. American Journal of Gastroenterology1978;69:443‐9. ">Shumaker 1978</a>; <a href="./references#CD011646-bbs2-0018" title="DepewW , BoyerT , OmataM . Double‐blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology1980;78:524‐9. DepewWT , BoyerTD , OmataM , RedekerAG , ReynoldsTB . Double‐blind controlled trial of corticosteroid‐therapy in severe alcoholic hepatitis with encephalopathy. Clinical Research1978;26(2):A150. ">Depew 1980</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0065" title="Serrano‐CancinoH , BoteroR , JeffersL , MarianiA , CowenG , RavendhranN . Treatment of severe alcoholic hepatitis with propythiouracil (PTU). American Journal of Gastroenterology1981;76:194. ">Serrano‐Cancino 1981</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0043" title="MirouzeD , RedekerA , ReynoldsT , MichelH . A randomized clinical trial of insulin and glucagon infusion for treatment of severe acute alcoholic hepatitis: Report in 26 patients. Scandinavian Journal of Gastroenterology1982;17:36. ">Mirouze 1982</a>; <a href="./references#CD011646-bbs2-0075" title="TheodossiA , EddlestonA L , WilliamsR . Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut1982;23:75‐9. ">Theodossi 1982</a>; <a href="./references#CD011646-bbs2-0059" title="RadvanG , KanelG , RedekerA . Management of acute alcoholic hepatitis with insulin and glucagon infusion. Australian and New Zealand Journal of Medicine1983;13:322. ">Radvan 1983</a>; <a href="./references#CD011646-bbs2-0041" title="MendenhallC . Survival after steroid treatment (T) for alcoholic hepatitis (AH). Hepatology1983;3(5):850. MendenhallC , GoldbergS . Risk factors and therapy in alcoholic hepatitis (AH). Gastroenterology1977;72(5):A‐77. MendenhallCL , AndersonS , Garcia‐PontP . Short‐term and long‐term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New England Journal of Medicine1984;311:1464‐70. ">Mendenhall 1984</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0039" title="McHutchinsonJG , RunyonBA , DragueskuJQ , CominelliF , PersonJL , CastracaneJ . Pentoxyfylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology1991;14(Suppl S4):96A. ">McHutchinson 1991</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0080" title="TrinchetJC , BalkauB , HeintzmannF , PouponRE , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon a multicentre sequential trial. Journal of Hepatology1990;11(Suppl 2):S63. TrinchetJC , BalkauB , PouponRE , HeintzmannF , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology1992;15:76‐81. ">Trinchet 1992</a>; <a href="./references#CD011646-bbs2-0062" title="MalF , Pham HuuT , RichardetJP , RoulotD , LabadieH , PolS , et al. Corticosteroids (Cs) does not influence plasma tumor necrosis factor‐alpha (pTNF) and interleukin 6 (pIl6) concentrations in severe alcoholic hepatitis (AH): a cross over study. Hepatology1992;16(2 (Pt 2)):234a. RichardetJP , DehouxM , MalF , RoulotD , LabadieH , PolS , et al. Influence of corticosteroids (Cs) on plasma cytokines concentrations in patients with severe alcoholic hepatitis (HA): Results of a randomized study. Journal of Hepatology1993;18(Suppl 1):S75. ">Richardet 1993</a>; <a href="./references#CD011646-bbs2-0006" title="BirdGL , PrachAT , McMahonAD , ForrestJA , MillsPR , DaneshBJ . Randomised controlled double‐blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology1998;28:194‐8. ">Bird 1998</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0073" title="StiglianoR , MarelliL , PangK , LowdellM , RollesK , PatchD , et al. G‐CSF mobilization of bone marrow‐derived hepatocyte and haematopoietic progenitors in acute alcoholic hepatitis ‐ a randomised controlled trial. Preliminary data. Hepatology2005;42:741A. ">Stigliano 2005</a>; <a href="./references#CD011646-bbs2-0050" title="PaladuguH , SawantP , DalviL , KudalkarJ . Role of pentoxifylline in treatment of severe acute alcoholic hepatitis ‐ a randomized controlled trial. Journal of Gastroenterology and Hepatology2006;21:A459. ">Paladugu 2006</a>; <a href="./references#CD011646-bbs2-0054" title="PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis‐a randomised clinical trial. Journal of Hepatology2006;44:784‐90. PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial. Hepatology2001;34(4):250A. ">Phillips 2006</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0057" title="PopescuA , VoiculescuM . Improved survival in patients with advanced alcoholic hepatitis (AAH) with a combined treatment associating a non‐absorbable antibiotic rifaximin to corticoids plus ursodeoxicholic acid (UDCA). Journal of Hepatology2009;50:S369. ">Popescu 2009</a>; <a href="./references#CD011646-bbs2-0033" title="LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline (PTX) reduces the risk of complications in patients with advanced cirrhosis. Analysis of the results of a pivotal phase 3 trial. Journal of Hepatology2009;50:S378. LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline does not decrease short‐term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology2010;138:1755‐U40. ">Lebrec 2010</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0004" title="BasuP , ShahNJ , AloysiusMM . Role of mycophenolate mofetil (mmf) in steroid non responsive severe acute alcoholic hepatitis: a randomized open label placebo control prospective clinical pilot trial. HPB2015;17:44. ">Basu 2015</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>), while 31 trials were conducted in people with different alcoholic disorders (fatty liver, alcoholic hepatitis, and cirrhosis) (<a href="./references#CD011646-bbs2-0022" title="FensterLF . The non efficacy of short‐term anabolic steroid therapy in alcoholic liver disease. Annals of Internal Medicine1966;65:738‐44. ">Fenster 1966</a>; <a href="./references#CD011646-bbs2-0026" title="GeminianiS , MazellaG , AldiniR , BazzoliF , MorselliA M , RossiR , et al. Effect of cycloxilic acid administration on ethanol‐induced hepatic steatosis. Controlled clinical trial. Farmaco ‐ Edizione Pratica1979;34:449‐55. ">Geminiani 1979</a>; <a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0055" title="PierriG , GiorgioA , AmorosoP , FicoP , FinelliL . Epomediol treatment of fatty liver in alcohol abuse. A controlled clinical double‐blind study. Clinica Terapeutica1985;112:527‐35. ">Pierri 1985</a>; <a href="./references#CD011646-bbs2-0064" title="SalvaqniniM , MartinesD , PiccoliA , SciarroneR , RizzoA , CampesatoA , et al. Silymarin treatment in alcoholic liver disease: a double blind randomized trial. Journal of Hepatology1985;1(Suppl 1):S124. ">Salvagnini 1985</a>; <a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0009" title="BoriesP , GuedjJY , MirouzeD , YousfiA , MichelH . Treatment of acute alcoholic hepatitis with prednisolone. 45 patients. Presse Medicale1987;16(16):769‐72. ">Bories 1987</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0021" title="FeherJ , DeakG , MuzesG , LangI , NiederlandV , NekamK , et al. Liver‐protective action of silymarin therapy in chronic alcoholic liver diseases. Orvosi Hetilap1989;130:2723‐7. ">Feher 1989</a>; <a href="./references#CD011646-bbs2-0074" title="TakaseS , MatsudaY , YasuharaM , TakadaA . Effects of malotilate treatment on alcoholic liver disease. Alcohol1989;6(3):219‐22. TakaseS , TakadaA , YasuharaM , SatoH , MatsudaY . Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis. Gastroenterologia Japonica1988 Dec;23(6):639‐45. ">Takase 1989</a>; <a href="./references#CD011646-bbs2-0056" title="PlevrisJN , HayesPC , BouchierIAD . Ursodeoxycholic acid in the treatment of alcoholic liver‐disease. European Journal of Gastroenterology &amp; Hepatology1991;3:653‐6. PlevrisJN , JonesAL , DawkesR , HowieAF , BouchierIAD , HayesPC . Ursodeoxycholic acid in the treatment of alcoholic liver disease. Gut1993;34(4):S7. ">Plevris 1991</a>; <a href="./references#CD011646-bbs2-0063" title="SainzS , GuarnerC , VillanuevaC , OrdonezJ , SanchoEJ , EnriquezJ . Colchicine treatment in alcoholic liver disease. A controlled and randomized study. Journal of Hepatology1992;16(Suppl 1):S64. ">Sainz 1992</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0017" title="De laMazaMP , PetermannM , BunoutD , HirschS . Effects of long‐term vitamin E supplementation in alcoholic cirrhotics. Journal of the American College of Nutrition1995;14:192‐6. ">De la Maza 1995</a>; <a href="./references#CD011646-bbs2-0034" title="LottererE , EtzelR . LIV. 52 in patients with alcoholic liver cirrhosis ‐ pilot study of a controlled clinical trial. Forschende Komplementärmedizin1995;2:12‐4. ">Lotterer 1995</a>; <a href="./references#CD011646-bbs2-0020" title="Diaz BelmontA , Dominguez HenkelR , Uribe AnciraF . Parenteral S‐adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases. Anales de Medicina Interna1996;13:9‐15. ">Diaz Belmont 1996</a>; <a href="./references#CD011646-bbs2-0024" title="FleigWE , MorganMY , HolzerMA . The ayurvedic medicine LIV.52 in alcoholic cirrhosis of the liver: Results of a prospective, randomised, double‐blind, placebo‐controlled, clinical study. Zeitschrift fur Gastroenterologie1998;36:100. FleigWE , MorganMY , HölzerMA . The ayurvedic drug Liv52 in patients with alcoholic cirrhosis results of a prospective, randomized, doubleblind, placebo‐controlled clinical trial. Journal of Hepatology1997;26(Suppl 1):S127. ">Fleig 1997</a>; <a href="./references#CD011646-bbs2-0081" title="VelussiM , CernigoiAM , DeMonteA , DapasF , CaffauC , ZilliM . Long‐term (12 months) treatment with an anti‐oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Journal of Hepatology1997;26:871‐9. VelussiM , CernigoiAM , ViezzoliL , DapasF , CaffauC , ZilliM . Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Current Therapeutic Research ‐ Clinical and Experimental1993;53(5):533‐45. ">Velussi 1997</a>; <a href="./references#CD011646-bbs2-0010" title="CaballeriaJ . Metadoxine in the treatment of alcoholic fatty liver a randomized multicenter trial. Hepatology1996;24(4 (Pt 2)):444a. CaballeriaJ , ParesA , BruC , MercaderJ , Garcia PlazaA , CaballeriaL , et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double‐blind, placebo‐control trial. Spanish Group for the Study of Alcoholic Fatty Liver. Journal of Hepatology1998;28:54‐60. ">Caballeria 1998</a>; <a href="./references#CD011646-bbs2-0013" title="ColmanJC , CromieSL , CoxJM , RobertsSK , DudleyE , DudleyFJ . The natural history of alcoholic cirrhosis: effect of colchicine. Hepatology1998;28:510A. ">Colman 1998</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>; <a href="./references#CD011646-bbs2-0071" title="StennerJ , JazrawiR , VermaA , AhmedH , NorthfieldT . Effect of UDCA on fibrosis markers in alcoholic liver disease. Clinical science2000;98:17p. ">Stenner 2000</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0019" title="deSilvaHA , SaparamaduPA , ThabrewMI , PathmeswaranA , FonsekaMM , deSilvaHJ . Liv.52 in alcoholic liver disease: a prospective, controlled trial. Journal of Ethnopharmacology2003;84:47‐50. ">De Silva 2003</a>; <a href="./references#CD011646-bbs2-0053" title="PelletierG , RoulotD , DavionT , MasliahC , CausseX , ObertiF , et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol‐induced cirrhosis and jaundice. Hepatology2003;37:887‐92. ">Pelletier 2003</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>; <a href="./references#CD011646-bbs2-0032" title="KimMY , BaikSK , JangYO , YeaCJ , WonCS , ByunJW , et al. The beneficial effect of angiotensin‐blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology2009;50:812A‐3A. KimMY , ChoMY , BaikSK , JeongPH , SukKT , JangYO , et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ a randomized open‐label controlled study. Liver International2012;32:977‐87. ">Kim 2012</a>). </p> <section id="CD011646-sec-0069"> <h5 class="title">Acute alcoholic hepatitis</h5> <p>We included a total of 4484 participants in 50 trials on acute alcoholic hepatitis (<a href="./references#CD011646-bbs2-0029" title="HelmanRA , TemkoMH , NyeSW , FallonHJ . Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine1971;74:311‐21. ">Helman 1971</a>; <a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0011" title="CampraJL , HamlinEMJr , KirshbaumRJ , OlivierM , RedekerAG , ReynoldsTB . Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Annals of Internal Medicine1973;79(5):625‐31. ">Campra 1973</a>; <a href="./references#CD011646-bbs2-0061" title="ResnickRH , BoitnottJ , IberFL , MakopourH , CerdaJJ . Preliminary observations of d‐penicillamine therapy in acute alcoholic liver disease. Digestion1974;11:257‐65. ">Resnick 1974</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0066" title="ShumakerJB , ResnickRH , GalambosJT . A controlled trial of 6‐methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. American Journal of Gastroenterology1978;69:443‐9. ">Shumaker 1978</a>; <a href="./references#CD011646-bbs2-0018" title="DepewW , BoyerT , OmataM . Double‐blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology1980;78:524‐9. DepewWT , BoyerTD , OmataM , RedekerAG , ReynoldsTB . Double‐blind controlled trial of corticosteroid‐therapy in severe alcoholic hepatitis with encephalopathy. Clinical Research1978;26(2):A150. ">Depew 1980</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0065" title="Serrano‐CancinoH , BoteroR , JeffersL , MarianiA , CowenG , RavendhranN . Treatment of severe alcoholic hepatitis with propythiouracil (PTU). American Journal of Gastroenterology1981;76:194. ">Serrano‐Cancino 1981</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0043" title="MirouzeD , RedekerA , ReynoldsT , MichelH . A randomized clinical trial of insulin and glucagon infusion for treatment of severe acute alcoholic hepatitis: Report in 26 patients. Scandinavian Journal of Gastroenterology1982;17:36. ">Mirouze 1982</a>; <a href="./references#CD011646-bbs2-0075" title="TheodossiA , EddlestonA L , WilliamsR . Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut1982;23:75‐9. ">Theodossi 1982</a>; <a href="./references#CD011646-bbs2-0059" title="RadvanG , KanelG , RedekerA . Management of acute alcoholic hepatitis with insulin and glucagon infusion. Australian and New Zealand Journal of Medicine1983;13:322. ">Radvan 1983</a>; <a href="./references#CD011646-bbs2-0041" title="MendenhallC . Survival after steroid treatment (T) for alcoholic hepatitis (AH). Hepatology1983;3(5):850. MendenhallC , GoldbergS . Risk factors and therapy in alcoholic hepatitis (AH). Gastroenterology1977;72(5):A‐77. MendenhallCL , AndersonS , Garcia‐PontP . Short‐term and long‐term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New England Journal of Medicine1984;311:1464‐70. ">Mendenhall 1984</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0039" title="McHutchinsonJG , RunyonBA , DragueskuJQ , CominelliF , PersonJL , CastracaneJ . Pentoxyfylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology1991;14(Suppl S4):96A. ">McHutchinson 1991</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0080" title="TrinchetJC , BalkauB , HeintzmannF , PouponRE , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon a multicentre sequential trial. Journal of Hepatology1990;11(Suppl 2):S63. TrinchetJC , BalkauB , PouponRE , HeintzmannF , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology1992;15:76‐81. ">Trinchet 1992</a>; <a href="./references#CD011646-bbs2-0062" title="MalF , Pham HuuT , RichardetJP , RoulotD , LabadieH , PolS , et al. Corticosteroids (Cs) does not influence plasma tumor necrosis factor‐alpha (pTNF) and interleukin 6 (pIl6) concentrations in severe alcoholic hepatitis (AH): a cross over study. Hepatology1992;16(2 (Pt 2)):234a. RichardetJP , DehouxM , MalF , RoulotD , LabadieH , PolS , et al. Influence of corticosteroids (Cs) on plasma cytokines concentrations in patients with severe alcoholic hepatitis (HA): Results of a randomized study. Journal of Hepatology1993;18(Suppl 1):S75. ">Richardet 1993</a>; <a href="./references#CD011646-bbs2-0006" title="BirdGL , PrachAT , McMahonAD , ForrestJA , MillsPR , DaneshBJ . Randomised controlled double‐blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology1998;28:194‐8. ">Bird 1998</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0073" title="StiglianoR , MarelliL , PangK , LowdellM , RollesK , PatchD , et al. G‐CSF mobilization of bone marrow‐derived hepatocyte and haematopoietic progenitors in acute alcoholic hepatitis ‐ a randomised controlled trial. Preliminary data. Hepatology2005;42:741A. ">Stigliano 2005</a>; <a href="./references#CD011646-bbs2-0050" title="PaladuguH , SawantP , DalviL , KudalkarJ . Role of pentoxifylline in treatment of severe acute alcoholic hepatitis ‐ a randomized controlled trial. Journal of Gastroenterology and Hepatology2006;21:A459. ">Paladugu 2006</a>; <a href="./references#CD011646-bbs2-0054" title="PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis‐a randomised clinical trial. Journal of Hepatology2006;44:784‐90. PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial. Hepatology2001;34(4):250A. ">Phillips 2006</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0057" title="PopescuA , VoiculescuM . Improved survival in patients with advanced alcoholic hepatitis (AAH) with a combined treatment associating a non‐absorbable antibiotic rifaximin to corticoids plus ursodeoxicholic acid (UDCA). Journal of Hepatology2009;50:S369. ">Popescu 2009</a>; <a href="./references#CD011646-bbs2-0033" title="LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline (PTX) reduces the risk of complications in patients with advanced cirrhosis. Analysis of the results of a pivotal phase 3 trial. Journal of Hepatology2009;50:S378. LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline does not decrease short‐term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology2010;138:1755‐U40. ">Lebrec 2010</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0004" title="BasuP , ShahNJ , AloysiusMM . Role of mycophenolate mofetil (mmf) in steroid non responsive severe acute alcoholic hepatitis: a randomized open label placebo control prospective clinical pilot trial. HPB2015;17:44. ">Basu 2015</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>). A total of 26 interventions (25 active and one inactive interventions) were evaluated in the 50 trials. One trial was a cross‐over randomised clinical trial (<a href="./references#CD011646-bbs2-0062" title="MalF , Pham HuuT , RichardetJP , RoulotD , LabadieH , PolS , et al. Corticosteroids (Cs) does not influence plasma tumor necrosis factor‐alpha (pTNF) and interleukin 6 (pIl6) concentrations in severe alcoholic hepatitis (AH): a cross over study. Hepatology1992;16(2 (Pt 2)):234a. RichardetJP , DehouxM , MalF , RoulotD , LabadieH , PolS , et al. Influence of corticosteroids (Cs) on plasma cytokines concentrations in patients with severe alcoholic hepatitis (HA): Results of a randomized study. Journal of Hepatology1993;18(Suppl 1):S75. ">Richardet 1993</a>); and the remaining trials were parallel‐group design trials. Two trials had three interventions (<a href="./references#CD011646-bbs2-0041" title="MendenhallC . Survival after steroid treatment (T) for alcoholic hepatitis (AH). Hepatology1983;3(5):850. MendenhallC , GoldbergS . Risk factors and therapy in alcoholic hepatitis (AH). Gastroenterology1977;72(5):A‐77. MendenhallCL , AndersonS , Garcia‐PontP . Short‐term and long‐term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New England Journal of Medicine1984;311:1464‐70. ">Mendenhall 1984</a>; <a href="./references#CD011646-bbs2-0004" title="BasuP , ShahNJ , AloysiusMM . Role of mycophenolate mofetil (mmf) in steroid non responsive severe acute alcoholic hepatitis: a randomized open label placebo control prospective clinical pilot trial. HPB2015;17:44. ">Basu 2015</a>); two trials had four interventions (<a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>); and the remaining trials had two interventions. A total of 48 trials (4335 participants) contributed to one or more outcomes. </p> <p>A total of 2545 participants included in 19 trials had severe acute alcoholic hepatitis, defined as Maddrey Discriminant Function (DF) &gt; 32 (<a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0050" title="PaladuguH , SawantP , DalviL , KudalkarJ . Role of pentoxifylline in treatment of severe acute alcoholic hepatitis ‐ a randomized controlled trial. Journal of Gastroenterology and Hepatology2006;21:A459. ">Paladugu 2006</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0004" title="BasuP , ShahNJ , AloysiusMM . Role of mycophenolate mofetil (mmf) in steroid non responsive severe acute alcoholic hepatitis: a randomized open label placebo control prospective clinical pilot trial. HPB2015;17:44. ">Basu 2015</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>). A total of 13 interventions (12 active and one inactive interventions) were evaluated in the 19 trials. All the trials were parallel‐group design trials. One trial had three interventions (<a href="./references#CD011646-bbs2-0004" title="BasuP , ShahNJ , AloysiusMM . Role of mycophenolate mofetil (mmf) in steroid non responsive severe acute alcoholic hepatitis: a randomized open label placebo control prospective clinical pilot trial. HPB2015;17:44. ">Basu 2015</a>); two trials had four interventions (<a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>); and the remaining trials had two interventions. A total of 18 trials (2477 participants contributed to one or more outcomes). </p> <p>Further details about the mean age in the participants, proportion of females, inclusion and exclusion criteria, details of the intervention, and the outcomes reported are available in the <a href="./references#CD011646-sec-0192" title="">Characteristics of included studies</a>. </p> <p><i>Source of funding:</i> Eleven trials were funded by parties with vested interest in the results (<a href="./references#CD011646-bbs2-0061" title="ResnickRH , BoitnottJ , IberFL , MakopourH , CerdaJJ . Preliminary observations of d‐penicillamine therapy in acute alcoholic liver disease. Digestion1974;11:257‐65. ">Resnick 1974</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0066" title="ShumakerJB , ResnickRH , GalambosJT . A controlled trial of 6‐methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. American Journal of Gastroenterology1978;69:443‐9. ">Shumaker 1978</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>). Sixteen trials were funded by parties without vested interest in the results (<a href="./references#CD011646-bbs2-0029" title="HelmanRA , TemkoMH , NyeSW , FallonHJ . Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine1971;74:311‐21. ">Helman 1971</a>; <a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0080" title="TrinchetJC , BalkauB , HeintzmannF , PouponRE , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon a multicentre sequential trial. Journal of Hepatology1990;11(Suppl 2):S63. TrinchetJC , BalkauB , PouponRE , HeintzmannF , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology1992;15:76‐81. ">Trinchet 1992</a>; <a href="./references#CD011646-bbs2-0006" title="BirdGL , PrachAT , McMahonAD , ForrestJA , MillsPR , DaneshBJ . Randomised controlled double‐blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology1998;28:194‐8. ">Bird 1998</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). The source of funding was not reported in the remaining trials. </p> </section> <section id="CD011646-sec-0070"> <h5 class="title">Alcohol‐related liver diseases (others)</h5> <p>We included a total of 3695 participants in 31 trials on alcohol‐related liver disease (<a href="./references#CD011646-bbs2-0022" title="FensterLF . The non efficacy of short‐term anabolic steroid therapy in alcoholic liver disease. Annals of Internal Medicine1966;65:738‐44. ">Fenster 1966</a>; <a href="./references#CD011646-bbs2-0026" title="GeminianiS , MazellaG , AldiniR , BazzoliF , MorselliA M , RossiR , et al. Effect of cycloxilic acid administration on ethanol‐induced hepatic steatosis. Controlled clinical trial. Farmaco ‐ Edizione Pratica1979;34:449‐55. ">Geminiani 1979</a>; <a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0055" title="PierriG , GiorgioA , AmorosoP , FicoP , FinelliL . Epomediol treatment of fatty liver in alcohol abuse. A controlled clinical double‐blind study. Clinica Terapeutica1985;112:527‐35. ">Pierri 1985</a>; <a href="./references#CD011646-bbs2-0064" title="SalvaqniniM , MartinesD , PiccoliA , SciarroneR , RizzoA , CampesatoA , et al. Silymarin treatment in alcoholic liver disease: a double blind randomized trial. Journal of Hepatology1985;1(Suppl 1):S124. ">Salvagnini 1985</a>; <a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0009" title="BoriesP , GuedjJY , MirouzeD , YousfiA , MichelH . Treatment of acute alcoholic hepatitis with prednisolone. 45 patients. Presse Medicale1987;16(16):769‐72. ">Bories 1987</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0021" title="FeherJ , DeakG , MuzesG , LangI , NiederlandV , NekamK , et al. Liver‐protective action of silymarin therapy in chronic alcoholic liver diseases. Orvosi Hetilap1989;130:2723‐7. ">Feher 1989</a>; <a href="./references#CD011646-bbs2-0074" title="TakaseS , MatsudaY , YasuharaM , TakadaA . Effects of malotilate treatment on alcoholic liver disease. Alcohol1989;6(3):219‐22. TakaseS , TakadaA , YasuharaM , SatoH , MatsudaY . Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis. Gastroenterologia Japonica1988 Dec;23(6):639‐45. ">Takase 1989</a>; <a href="./references#CD011646-bbs2-0056" title="PlevrisJN , HayesPC , BouchierIAD . Ursodeoxycholic acid in the treatment of alcoholic liver‐disease. European Journal of Gastroenterology &amp; Hepatology1991;3:653‐6. PlevrisJN , JonesAL , DawkesR , HowieAF , BouchierIAD , HayesPC . Ursodeoxycholic acid in the treatment of alcoholic liver disease. Gut1993;34(4):S7. ">Plevris 1991</a>; <a href="./references#CD011646-bbs2-0063" title="SainzS , GuarnerC , VillanuevaC , OrdonezJ , SanchoEJ , EnriquezJ . Colchicine treatment in alcoholic liver disease. A controlled and randomized study. Journal of Hepatology1992;16(Suppl 1):S64. ">Sainz 1992</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0017" title="De laMazaMP , PetermannM , BunoutD , HirschS . Effects of long‐term vitamin E supplementation in alcoholic cirrhotics. Journal of the American College of Nutrition1995;14:192‐6. ">De la Maza 1995</a>; <a href="./references#CD011646-bbs2-0034" title="LottererE , EtzelR . LIV. 52 in patients with alcoholic liver cirrhosis ‐ pilot study of a controlled clinical trial. Forschende Komplementärmedizin1995;2:12‐4. ">Lotterer 1995</a>; <a href="./references#CD011646-bbs2-0020" title="Diaz BelmontA , Dominguez HenkelR , Uribe AnciraF . Parenteral S‐adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases. Anales de Medicina Interna1996;13:9‐15. ">Diaz Belmont 1996</a>; <a href="./references#CD011646-bbs2-0024" title="FleigWE , MorganMY , HolzerMA . The ayurvedic medicine LIV.52 in alcoholic cirrhosis of the liver: Results of a prospective, randomised, double‐blind, placebo‐controlled, clinical study. Zeitschrift fur Gastroenterologie1998;36:100. FleigWE , MorganMY , HölzerMA . The ayurvedic drug Liv52 in patients with alcoholic cirrhosis results of a prospective, randomized, doubleblind, placebo‐controlled clinical trial. Journal of Hepatology1997;26(Suppl 1):S127. ">Fleig 1997</a>; <a href="./references#CD011646-bbs2-0081" title="VelussiM , CernigoiAM , DeMonteA , DapasF , CaffauC , ZilliM . Long‐term (12 months) treatment with an anti‐oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Journal of Hepatology1997;26:871‐9. VelussiM , CernigoiAM , ViezzoliL , DapasF , CaffauC , ZilliM . Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Current Therapeutic Research ‐ Clinical and Experimental1993;53(5):533‐45. ">Velussi 1997</a>; <a href="./references#CD011646-bbs2-0010" title="CaballeriaJ . Metadoxine in the treatment of alcoholic fatty liver a randomized multicenter trial. Hepatology1996;24(4 (Pt 2)):444a. CaballeriaJ , ParesA , BruC , MercaderJ , Garcia PlazaA , CaballeriaL , et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double‐blind, placebo‐control trial. Spanish Group for the Study of Alcoholic Fatty Liver. Journal of Hepatology1998;28:54‐60. ">Caballeria 1998</a>; <a href="./references#CD011646-bbs2-0013" title="ColmanJC , CromieSL , CoxJM , RobertsSK , DudleyE , DudleyFJ . The natural history of alcoholic cirrhosis: effect of colchicine. Hepatology1998;28:510A. ">Colman 1998</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>; <a href="./references#CD011646-bbs2-0071" title="StennerJ , JazrawiR , VermaA , AhmedH , NorthfieldT . Effect of UDCA on fibrosis markers in alcoholic liver disease. Clinical science2000;98:17p. ">Stenner 2000</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0019" title="deSilvaHA , SaparamaduPA , ThabrewMI , PathmeswaranA , FonsekaMM , deSilvaHJ . Liv.52 in alcoholic liver disease: a prospective, controlled trial. Journal of Ethnopharmacology2003;84:47‐50. ">De Silva 2003</a>; <a href="./references#CD011646-bbs2-0053" title="PelletierG , RoulotD , DavionT , MasliahC , CausseX , ObertiF , et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol‐induced cirrhosis and jaundice. Hepatology2003;37:887‐92. ">Pelletier 2003</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>; <a href="./references#CD011646-bbs2-0032" title="KimMY , BaikSK , JangYO , YeaCJ , WonCS , ByunJW , et al. The beneficial effect of angiotensin‐blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology2009;50:812A‐3A. KimMY , ChoMY , BaikSK , JeongPH , SukKT , JangYO , et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ a randomized open‐label controlled study. Liver International2012;32:977‐87. ">Kim 2012</a>). A total of 15 interventions (14 active and one inactive interventions) were evaluated in the 31 trials. One trial was a cross‐over randomised clinical trial (<a href="./references#CD011646-bbs2-0056" title="PlevrisJN , HayesPC , BouchierIAD . Ursodeoxycholic acid in the treatment of alcoholic liver‐disease. European Journal of Gastroenterology &amp; Hepatology1991;3:653‐6. PlevrisJN , JonesAL , DawkesR , HowieAF , BouchierIAD , HayesPC . Ursodeoxycholic acid in the treatment of alcoholic liver disease. Gut1993;34(4):S7. ">Plevris 1991</a>); the remaining trials were parallel‐group design trials. All the trials had only two interventions. A total of 26 trials (3212 participants contributed to one or more outcomes). </p> <p>Further details about the mean age in the participants, proportion of females, inclusion and exclusion criteria, details of the intervention, and the outcomes reported are available in the <a href="./references#CD011646-sec-0192" title="">Characteristics of included studies</a>. </p> <p><i>Source of funding:</i> Twelve trials were funded by parties with vested interest in the results (<a href="./references#CD011646-bbs2-0022" title="FensterLF . The non efficacy of short‐term anabolic steroid therapy in alcoholic liver disease. Annals of Internal Medicine1966;65:738‐44. ">Fenster 1966</a>; <a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0017" title="De laMazaMP , PetermannM , BunoutD , HirschS . Effects of long‐term vitamin E supplementation in alcoholic cirrhotics. Journal of the American College of Nutrition1995;14:192‐6. ">De la Maza 1995</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0019" title="deSilvaHA , SaparamaduPA , ThabrewMI , PathmeswaranA , FonsekaMM , deSilvaHJ . Liv.52 in alcoholic liver disease: a prospective, controlled trial. Journal of Ethnopharmacology2003;84:47‐50. ">De Silva 2003</a>; <a href="./references#CD011646-bbs2-0053" title="PelletierG , RoulotD , DavionT , MasliahC , CausseX , ObertiF , et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol‐induced cirrhosis and jaundice. Hepatology2003;37:887‐92. ">Pelletier 2003</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>). Three trials were funded by parties without vested interest in the results (<a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0032" title="KimMY , BaikSK , JangYO , YeaCJ , WonCS , ByunJW , et al. The beneficial effect of angiotensin‐blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology2009;50:812A‐3A. KimMY , ChoMY , BaikSK , JeongPH , SukKT , JangYO , et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ a randomized open‐label controlled study. Liver International2012;32:977‐87. ">Kim 2012</a>). The source of funding was not reported in the remaining trials. </p> </section> </section> <section id="CD011646-sec-0071"> <h4 class="title">Excluded studies</h4> <p>Twenty‐seven studies were excluded because of the reasons listed in the <a href="./references#CD011646-sec-0193" title="">Characteristics of excluded studies</a>. While the reasons for exclusion of 24 studies are clear and do not warrant further discussion, exclusion of three studies warrants further discussion (<a href="./references#CD011646-bbs2-0096" title="MathurinP , DuchatelleV , RamondMJ , DegottC , BedossaP , ErlingerS , et al. Long term survival and prognostic factors in patients with severe biopsy‐proved alcoholic hepatitis (ah) treated by prednisolone: Randomized trial, new cohort and simulation. Hepatology1994;20(4 (Pt 2)):319a. MathurinP , DuchatelleV , RamondMJ , DegottC , BedossaP , ErlingerS , et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology1996;110(6):1847‐53. ">Mathurin 1996</a>; <a href="./references#CD011646-bbs2-0105" title="SpahrL , LambertJF , Rubbia‐BrandtL , ChalandonY , FrossardJL , GiostraE , et al. Granulocyte‐colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology2008;48(1):221‐9. ">Spahr 2008</a>; <a href="./references#CD011646-bbs2-0093" title="KolasaniBP , SasidharanP , DivyashanthiCM , KumarA . Vitamin e improves quality of life in patients with alcoholic liver disease. National Journal of Physiology, Pharmacy and Pharmacology2016;6(4):269‐75. KolasaniBP , SasidharanP , KumarA . Efficacy of vitamin e supplementation in patients with alcoholic liver disease: an open‐label, prospective, randomized comparative study. International Journal of Nutrition, Pharmacology, Neurological Diseases2016;6(3):101‐10. ">Kolasani 2016</a>). <a href="./references#CD011646-bbs2-0096" title="MathurinP , DuchatelleV , RamondMJ , DegottC , BedossaP , ErlingerS , et al. Long term survival and prognostic factors in patients with severe biopsy‐proved alcoholic hepatitis (ah) treated by prednisolone: Randomized trial, new cohort and simulation. Hepatology1994;20(4 (Pt 2)):319a. MathurinP , DuchatelleV , RamondMJ , DegottC , BedossaP , ErlingerS , et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology1996;110(6):1847‐53. ">Mathurin 1996</a> reported the long‐term follow‐up of participants included in <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; however, at the end of the study period, all the participants were administered the intervention, and the randomisation was lost. Therefore, we did not include this study in our analysis (<a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>). In <a href="./references#CD011646-bbs2-0105" title="SpahrL , LambertJF , Rubbia‐BrandtL , ChalandonY , FrossardJL , GiostraE , et al. Granulocyte‐colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology2008;48(1):221‐9. ">Spahr 2008</a> and <a href="./references#CD011646-bbs2-0093" title="KolasaniBP , SasidharanP , DivyashanthiCM , KumarA . Vitamin e improves quality of life in patients with alcoholic liver disease. National Journal of Physiology, Pharmacy and Pharmacology2016;6(4):269‐75. KolasaniBP , SasidharanP , KumarA . Efficacy of vitamin e supplementation in patients with alcoholic liver disease: an open‐label, prospective, randomized comparative study. International Journal of Nutrition, Pharmacology, Neurological Diseases2016;6(3):101‐10. ">Kolasani 2016</a>, the intervention and control groups were allowed to take other drugs targeted at treatment of alcoholic liver disease as per clinicians' discretion. We accepted only when it was possible to know that the co‐interventions were administered equally in the intervention and control groups of the trial; therefore, we excluded these two studies (<a href="./references#CD011646-bbs2-0105" title="SpahrL , LambertJF , Rubbia‐BrandtL , ChalandonY , FrossardJL , GiostraE , et al. Granulocyte‐colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology2008;48(1):221‐9. ">Spahr 2008</a>; <a href="./references#CD011646-bbs2-0093" title="KolasaniBP , SasidharanP , DivyashanthiCM , KumarA . Vitamin e improves quality of life in patients with alcoholic liver disease. National Journal of Physiology, Pharmacy and Pharmacology2016;6(4):269‐75. KolasaniBP , SasidharanP , KumarA . Efficacy of vitamin e supplementation in patients with alcoholic liver disease: an open‐label, prospective, randomized comparative study. International Journal of Nutrition, Pharmacology, Neurological Diseases2016;6(3):101‐10. ">Kolasani 2016</a>). </p> </section> </section> <section id="CD011646-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias in trials is summarised in <a href="#CD011646-fig-0002">Figure 2</a> and <a href="#CD011646-fig-0003">Figure 3</a>. As shown in these figures, none of the trials were at low risk of bias in all the domains and were considered to be at high risk of bias. </p> <div class="figure" id="CD011646-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD011646-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> </div> <div class="figure" id="CD011646-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011646-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011646-sec-0073"> <h4 class="title">Allocation</h4> <section id="CD011646-sec-0074"> <h5 class="title">Alcoholic hepatitis</h5> <p>Twenty‐one trials were at low risk of bias due to random sequence generation (<a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0054" title="PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis‐a randomised clinical trial. Journal of Hepatology2006;44:784‐90. PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial. Hepatology2001;34(4):250A. ">Phillips 2006</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0033" title="LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline (PTX) reduces the risk of complications in patients with advanced cirrhosis. Analysis of the results of a pivotal phase 3 trial. Journal of Hepatology2009;50:S378. LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline does not decrease short‐term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology2010;138:1755‐U40. ">Lebrec 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). The remaining trials were at unclear risk of bias. </p> <p>Fourteen trials were at low risk of bias due allocation concealment (<a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0075" title="TheodossiA , EddlestonA L , WilliamsR . Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut1982;23:75‐9. ">Theodossi 1982</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>).The remaining trials were at unclear risk of bias. </p> <p>Overall, seven trials were at low risk of bias due to both random sequence generation and allocation concealment and were considered to be at low risk of selection bias (<a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). </p> </section> <section id="CD011646-sec-0075"> <h5 class="title">Alcohol‐related liver disease (others)</h5> <p>Sixteen trials were at low risk of bias due to random sequence generation (<a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0009" title="BoriesP , GuedjJY , MirouzeD , YousfiA , MichelH . Treatment of acute alcoholic hepatitis with prednisolone. 45 patients. Presse Medicale1987;16(16):769‐72. ">Bories 1987</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0010" title="CaballeriaJ . Metadoxine in the treatment of alcoholic fatty liver a randomized multicenter trial. Hepatology1996;24(4 (Pt 2)):444a. CaballeriaJ , ParesA , BruC , MercaderJ , Garcia PlazaA , CaballeriaL , et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double‐blind, placebo‐control trial. Spanish Group for the Study of Alcoholic Fatty Liver. Journal of Hepatology1998;28:54‐60. ">Caballeria 1998</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0019" title="deSilvaHA , SaparamaduPA , ThabrewMI , PathmeswaranA , FonsekaMM , deSilvaHJ . Liv.52 in alcoholic liver disease: a prospective, controlled trial. Journal of Ethnopharmacology2003;84:47‐50. ">De Silva 2003</a>; <a href="./references#CD011646-bbs2-0053" title="PelletierG , RoulotD , DavionT , MasliahC , CausseX , ObertiF , et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol‐induced cirrhosis and jaundice. Hepatology2003;37:887‐92. ">Pelletier 2003</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>; <a href="./references#CD011646-bbs2-0032" title="KimMY , BaikSK , JangYO , YeaCJ , WonCS , ByunJW , et al. The beneficial effect of angiotensin‐blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology2009;50:812A‐3A. KimMY , ChoMY , BaikSK , JeongPH , SukKT , JangYO , et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ a randomized open‐label controlled study. Liver International2012;32:977‐87. ">Kim 2012</a>). The remaining trials were at unclear risk of bias. </p> <p>Nine trials were at low risk of bias due allocation concealment (<a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>; <a href="./references#CD011646-bbs2-0032" title="KimMY , BaikSK , JangYO , YeaCJ , WonCS , ByunJW , et al. The beneficial effect of angiotensin‐blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology2009;50:812A‐3A. KimMY , ChoMY , BaikSK , JeongPH , SukKT , JangYO , et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ a randomized open‐label controlled study. Liver International2012;32:977‐87. ">Kim 2012</a>). The remaining trials were at unclear risk of bias. </p> <p>Overall, nine trials were at low risk of bias due to both random sequence generation and allocation concealment, and were considered to be at low risk of selection bias (<a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>; <a href="./references#CD011646-bbs2-0032" title="KimMY , BaikSK , JangYO , YeaCJ , WonCS , ByunJW , et al. The beneficial effect of angiotensin‐blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology2009;50:812A‐3A. KimMY , ChoMY , BaikSK , JeongPH , SukKT , JangYO , et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ a randomized open‐label controlled study. Liver International2012;32:977‐87. ">Kim 2012</a>) </p> </section> </section> <section id="CD011646-sec-0076"> <h4 class="title">Blinding</h4> <section id="CD011646-sec-0077"> <h5 class="title">Alcoholic hepatitis</h5> <p>Twenty‐three trials were at low risk of performance bias (<a href="./references#CD011646-bbs2-0029" title="HelmanRA , TemkoMH , NyeSW , FallonHJ . Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine1971;74:311‐21. ">Helman 1971</a>; <a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0066" title="ShumakerJB , ResnickRH , GalambosJT . A controlled trial of 6‐methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. American Journal of Gastroenterology1978;69:443‐9. ">Shumaker 1978</a>; <a href="./references#CD011646-bbs2-0018" title="DepewW , BoyerT , OmataM . Double‐blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology1980;78:524‐9. DepewWT , BoyerTD , OmataM , RedekerAG , ReynoldsTB . Double‐blind controlled trial of corticosteroid‐therapy in severe alcoholic hepatitis with encephalopathy. Clinical Research1978;26(2):A150. ">Depew 1980</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0041" title="MendenhallC . Survival after steroid treatment (T) for alcoholic hepatitis (AH). Hepatology1983;3(5):850. MendenhallC , GoldbergS . Risk factors and therapy in alcoholic hepatitis (AH). Gastroenterology1977;72(5):A‐77. MendenhallCL , AndersonS , Garcia‐PontP . Short‐term and long‐term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New England Journal of Medicine1984;311:1464‐70. ">Mendenhall 1984</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). Twelve trials were at high risk of performance bias (<a href="./references#CD011646-bbs2-0011" title="CampraJL , HamlinEMJr , KirshbaumRJ , OlivierM , RedekerAG , ReynoldsTB . Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Annals of Internal Medicine1973;79(5):625‐31. ">Campra 1973</a>; <a href="./references#CD011646-bbs2-0075" title="TheodossiA , EddlestonA L , WilliamsR . Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut1982;23:75‐9. ">Theodossi 1982</a>; <a href="./references#CD011646-bbs2-0054" title="PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis‐a randomised clinical trial. Journal of Hepatology2006;44:784‐90. PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial. Hepatology2001;34(4):250A. ">Phillips 2006</a>; <a href="./references#CD011646-bbs2-0057" title="PopescuA , VoiculescuM . Improved survival in patients with advanced alcoholic hepatitis (AAH) with a combined treatment associating a non‐absorbable antibiotic rifaximin to corticoids plus ursodeoxicholic acid (UDCA). Journal of Hepatology2009;50:S369. ">Popescu 2009</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0004" title="BasuP , ShahNJ , AloysiusMM . Role of mycophenolate mofetil (mmf) in steroid non responsive severe acute alcoholic hepatitis: a randomized open label placebo control prospective clinical pilot trial. HPB2015;17:44. ">Basu 2015</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>). The remaining trials were at unclear risk of performance bias. </p> <p>Fifteen trials were at low risk of detection bias (<a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0033" title="LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline (PTX) reduces the risk of complications in patients with advanced cirrhosis. Analysis of the results of a pivotal phase 3 trial. Journal of Hepatology2009;50:S378. LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline does not decrease short‐term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology2010;138:1755‐U40. ">Lebrec 2010</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). Seven trials were at high risk of detection bias (<a href="./references#CD011646-bbs2-0011" title="CampraJL , HamlinEMJr , KirshbaumRJ , OlivierM , RedekerAG , ReynoldsTB . Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Annals of Internal Medicine1973;79(5):625‐31. ">Campra 1973</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0004" title="BasuP , ShahNJ , AloysiusMM . Role of mycophenolate mofetil (mmf) in steroid non responsive severe acute alcoholic hepatitis: a randomized open label placebo control prospective clinical pilot trial. HPB2015;17:44. ">Basu 2015</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>). The remaining trials were at unclear risk of detection bias. </p> <p>Overall, 12 trials were at low risk of performance bias and detection bias (<a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). </p> </section> <section id="CD011646-sec-0078"> <h5 class="title">Alcohol‐related liver disease (others)</h5> <p>Ten trials were at low risk of performance bias (<a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0019" title="deSilvaHA , SaparamaduPA , ThabrewMI , PathmeswaranA , FonsekaMM , deSilvaHJ . Liv.52 in alcoholic liver disease: a prospective, controlled trial. Journal of Ethnopharmacology2003;84:47‐50. ">De Silva 2003</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>). Five trials were at high risk of performance bias (<a href="./references#CD011646-bbs2-0074" title="TakaseS , MatsudaY , YasuharaM , TakadaA . Effects of malotilate treatment on alcoholic liver disease. Alcohol1989;6(3):219‐22. TakaseS , TakadaA , YasuharaM , SatoH , MatsudaY . Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis. Gastroenterologia Japonica1988 Dec;23(6):639‐45. ">Takase 1989</a>; <a href="./references#CD011646-bbs2-0056" title="PlevrisJN , HayesPC , BouchierIAD . Ursodeoxycholic acid in the treatment of alcoholic liver‐disease. European Journal of Gastroenterology &amp; Hepatology1991;3:653‐6. PlevrisJN , JonesAL , DawkesR , HowieAF , BouchierIAD , HayesPC . Ursodeoxycholic acid in the treatment of alcoholic liver disease. Gut1993;34(4):S7. ">Plevris 1991</a>; <a href="./references#CD011646-bbs2-0063" title="SainzS , GuarnerC , VillanuevaC , OrdonezJ , SanchoEJ , EnriquezJ . Colchicine treatment in alcoholic liver disease. A controlled and randomized study. Journal of Hepatology1992;16(Suppl 1):S64. ">Sainz 1992</a>; <a href="./references#CD011646-bbs2-0081" title="VelussiM , CernigoiAM , DeMonteA , DapasF , CaffauC , ZilliM . Long‐term (12 months) treatment with an anti‐oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Journal of Hepatology1997;26:871‐9. VelussiM , CernigoiAM , ViezzoliL , DapasF , CaffauC , ZilliM . Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Current Therapeutic Research ‐ Clinical and Experimental1993;53(5):533‐45. ">Velussi 1997</a>; <a href="./references#CD011646-bbs2-0032" title="KimMY , BaikSK , JangYO , YeaCJ , WonCS , ByunJW , et al. The beneficial effect of angiotensin‐blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology2009;50:812A‐3A. KimMY , ChoMY , BaikSK , JeongPH , SukKT , JangYO , et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ a randomized open‐label controlled study. Liver International2012;32:977‐87. ">Kim 2012</a>). The remaining trials were at unclear risk of performance bias. </p> <p>Ten trials were at low risk of detection bias (<a href="./references#CD011646-bbs2-0055" title="PierriG , GiorgioA , AmorosoP , FicoP , FinelliL . Epomediol treatment of fatty liver in alcohol abuse. A controlled clinical double‐blind study. Clinica Terapeutica1985;112:527‐35. ">Pierri 1985</a>; <a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0019" title="deSilvaHA , SaparamaduPA , ThabrewMI , PathmeswaranA , FonsekaMM , deSilvaHJ . Liv.52 in alcoholic liver disease: a prospective, controlled trial. Journal of Ethnopharmacology2003;84:47‐50. ">De Silva 2003</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>). Two trials were at high risk of detection bias (<a href="./references#CD011646-bbs2-0056" title="PlevrisJN , HayesPC , BouchierIAD . Ursodeoxycholic acid in the treatment of alcoholic liver‐disease. European Journal of Gastroenterology &amp; Hepatology1991;3:653‐6. PlevrisJN , JonesAL , DawkesR , HowieAF , BouchierIAD , HayesPC . Ursodeoxycholic acid in the treatment of alcoholic liver disease. Gut1993;34(4):S7. ">Plevris 1991</a>; <a href="./references#CD011646-bbs2-0032" title="KimMY , BaikSK , JangYO , YeaCJ , WonCS , ByunJW , et al. The beneficial effect of angiotensin‐blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology2009;50:812A‐3A. KimMY , ChoMY , BaikSK , JeongPH , SukKT , JangYO , et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ a randomized open‐label controlled study. Liver International2012;32:977‐87. ">Kim 2012</a>). The remaining trials were at unclear risk of detection bias. </p> <p>Overall, nine trials were at low risk of performance bias and detection bias (<a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0019" title="deSilvaHA , SaparamaduPA , ThabrewMI , PathmeswaranA , FonsekaMM , deSilvaHJ . Liv.52 in alcoholic liver disease: a prospective, controlled trial. Journal of Ethnopharmacology2003;84:47‐50. ">De Silva 2003</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>). </p> </section> </section> <section id="CD011646-sec-0079"> <h4 class="title">Incomplete outcome data</h4> <section id="CD011646-sec-0080"> <h5 class="title">Alcoholic hepatitis</h5> <p>Thirteen trials were at low risk of attrition bias (<a href="./references#CD011646-bbs2-0029" title="HelmanRA , TemkoMH , NyeSW , FallonHJ . Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine1971;74:311‐21. ">Helman 1971</a>; <a href="./references#CD011646-bbs2-0066" title="ShumakerJB , ResnickRH , GalambosJT . A controlled trial of 6‐methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. American Journal of Gastroenterology1978;69:443‐9. ">Shumaker 1978</a>; <a href="./references#CD011646-bbs2-0018" title="DepewW , BoyerT , OmataM . Double‐blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology1980;78:524‐9. DepewWT , BoyerTD , OmataM , RedekerAG , ReynoldsTB . Double‐blind controlled trial of corticosteroid‐therapy in severe alcoholic hepatitis with encephalopathy. Clinical Research1978;26(2):A150. ">Depew 1980</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0054" title="PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis‐a randomised clinical trial. Journal of Hepatology2006;44:784‐90. PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial. Hepatology2001;34(4):250A. ">Phillips 2006</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>). Sixteen trials were at high risk of attrition bias (<a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0011" title="CampraJL , HamlinEMJr , KirshbaumRJ , OlivierM , RedekerAG , ReynoldsTB . Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Annals of Internal Medicine1973;79(5):625‐31. ">Campra 1973</a>; <a href="./references#CD011646-bbs2-0061" title="ResnickRH , BoitnottJ , IberFL , MakopourH , CerdaJJ . Preliminary observations of d‐penicillamine therapy in acute alcoholic liver disease. Digestion1974;11:257‐65. ">Resnick 1974</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0075" title="TheodossiA , EddlestonA L , WilliamsR . Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut1982;23:75‐9. ">Theodossi 1982</a>; <a href="./references#CD011646-bbs2-0059" title="RadvanG , KanelG , RedekerA . Management of acute alcoholic hepatitis with insulin and glucagon infusion. Australian and New Zealand Journal of Medicine1983;13:322. ">Radvan 1983</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0080" title="TrinchetJC , BalkauB , HeintzmannF , PouponRE , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon a multicentre sequential trial. Journal of Hepatology1990;11(Suppl 2):S63. TrinchetJC , BalkauB , PouponRE , HeintzmannF , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology1992;15:76‐81. ">Trinchet 1992</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). The remaining trials were at unclear risk of attrition bias. </p> </section> <section id="CD011646-sec-0081"> <h5 class="title">Alcohol‐related liver disease (others)</h5> <p>Nine trials were at low risk of attrition bias (<a href="./references#CD011646-bbs2-0026" title="GeminianiS , MazellaG , AldiniR , BazzoliF , MorselliA M , RossiR , et al. Effect of cycloxilic acid administration on ethanol‐induced hepatic steatosis. Controlled clinical trial. Farmaco ‐ Edizione Pratica1979;34:449‐55. ">Geminiani 1979</a>; <a href="./references#CD011646-bbs2-0055" title="PierriG , GiorgioA , AmorosoP , FicoP , FinelliL . Epomediol treatment of fatty liver in alcohol abuse. A controlled clinical double‐blind study. Clinica Terapeutica1985;112:527‐35. ">Pierri 1985</a>; <a href="./references#CD011646-bbs2-0009" title="BoriesP , GuedjJY , MirouzeD , YousfiA , MichelH . Treatment of acute alcoholic hepatitis with prednisolone. 45 patients. Presse Medicale1987;16(16):769‐72. ">Bories 1987</a>; <a href="./references#CD011646-bbs2-0074" title="TakaseS , MatsudaY , YasuharaM , TakadaA . Effects of malotilate treatment on alcoholic liver disease. Alcohol1989;6(3):219‐22. TakaseS , TakadaA , YasuharaM , SatoH , MatsudaY . Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis. Gastroenterologia Japonica1988 Dec;23(6):639‐45. ">Takase 1989</a>; <a href="./references#CD011646-bbs2-0034" title="LottererE , EtzelR . LIV. 52 in patients with alcoholic liver cirrhosis ‐ pilot study of a controlled clinical trial. Forschende Komplementärmedizin1995;2:12‐4. ">Lotterer 1995</a>; <a href="./references#CD011646-bbs2-0020" title="Diaz BelmontA , Dominguez HenkelR , Uribe AnciraF . Parenteral S‐adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases. Anales de Medicina Interna1996;13:9‐15. ">Diaz Belmont 1996</a>; <a href="./references#CD011646-bbs2-0081" title="VelussiM , CernigoiAM , DeMonteA , DapasF , CaffauC , ZilliM . Long‐term (12 months) treatment with an anti‐oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Journal of Hepatology1997;26:871‐9. VelussiM , CernigoiAM , ViezzoliL , DapasF , CaffauC , ZilliM . Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Current Therapeutic Research ‐ Clinical and Experimental1993;53(5):533‐45. ">Velussi 1997</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>). Eleven trials were at high risk of attrition bias (<a href="./references#CD011646-bbs2-0022" title="FensterLF . The non efficacy of short‐term anabolic steroid therapy in alcoholic liver disease. Annals of Internal Medicine1966;65:738‐44. ">Fenster 1966</a>; <a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0056" title="PlevrisJN , HayesPC , BouchierIAD . Ursodeoxycholic acid in the treatment of alcoholic liver‐disease. European Journal of Gastroenterology &amp; Hepatology1991;3:653‐6. PlevrisJN , JonesAL , DawkesR , HowieAF , BouchierIAD , HayesPC . Ursodeoxycholic acid in the treatment of alcoholic liver disease. Gut1993;34(4):S7. ">Plevris 1991</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0017" title="De laMazaMP , PetermannM , BunoutD , HirschS . Effects of long‐term vitamin E supplementation in alcoholic cirrhotics. Journal of the American College of Nutrition1995;14:192‐6. ">De la Maza 1995</a>; <a href="./references#CD011646-bbs2-0010" title="CaballeriaJ . Metadoxine in the treatment of alcoholic fatty liver a randomized multicenter trial. Hepatology1996;24(4 (Pt 2)):444a. CaballeriaJ , ParesA , BruC , MercaderJ , Garcia PlazaA , CaballeriaL , et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double‐blind, placebo‐control trial. Spanish Group for the Study of Alcoholic Fatty Liver. Journal of Hepatology1998;28:54‐60. ">Caballeria 1998</a>; <a href="./references#CD011646-bbs2-0071" title="StennerJ , JazrawiR , VermaA , AhmedH , NorthfieldT . Effect of UDCA on fibrosis markers in alcoholic liver disease. Clinical science2000;98:17p. ">Stenner 2000</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0019" title="deSilvaHA , SaparamaduPA , ThabrewMI , PathmeswaranA , FonsekaMM , deSilvaHJ . Liv.52 in alcoholic liver disease: a prospective, controlled trial. Journal of Ethnopharmacology2003;84:47‐50. ">De Silva 2003</a>). The remaining trials were at unclear risk of attrition bias. </p> </section> </section> <section id="CD011646-sec-0082"> <h4 class="title">Selective reporting</h4> <section id="CD011646-sec-0083"> <h5 class="title">Alcoholic hepatitis</h5> <p>We could find a published protocol for only one trial (<a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). Forty‐one trials were at low risk of selecting outcome reporting bias as they reported the important clinical outcomes (mortality and adverse events) (<a href="./references#CD011646-bbs2-0029" title="HelmanRA , TemkoMH , NyeSW , FallonHJ . Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine1971;74:311‐21. ">Helman 1971</a>; <a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0061" title="ResnickRH , BoitnottJ , IberFL , MakopourH , CerdaJJ . Preliminary observations of d‐penicillamine therapy in acute alcoholic liver disease. Digestion1974;11:257‐65. ">Resnick 1974</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0018" title="DepewW , BoyerT , OmataM . Double‐blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology1980;78:524‐9. DepewWT , BoyerTD , OmataM , RedekerAG , ReynoldsTB . Double‐blind controlled trial of corticosteroid‐therapy in severe alcoholic hepatitis with encephalopathy. Clinical Research1978;26(2):A150. ">Depew 1980</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0065" title="Serrano‐CancinoH , BoteroR , JeffersL , MarianiA , CowenG , RavendhranN . Treatment of severe alcoholic hepatitis with propythiouracil (PTU). American Journal of Gastroenterology1981;76:194. ">Serrano‐Cancino 1981</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0043" title="MirouzeD , RedekerA , ReynoldsT , MichelH . A randomized clinical trial of insulin and glucagon infusion for treatment of severe acute alcoholic hepatitis: Report in 26 patients. Scandinavian Journal of Gastroenterology1982;17:36. ">Mirouze 1982</a>; <a href="./references#CD011646-bbs2-0075" title="TheodossiA , EddlestonA L , WilliamsR . Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut1982;23:75‐9. ">Theodossi 1982</a>; <a href="./references#CD011646-bbs2-0059" title="RadvanG , KanelG , RedekerA . Management of acute alcoholic hepatitis with insulin and glucagon infusion. Australian and New Zealand Journal of Medicine1983;13:322. ">Radvan 1983</a>; <a href="./references#CD011646-bbs2-0041" title="MendenhallC . Survival after steroid treatment (T) for alcoholic hepatitis (AH). Hepatology1983;3(5):850. MendenhallC , GoldbergS . Risk factors and therapy in alcoholic hepatitis (AH). Gastroenterology1977;72(5):A‐77. MendenhallCL , AndersonS , Garcia‐PontP . Short‐term and long‐term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New England Journal of Medicine1984;311:1464‐70. ">Mendenhall 1984</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0080" title="TrinchetJC , BalkauB , HeintzmannF , PouponRE , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon a multicentre sequential trial. Journal of Hepatology1990;11(Suppl 2):S63. TrinchetJC , BalkauB , PouponRE , HeintzmannF , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology1992;15:76‐81. ">Trinchet 1992</a>; <a href="./references#CD011646-bbs2-0006" title="BirdGL , PrachAT , McMahonAD , ForrestJA , MillsPR , DaneshBJ . Randomised controlled double‐blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology1998;28:194‐8. ">Bird 1998</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0054" title="PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis‐a randomised clinical trial. Journal of Hepatology2006;44:784‐90. PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial. Hepatology2001;34(4):250A. ">Phillips 2006</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0057" title="PopescuA , VoiculescuM . Improved survival in patients with advanced alcoholic hepatitis (AAH) with a combined treatment associating a non‐absorbable antibiotic rifaximin to corticoids plus ursodeoxicholic acid (UDCA). Journal of Hepatology2009;50:S369. ">Popescu 2009</a>; <a href="./references#CD011646-bbs2-0033" title="LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline (PTX) reduces the risk of complications in patients with advanced cirrhosis. Analysis of the results of a pivotal phase 3 trial. Journal of Hepatology2009;50:S378. LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline does not decrease short‐term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology2010;138:1755‐U40. ">Lebrec 2010</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>). The remaining trials were considered to be at high risk of selective outcome reporting bias because they did not report either mortality or adverse events or both, outcomes expected to be measured in such clinical outcomes. </p> </section> <section id="CD011646-sec-0084"> <h5 class="title">Alcohol‐related liver disease (others)</h5> <p>We were unable to find a published protocol for any trial. Ten trials were at low risk of due to selecting outcome reporting bias as they reported the important clinical outcomes (mortality and adverse events) (<a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0017" title="De laMazaMP , PetermannM , BunoutD , HirschS . Effects of long‐term vitamin E supplementation in alcoholic cirrhotics. Journal of the American College of Nutrition1995;14:192‐6. ">De la Maza 1995</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0053" title="PelletierG , RoulotD , DavionT , MasliahC , CausseX , ObertiF , et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol‐induced cirrhosis and jaundice. Hepatology2003;37:887‐92. ">Pelletier 2003</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>). The remaining trials were considered to be at high risk of selective outcome reporting bias because they reported neither mortality nor adverse events nor both and these are outcomes expected otherwise to be measured in such clinical outcomes. </p> </section> </section> <section id="CD011646-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <section id="CD011646-sec-0086"> <h5 class="title">Alcoholic hepatitis</h5> <p>Sixteen trials were at low risk of for‐profit bias (<a href="./references#CD011646-bbs2-0029" title="HelmanRA , TemkoMH , NyeSW , FallonHJ . Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine1971;74:311‐21. ">Helman 1971</a>; <a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0080" title="TrinchetJC , BalkauB , HeintzmannF , PouponRE , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon a multicentre sequential trial. Journal of Hepatology1990;11(Suppl 2):S63. TrinchetJC , BalkauB , PouponRE , HeintzmannF , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology1992;15:76‐81. ">Trinchet 1992</a>; <a href="./references#CD011646-bbs2-0006" title="BirdGL , PrachAT , McMahonAD , ForrestJA , MillsPR , DaneshBJ . Randomised controlled double‐blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology1998;28:194‐8. ">Bird 1998</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). Eleven trials funded by pharmaceutical industry were considered to be at high risk of for‐profit bias (<a href="./references#CD011646-bbs2-0061" title="ResnickRH , BoitnottJ , IberFL , MakopourH , CerdaJJ . Preliminary observations of d‐penicillamine therapy in acute alcoholic liver disease. Digestion1974;11:257‐65. ">Resnick 1974</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0066" title="ShumakerJB , ResnickRH , GalambosJT . A controlled trial of 6‐methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. American Journal of Gastroenterology1978;69:443‐9. ">Shumaker 1978</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>). The remaining trials were at unclear risk of for‐profit bias. </p> <p>All the trials were at low of other bias.</p> </section> <section id="CD011646-sec-0087"> <h5 class="title">Alcohol‐related liver disease (others)</h5> <p>Three trials were at low risk of for‐profit bias (<a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0032" title="KimMY , BaikSK , JangYO , YeaCJ , WonCS , ByunJW , et al. The beneficial effect of angiotensin‐blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology2009;50:812A‐3A. KimMY , ChoMY , BaikSK , JeongPH , SukKT , JangYO , et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ a randomized open‐label controlled study. Liver International2012;32:977‐87. ">Kim 2012</a>). Twelve trials funded by pharmaceutical industry were considered to be at high risk of for‐profit bias (<a href="./references#CD011646-bbs2-0022" title="FensterLF . The non efficacy of short‐term anabolic steroid therapy in alcoholic liver disease. Annals of Internal Medicine1966;65:738‐44. ">Fenster 1966</a>; <a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0017" title="De laMazaMP , PetermannM , BunoutD , HirschS . Effects of long‐term vitamin E supplementation in alcoholic cirrhotics. Journal of the American College of Nutrition1995;14:192‐6. ">De la Maza 1995</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>; <a href="./references#CD011646-bbs2-0035" title="LucenaMI , AndradeRJ , CruzJP , Rodriguez‐MendizabalM , BlancoE , Sanchez de la CuestaF . Effects of silymarin MZ‐80 on oxidative stress in patients with alcoholic cirrhosis. International Journal of Clinical Pharmacology &amp; Therapeutics2002;40:2‐8. ">Lucena 2002</a>; <a href="./references#CD011646-bbs2-0019" title="deSilvaHA , SaparamaduPA , ThabrewMI , PathmeswaranA , FonsekaMM , deSilvaHJ . Liv.52 in alcoholic liver disease: a prospective, controlled trial. Journal of Ethnopharmacology2003;84:47‐50. ">De Silva 2003</a>; <a href="./references#CD011646-bbs2-0053" title="PelletierG , RoulotD , DavionT , MasliahC , CausseX , ObertiF , et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol‐induced cirrhosis and jaundice. Hepatology2003;37:887‐92. ">Pelletier 2003</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>). The remaining trials were at unclear risk of for‐profit bias. </p> <p>All the trials were at low risk of other bias.</p> </section> </section> </section> <section id="CD011646-sec-0088"> <h3 class="title" id="CD011646-sec-0088">Effects of interventions</h3> <p>See: <a href="./full#CD011646-tbl-0001"><b>Summary of findings for the main comparison</b> Glucocorticosteroids compared with no intervention for alcoholic hepatitis (all severity)</a>; <a href="./full#CD011646-tbl-0002"><b>Summary of findings 2</b> Pentoxifylline compared with no intervention for alcoholic hepatitis (all severity)</a>; <a href="./full#CD011646-tbl-0003"><b>Summary of findings 3</b> Colchicine compared with no intervention for alcoholic hepatitis (all severity)</a>; <a href="./full#CD011646-tbl-0004"><b>Summary of findings 4</b> Insulin plus glucagon compared with no intervention for alcoholic hepatitis (all severity)</a>; <a href="./full#CD011646-tbl-0005"><b>Summary of findings 5</b> Propylthiouracil compared with no intervention for alcoholic hepatitis (all severity)</a>; <a href="./full#CD011646-tbl-0006"><b>Summary of findings 6</b> Glucocorticosteroids compared with no intervention for severe alcoholic hepatitis</a>; <a href="./full#CD011646-tbl-0007"><b>Summary of findings 7</b> Pentoxifylline compared with no intervention for severe alcoholic hepatitis</a>; <a href="./full#CD011646-tbl-0008"><b>Summary of findings 8</b> Anabolic steroids compared with no intervention for alcohol‐related disorders (others)</a>; <a href="./full#CD011646-tbl-0009"><b>Summary of findings 9</b> Antioxidants compared with no intervention for alcohol‐related disorders (others)</a>; <a href="./full#CD011646-tbl-0010"><b>Summary of findings 10</b> Colchicine compared with no intervention for alcohol‐related disorders (others)</a>; <a href="./full#CD011646-tbl-0011"><b>Summary of findings 11</b> Propylthiouracil compared with no intervention for alcohol‐related disorders (others)</a> </p> <section id="CD011646-sec-0089"> <h4 class="title">Alcoholic hepatitis</h4> <section id="CD011646-sec-0090"> <h5 class="title">Mortality at maximal follow‐up</h5> <p>A total of 48 trials including 4337 participants reported mortality at maximal follow‐up (<a href="./references#CD011646-bbs2-0029" title="HelmanRA , TemkoMH , NyeSW , FallonHJ . Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine1971;74:311‐21. ">Helman 1971</a>; <a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0011" title="CampraJL , HamlinEMJr , KirshbaumRJ , OlivierM , RedekerAG , ReynoldsTB . Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Annals of Internal Medicine1973;79(5):625‐31. ">Campra 1973</a>; <a href="./references#CD011646-bbs2-0061" title="ResnickRH , BoitnottJ , IberFL , MakopourH , CerdaJJ . Preliminary observations of d‐penicillamine therapy in acute alcoholic liver disease. Digestion1974;11:257‐65. ">Resnick 1974</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0066" title="ShumakerJB , ResnickRH , GalambosJT . A controlled trial of 6‐methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. American Journal of Gastroenterology1978;69:443‐9. ">Shumaker 1978</a>; <a href="./references#CD011646-bbs2-0018" title="DepewW , BoyerT , OmataM . Double‐blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology1980;78:524‐9. DepewWT , BoyerTD , OmataM , RedekerAG , ReynoldsTB . Double‐blind controlled trial of corticosteroid‐therapy in severe alcoholic hepatitis with encephalopathy. Clinical Research1978;26(2):A150. ">Depew 1980</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0065" title="Serrano‐CancinoH , BoteroR , JeffersL , MarianiA , CowenG , RavendhranN . Treatment of severe alcoholic hepatitis with propythiouracil (PTU). American Journal of Gastroenterology1981;76:194. ">Serrano‐Cancino 1981</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0043" title="MirouzeD , RedekerA , ReynoldsT , MichelH . A randomized clinical trial of insulin and glucagon infusion for treatment of severe acute alcoholic hepatitis: Report in 26 patients. Scandinavian Journal of Gastroenterology1982;17:36. ">Mirouze 1982</a>; <a href="./references#CD011646-bbs2-0075" title="TheodossiA , EddlestonA L , WilliamsR . Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut1982;23:75‐9. ">Theodossi 1982</a>; <a href="./references#CD011646-bbs2-0059" title="RadvanG , KanelG , RedekerA . Management of acute alcoholic hepatitis with insulin and glucagon infusion. Australian and New Zealand Journal of Medicine1983;13:322. ">Radvan 1983</a>; <a href="./references#CD011646-bbs2-0041" title="MendenhallC . Survival after steroid treatment (T) for alcoholic hepatitis (AH). Hepatology1983;3(5):850. MendenhallC , GoldbergS . Risk factors and therapy in alcoholic hepatitis (AH). Gastroenterology1977;72(5):A‐77. MendenhallCL , AndersonS , Garcia‐PontP . Short‐term and long‐term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. New England Journal of Medicine1984;311:1464‐70. ">Mendenhall 1984</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0039" title="McHutchinsonJG , RunyonBA , DragueskuJQ , CominelliF , PersonJL , CastracaneJ . Pentoxyfylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology1991;14(Suppl S4):96A. ">McHutchinson 1991</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0080" title="TrinchetJC , BalkauB , HeintzmannF , PouponRE , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon a multicentre sequential trial. Journal of Hepatology1990;11(Suppl 2):S63. TrinchetJC , BalkauB , PouponRE , HeintzmannF , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology1992;15:76‐81. ">Trinchet 1992</a>; <a href="./references#CD011646-bbs2-0006" title="BirdGL , PrachAT , McMahonAD , ForrestJA , MillsPR , DaneshBJ . Randomised controlled double‐blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology1998;28:194‐8. ">Bird 1998</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0073" title="StiglianoR , MarelliL , PangK , LowdellM , RollesK , PatchD , et al. G‐CSF mobilization of bone marrow‐derived hepatocyte and haematopoietic progenitors in acute alcoholic hepatitis ‐ a randomised controlled trial. Preliminary data. Hepatology2005;42:741A. ">Stigliano 2005</a>; <a href="./references#CD011646-bbs2-0050" title="PaladuguH , SawantP , DalviL , KudalkarJ . Role of pentoxifylline in treatment of severe acute alcoholic hepatitis ‐ a randomized controlled trial. Journal of Gastroenterology and Hepatology2006;21:A459. ">Paladugu 2006</a>; <a href="./references#CD011646-bbs2-0054" title="PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis‐a randomised clinical trial. Journal of Hepatology2006;44:784‐90. PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial. Hepatology2001;34(4):250A. ">Phillips 2006</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0057" title="PopescuA , VoiculescuM . Improved survival in patients with advanced alcoholic hepatitis (AAH) with a combined treatment associating a non‐absorbable antibiotic rifaximin to corticoids plus ursodeoxicholic acid (UDCA). Journal of Hepatology2009;50:S369. ">Popescu 2009</a>; <a href="./references#CD011646-bbs2-0033" title="LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline (PTX) reduces the risk of complications in patients with advanced cirrhosis. Analysis of the results of a pivotal phase 3 trial. Journal of Hepatology2009;50:S378. LebrecD , ThabutD , ObertiF , PerarnauJM , CondatB , BarraudH , et al. Pentoxifylline does not decrease short‐term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology2010;138:1755‐U40. ">Lebrec 2010</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>) (<a href="./references#CD011646-fig-0010" title="">Analysis 1.1</a>). The period of follow‐up ranged from one month to 12 months. The risk of mortality at maximal follow‐up was higher in the anti‐tumour necrosis factor (anti‐TNF) group versus the no intervention group (odds ratio (OR) 4.64, 95% confidence interval (CI) 1.31 to 16.42; 48 participants; 1 trial). There was no evidence of differences in any of the remaining comparisons of active interventions versus no intervention. The results did not change using the random‐effects model. </p> </section> <section id="CD011646-sec-0091"> <h5 class="title">Early mortality (up to three months)</h5> <section id="CD011646-sec-0092"> <h6 class="title">Thirty‐days mortality</h6> <p>A total of 38 trials including 3433 participants reported 30‐days mortality (<a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0066" title="ShumakerJB , ResnickRH , GalambosJT . A controlled trial of 6‐methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. American Journal of Gastroenterology1978;69:443‐9. ">Shumaker 1978</a>; <a href="./references#CD011646-bbs2-0018" title="DepewW , BoyerT , OmataM . Double‐blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology1980;78:524‐9. DepewWT , BoyerTD , OmataM , RedekerAG , ReynoldsTB . Double‐blind controlled trial of corticosteroid‐therapy in severe alcoholic hepatitis with encephalopathy. Clinical Research1978;26(2):A150. ">Depew 1980</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0065" title="Serrano‐CancinoH , BoteroR , JeffersL , MarianiA , CowenG , RavendhranN . Treatment of severe alcoholic hepatitis with propythiouracil (PTU). American Journal of Gastroenterology1981;76:194. ">Serrano‐Cancino 1981</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0043" title="MirouzeD , RedekerA , ReynoldsT , MichelH . A randomized clinical trial of insulin and glucagon infusion for treatment of severe acute alcoholic hepatitis: Report in 26 patients. Scandinavian Journal of Gastroenterology1982;17:36. ">Mirouze 1982</a>; <a href="./references#CD011646-bbs2-0075" title="TheodossiA , EddlestonA L , WilliamsR . Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut1982;23:75‐9. ">Theodossi 1982</a>; <a href="./references#CD011646-bbs2-0059" title="RadvanG , KanelG , RedekerA . Management of acute alcoholic hepatitis with insulin and glucagon infusion. Australian and New Zealand Journal of Medicine1983;13:322. ">Radvan 1983</a>; <a href="./references#CD011646-bbs2-0012" title="CarithersRLJr , HerlongF , DiehlAM , ShawEW , CombesB , FallonHJ , et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Annals of Internal Medicine1989;110(9):685‐90. MaddreyWC , CarithersRL , HerlongHF , CombesB , DiehlAM , ShawE , et al. Prednisolone therapy in patients with severe alcoholic hepatitis: results of a multicenter trial. Hepatology1986;6:1202. ">Carithers 1989</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0039" title="McHutchinsonJG , RunyonBA , DragueskuJQ , CominelliF , PersonJL , CastracaneJ . Pentoxyfylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology1991;14(Suppl S4):96A. ">McHutchinson 1991</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0080" title="TrinchetJC , BalkauB , HeintzmannF , PouponRE , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon a multicentre sequential trial. Journal of Hepatology1990;11(Suppl 2):S63. TrinchetJC , BalkauB , PouponRE , HeintzmannF , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology1992;15:76‐81. ">Trinchet 1992</a>; <a href="./references#CD011646-bbs2-0006" title="BirdGL , PrachAT , McMahonAD , ForrestJA , MillsPR , DaneshBJ . Randomised controlled double‐blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology1998;28:194‐8. ">Bird 1998</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0073" title="StiglianoR , MarelliL , PangK , LowdellM , RollesK , PatchD , et al. G‐CSF mobilization of bone marrow‐derived hepatocyte and haematopoietic progenitors in acute alcoholic hepatitis ‐ a randomised controlled trial. Preliminary data. Hepatology2005;42:741A. ">Stigliano 2005</a>; <a href="./references#CD011646-bbs2-0050" title="PaladuguH , SawantP , DalviL , KudalkarJ . Role of pentoxifylline in treatment of severe acute alcoholic hepatitis ‐ a randomized controlled trial. Journal of Gastroenterology and Hepatology2006;21:A459. ">Paladugu 2006</a>; <a href="./references#CD011646-bbs2-0054" title="PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis‐a randomised clinical trial. Journal of Hepatology2006;44:784‐90. PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial. Hepatology2001;34(4):250A. ">Phillips 2006</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0057" title="PopescuA , VoiculescuM . Improved survival in patients with advanced alcoholic hepatitis (AAH) with a combined treatment associating a non‐absorbable antibiotic rifaximin to corticoids plus ursodeoxicholic acid (UDCA). Journal of Hepatology2009;50:S369. ">Popescu 2009</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>) (<a href="./references#CD011646-fig-0011" title="">Analysis 1.2</a>). The more conservative random‐effects model was used. There was no evidence of any differences in 30‐days mortality in any of the comparisons comparing active intervention versus no intervention. </p> </section> <section id="CD011646-sec-0093"> <h6 class="title">Ninety‐days mortality</h6> <p>A total of 14 trials including 2027 participants reported 90‐days mortality (<a href="./references#CD011646-bbs2-0029" title="HelmanRA , TemkoMH , NyeSW , FallonHJ . Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine1971;74:311‐21. ">Helman 1971</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0080" title="TrinchetJC , BalkauB , HeintzmannF , PouponRE , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon a multicentre sequential trial. Journal of Hepatology1990;11(Suppl 2):S63. TrinchetJC , BalkauB , PouponRE , HeintzmannF , CallardP , GotheilC , et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology1992;15:76‐81. ">Trinchet 1992</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0042" title="MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology2004;40:40‐6. MezeyE , PotterJJ , Rennie‐TankersleyL , CaballeriaJ , ParesA . A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology2003;38(4):264A. ">Mezey 2004</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>) (<a href="./references#CD011646-fig-0012" title="">Analysis 1.3</a>). There was no evidence of any differences in 90‐days mortality in any of the comparisons comparing active intervention versus no intervention. The results did not change using the random‐effects model. </p> </section> </section> <section id="CD011646-sec-0094"> <h5 class="title">Serious adverse events</h5> <p>Two trials (1140 participants) reported serious adverse events (proportion) (<a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>) (<a href="./references#CD011646-fig-0013" title="">Analysis 1.4</a>). There was no evidence of any differences in serious adverse events (proportion) in any of the comparisons. There was only one trial included in each comparison. Therefore, random‐effects model is not applicable. </p> <p>Two trials (73 participants) reported serious adverse events (number) (<a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>) (<a href="./references#CD011646-fig-0014" title="">Analysis 1.5</a>). The number of serious adverse events was higher in the anti‐TNF group versus the no intervention group (rate ratio 1.86; 95% CI 1.01 to 3.43). The number of serious adverse events was higher in the glucocorticosteroids plus anti‐TNF group versus the glucocorticosteroids group (rate ratio 4.72; 95% CrI 1.37 to 16.31). There was only one trial included in each comparison. Therefore, random‐effects model is not applicable. </p> </section> <section id="CD011646-sec-0095"> <h5 class="title">Health‐related quality of life</h5> <p>None of the trials reported health‐related quality of life at any time point.</p> </section> <section id="CD011646-sec-0096"> <h5 class="title">Liver transplantation</h5> <p>A total of three trials including 530 participants reported liver transplantation (<a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>) (<a href="./references#CD011646-fig-0015" title="">Analysis 1.6</a>). There was no evidence of differences in any of the comparisons. There was only one trial included in each comparison. Therefore, random‐effects model is not applicable. </p> </section> <section id="CD011646-sec-0097"> <h5 class="title">Decompensated cirrhosis</h5> <p>A total of 17 trials including 2405 participants reported decompensated cirrhosis (<a href="./references#CD011646-bbs2-0066" title="ShumakerJB , ResnickRH , GalambosJT . A controlled trial of 6‐methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. American Journal of Gastroenterology1978;69:443‐9. ">Shumaker 1978</a>; <a href="./references#CD011646-bbs2-0018" title="DepewW , BoyerT , OmataM . Double‐blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology1980;78:524‐9. DepewWT , BoyerTD , OmataM , RedekerAG , ReynoldsTB . Double‐blind controlled trial of corticosteroid‐therapy in severe alcoholic hepatitis with encephalopathy. Clinical Research1978;26(2):A150. ">Depew 1980</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0050" title="PaladuguH , SawantP , DalviL , KudalkarJ . Role of pentoxifylline in treatment of severe acute alcoholic hepatitis ‐ a randomized controlled trial. Journal of Gastroenterology and Hepatology2006;21:A459. ">Paladugu 2006</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>) (<a href="./references#CD011646-fig-0016" title="">Analysis 1.7</a>). There was no evidence of any differences in decompensated cirrhosis in any of the comparisons comparing active intervention versus no intervention. The results did not change using the random‐effects model. </p> </section> <section id="CD011646-sec-0098"> <h5 class="title">Cirrhosis</h5> <p>One trial including 37 participants reported new onset cirrhosis (<a href="./references#CD011646-bbs2-0029" title="HelmanRA , TemkoMH , NyeSW , FallonHJ . Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Annals of Internal Medicine1971;74:311‐21. ">Helman 1971</a>) (<a href="./references#CD011646-fig-0017" title="">Analysis 1.8</a>). There was no evidence of difference in the proportion of people who developed cirrhosis between glucocorticosteroids and no intervention groups (OR 1.32, 95% CI 0.19 to 9.02). </p> </section> <section id="CD011646-sec-0099"> <h5 class="title">Hepatocellular carcinoma</h5> <p>None of the trials reported hepatocellular carcinoma.</p> </section> <section id="CD011646-sec-0100"> <h5 class="title">Any adverse events</h5> <p>A total of 21 trials including 1458 participants reported adverse events (proportion) (<a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0075" title="TheodossiA , EddlestonA L , WilliamsR . Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut1982;23:75‐9. ">Theodossi 1982</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0079" title="TrinchetJC , CosteT , LevyVG , GripponP , VivetF , DuchatelleV , et al. Treatment of alcoholic hepatitis by silymarine, a double blind multicenter study in 116 patients. Gastroenterologie Clinique Et Biologique1987;11(2 bis):167a. TrinchetJC , CosteT , LevyVG , VivetF , DuchatelleV , LegendreC , et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterologie Clinique Et Biologique1989;13(2):120‐4. ">Trinchet 1989b</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0006" title="BirdGL , PrachAT , McMahonAD , ForrestJA , MillsPR , DaneshBJ . Randomised controlled double‐blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology1998;28:194‐8. ">Bird 1998</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0054" title="PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis‐a randomised clinical trial. Journal of Hepatology2006;44:784‐90. PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial. Hepatology2001;34(4):250A. ">Phillips 2006</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0057" title="PopescuA , VoiculescuM . Improved survival in patients with advanced alcoholic hepatitis (AAH) with a combined treatment associating a non‐absorbable antibiotic rifaximin to corticoids plus ursodeoxicholic acid (UDCA). Journal of Hepatology2009;50:S369. ">Popescu 2009</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>) (<a href="./references#CD011646-fig-0018" title="">Analysis 1.9</a>). The proportion of people with any adverse events was higher in the glucocorticosteroids group (OR 4.00, 95% CI 1.80 to 8.88; 159 participants; 4 trials) and in the pentoxifylline group (OR 2.21, 95% CI 1.10 to 4.46; 151 participants = 151; 2 trials) versus the no intervention group. There was no evidence of any differences in any adverse events (proportion) in any of the remaining comparisons comparing active intervention versus no intervention. The results did not change using the random‐effects model. </p> <p>A total of 32 trials including 3221 participants reported adverse events (number) (<a href="./references#CD011646-bbs2-0058" title="PorterHP , SimonFR , PopeCE , VolwilerW , FensterLF . Corticosteroid therapy in severe alcoholic hepatitis ‐ double‐blind drug trial. New England Journal of Medicine1971;284:1350‐5. ">Porter 1971</a>; <a href="./references#CD011646-bbs2-0007" title="BlitzerBL , MutchnicMG , JoshiPH , PhillipsMM , FesselJM , ConnHO . Adrenocorticosteroid therapy in alcoholic hepatitis ‐ prospective, double‐blind, randomized study. Gastroenterology1973;64(4):880. BlitzerBL , MutchnickMG , JoshiPH . Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study. American Journal of Digestive Diseases1977;22:477‐84. ">Blitzer 1977</a>; <a href="./references#CD011646-bbs2-0036" title="MaddreyWC , BoitnottJK , BedineMS , WeberFLJr , MezeyE , WhiteRIJr . Corticosteroid therapy of alcoholic hepatitis. Gastroenterology1978;75:193‐9. ">Maddrey 1978</a>; <a href="./references#CD011646-bbs2-0066" title="ShumakerJB , ResnickRH , GalambosJT . A controlled trial of 6‐methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. American Journal of Gastroenterology1978;69:443‐9. ">Shumaker 1978</a>; <a href="./references#CD011646-bbs2-0018" title="DepewW , BoyerT , OmataM . Double‐blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology1980;78:524‐9. DepewWT , BoyerTD , OmataM , RedekerAG , ReynoldsTB . Double‐blind controlled trial of corticosteroid‐therapy in severe alcoholic hepatitis with encephalopathy. Clinical Research1978;26(2):A150. ">Depew 1980</a>; <a href="./references#CD011646-bbs2-0003" title="BakerAL , JaspanJB , HainesNW . A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology1981;80:1410‐4. HatfieldG , HainesN , SchneiderJ . Randomized clinical trial of insulin and glucagon for alcoholic hepatitis. Gastroenterology1979;76:1284. ">Baker 1981</a>; <a href="./references#CD011646-bbs2-0028" title="HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Double‐blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology1982;82:925‐31. HalleP , PareP , KapteinE , KanelG , RedekerAG , ReynoldsTB . Propylthiouracil therapy in severe acute alcoholic hepatitis. Gastroenterology1980;79(5 (Pt 2)):1024. ">Halle 1982</a>; <a href="./references#CD011646-bbs2-0075" title="TheodossiA , EddlestonA L , WilliamsR . Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut1982;23:75‐9. ">Theodossi 1982</a>; <a href="./references#CD011646-bbs2-0078" title="TrinchetJC , BeaugrandM , CallardP , HartmannDJ , GotheilC , NusgensBV , et al. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterologie Clinique et Biologique1989;13:551‐5. TrinchetJC , BeaugrandM , FerrierJP , GaletB , CallardP , HartmannD , et al. Treatment of active alcoholic liver disease (AADL) by colchicine: Results of a 6 months double blind trial. Journal of Hepatology1985;1(Suppl 1):S142. TrinchetJC , GaletB , BeaugrandM , CallardP , FerrierJP . Treatment of alcoholic hepatitis with colchicine. Preliminary results of a double blind study in 46 patients. Gastroenterologie Clinique Et Biologique1983;7(2):103a. ">Trinchet 1989a</a>; <a href="./references#CD011646-bbs2-0001" title="AkriviadisEA , SteindelH , PintoPC , FongTL , KanelG , ReynoldsTB , et al. Failure of colchicine to improve short‐term survival in patients with alcoholic hepatitis. Gastroenterology1990;99:811‐8. ">Akriviadis 1990</a>; <a href="./references#CD011646-bbs2-0005" title="BirdG , LauJY , KoskinasJ , WicksC , WilliamsR . Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology1991;14:1097‐101. ">Bird 1991</a>; <a href="./references#CD011646-bbs2-0006" title="BirdGL , PrachAT , McMahonAD , ForrestJA , MillsPR , DaneshBJ . Randomised controlled double‐blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. Journal of Hepatology1998;28:194‐8. ">Bird 1998</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0054" title="PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis‐a randomised clinical trial. Journal of Hepatology2006;44:784‐90. PhillipsM , CurtisH , PortmannB , DonaldsonN , BomfordA , O'GradyJ . Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis: a randomized trial. Hepatology2001;34(4):250A. ">Phillips 2006</a>; <a href="./references#CD011646-bbs2-0072" title="StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2007;47:277‐83. StewartS , PrinceM , BassendineM , HudsonM , JamesO , JonesD , et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of Hepatology2002;36(Suppl 1):16. ">Stewart 2007</a>; <a href="./references#CD011646-bbs2-0008" title="BoetticherNC , PeineCJ , KwoP , AbramsGA , PatelT , AqelB , et al. A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953‐60. ">Boetticher 2008</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0057" title="PopescuA , VoiculescuM . Improved survival in patients with advanced alcoholic hepatitis (AAH) with a combined treatment associating a non‐absorbable antibiotic rifaximin to corticoids plus ursodeoxicholic acid (UDCA). Journal of Hepatology2009;50:S369. ">Popescu 2009</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>) (<a href="./references#CD011646-fig-0019" title="">Analysis 1.10</a>). The more conservative random‐effects model was used. The number of any adverse events was higher in the anti‐TNF group versus the no intervention group (rate ratio 2.26, 95% CI 1.05 to 4.85; 48 participants; 1 trial) and in the glucocorticosteroids group (rate ratio 1.43, 95% CI 1.10 to 1.87; 760 participants; 7 trials) versus the no intervention group (rate ratio 1.34; 95% CrI 1.02 to 1.76; 201 participants; 2 trials). There was no evidence of any differences in any adverse events (number) in any of the remaining comparisons comparing active intervention versus no intervention. </p> </section> <section id="CD011646-sec-0101"> <h5 class="title">Subgroup analysis and sensitivity analysis</h5> <p>We did not perform any subgroup analysis other than performing an analysis of a subset of trials including severe alcoholic hepatitis exclusively, which we have presented below. We did not perform the other subgroup analyses because all the trials were at high risk of bias; separate data were not available in biopsy‐confirmed alcohol‐related liver disease in many trials, and because of the few trials included in each comparison. We did not perform a sensitivity analysis since the reasons for dropouts were not adequately described in each intervention group to perform a meaningful sensitivity analysis. </p> </section> <section id="CD011646-sec-0102"> <h5 class="title">Reporting bias</h5> <p>As there was only comparison with more than 10 trials (glucocorticosteroids versus no intervention), we explored reporting bias via funnel plot for this comparison only. Although the Egger's test did not reveal any evidence of reporting bias (P = 0.11), visualisation appears to suggest that there was reporting bias favouring glucocorticoids. </p> </section> </section> <section id="CD011646-sec-0103"> <h4 class="title">Sample size calculations and Trial Sequential Analysis</h4> <p>As shown in <a href="#CD011646-fig-0004">Figure 4</a>, <a href="#CD011646-fig-0005">Figure 5</a>, and <a href="#CD011646-fig-0006">Figure 6</a>, the accrued sample sizes were only small fractions of the diversity‐adjusted required information size (DARIS). The Z‐curve did not cross any of the trial sequential boundaries indicating that there was a high risk of random errors. The Trial Sequential Analysis‐adjusted CIs were as follows. </p> <div class="figure" id="CD011646-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis): glucocorticosteroids versus no intervention and pentoxifylline versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (78% and 56%), the accrued sample size (1147 participants for glucocorticosteroids versus no intervention and 881 participants for pentoxifylline versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (10,187 participants for glucocorticosteroids versus no intervention and 5232 participants for pentoxifylline versus no intervention). The Z‐curve (blue line) crosses the conventional boundaries (dotted green lines) favouring glucocorticosteroids and pentoxifylline for the two comparisons, but does not cross the conventional boundaries after the large trial (Thursz 2015). The Z‐curve does not cross any of trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons." data-id="CD011646-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis):</b> glucocorticosteroids versus no intervention and pentoxifylline versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (78% and 56%), the accrued sample size (1147 participants for glucocorticosteroids versus no intervention and 881 participants for pentoxifylline versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (10,187 participants for glucocorticosteroids versus no intervention and 5232 participants for pentoxifylline versus no intervention). The Z‐curve (blue line) crosses the conventional boundaries (dotted green lines) favouring glucocorticosteroids and pentoxifylline for the two comparisons, but does not cross the conventional boundaries after the large trial (<a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). The Z‐curve does not cross any of trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons. </p> </div> </div> </div> <div class="figure" id="CD011646-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis): colchicine versus no intervention and insulin plus glucagon versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (0% and 52%), the accrued sample size (139 participants for colchicine versus no intervention and 265 participants for insulin plus glucagon versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (2205 participants for colchicine versus no intervention and 4579 participants for insulin plus glucagon versus no intervention). The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons." data-id="CD011646-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis):</b> colchicine versus no intervention and insulin plus glucagon versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (0% and 52%), the accrued sample size (139 participants for colchicine versus no intervention and 265 participants for insulin plus glucagon versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (2205 participants for colchicine versus no intervention and 4579 participants for insulin plus glucagon versus no intervention). The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons. </p> </div> </div> </div> <div class="figure" id="CD011646-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis): propylthiouracil versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (0%), the accrued sample size (108 participants) was only a small proportion of the diversity‐adjusted required information size (DARIS) (2205 participants); therefore, the trial sequential monitoring boundaries were not drawn.The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines). This indicates that there is a high risk of random errors in this comparison." data-id="CD011646-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis):</b> propylthiouracil versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (0%), the accrued sample size (108 participants) was only a small proportion of the diversity‐adjusted required information size (DARIS) (2205 participants); therefore, the trial sequential monitoring boundaries were not drawn.The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines). This indicates that there is a high risk of random errors in this comparison. </p> </div> </div> </div> <p> <ul id="CD011646-list-0025"> <li> <p>Glucocorticosteroids versus no intervention: 0.66 (95% CI 0.07 to 6.05).</p> </li> <li> <p>Pentoxifylline versus no intervention: 0.77 (95% CI 0.25 to 2.39).</p> </li> <li> <p>Colchicine versus no intervention: 1.31 (95% CI 0.02 to 84.61).</p> </li> <li> <p>Insulin plus glucagon versus no intervention: 1.14 (95% CI 0.14 to 9.14).</p> </li> <li> <p>Propylthiouracil versus no intervention: not estimable (as the accrued sample size was very small). </p> </li> </ul> </p> <p>These wide confidence intervals indicate that there is high risk of random error.</p> <section id="CD011646-sec-0104"> <h5 class="title">Quality of the evidence</h5> <p>The quality of the evidence was low or very low for all the outcomes (<a href="./full#CD011646-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011646-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011646-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011646-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD011646-tbl-0005">summary of findings Table 5</a>). The reasons for downgrading include: high risk of bias in trials (downgraded by one level), heterogeneity in some comparisons as evidenced by differences in the effect estimates obtained by the fixed‐effect model and random‐effects model (downgraded by one level), imprecision (small sample size; downgraded by one level), and imprecision (confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction; downgraded by one level). </p> </section> </section> <section id="CD011646-sec-0105"> <h4 class="title">Subset of trials including severe alcoholic hepatitis exclusively</h4> <section id="CD011646-sec-0106"> <h5 class="title">Mortality at maximal follow‐up</h5> <p>A total of 18 trials including 2477 participants reported mortality at maximal follow‐up (<a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0050" title="PaladuguH , SawantP , DalviL , KudalkarJ . Role of pentoxifylline in treatment of severe acute alcoholic hepatitis ‐ a randomized controlled trial. Journal of Gastroenterology and Hepatology2006;21:A459. ">Paladugu 2006</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>) (<a href="./references#CD011646-fig-0020" title="">Analysis 2.1</a>). The follow‐up varied between one month and 12 months. There was no evidence of any differences in mortality at maximal follow‐up in any of the comparisons comparing active intervention versus no intervention. The results did not change using the random‐effects model. </p> </section> <section id="CD011646-sec-0107"> <h5 class="title">Early mortality (up to three months)</h5> <section id="CD011646-sec-0108"> <h6 class="title">Thirty‐days mortality</h6> <p>A total of 16 trials including 2330 participants reported 30‐days mortality (<a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0050" title="PaladuguH , SawantP , DalviL , KudalkarJ . Role of pentoxifylline in treatment of severe acute alcoholic hepatitis ‐ a randomized controlled trial. Journal of Gastroenterology and Hepatology2006;21:A459. ">Paladugu 2006</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>) (<a href="./references#CD011646-fig-0021" title="">Analysis 2.2</a>). There was no evidence of any differences in 30‐days mortality in any of the comparisons comparing active intervention versus no intervention. The results did not change using the random‐effects model. </p> </section> <section id="CD011646-sec-0109"> <h6 class="title">Ninety‐days mortality</h6> <p>A total of eight trials including 1656 participants reported 90‐days mortality (<a href="./references#CD011646-bbs2-0060" title="RamondMJ , PoynardT , RueffB , MathurinP , ChaputJC , BenhamouJP . [corticotherapy improves short‐term survival in patients with severe acute alcoholic hepatitis. A bicenter double‐blind randomized study]. Gastroenterologie Clinique Et Biologique1991;15(2 bis):A4. RamondMJ , PoynardT , RueffB , MathurinP , TheodoreC , ChaputJC , et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. New England Journal of Medicine1992;326:507‐12. RamondMJ , PoynardT , RueffB , TheodoreC , MatthurinP , ChaputJC , et al. Prednisolone markedly improves short‐term survival of patients with severe biopsy‐proven alcoholic hepatitis a double blind randomized bicenter trial. Journal of Hepatology1991;13(Suppl 2):S63. ">Ramond 1992</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>) (<a href="./references#CD011646-fig-0022" title="">Analysis 2.3</a>). There was no evidence of any differences in 90‐days mortality in any of the comparisons comparing active intervention versus no intervention. The results did not change using the random‐effects model. </p> </section> </section> <section id="CD011646-sec-0110"> <h5 class="title">Serious adverse events</h5> <p>Only one trial (1092 participants; four interventions) reported serious adverse events (proportion) (<a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>) (<a href="./references#CD011646-fig-0023" title="">Analysis 2.4</a>). There was no evidence of differences in any of the comparisons. Only one trial (35 participants) reported serious adverse events (number) (<a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>) (<a href="./references#CD011646-fig-0025" title="">Analysis 2.6</a>). The number of serious adverse events was higher in the glucocorticosteroids plus anti‐TNF group versus the glucocorticosteroids group (rate ratio 4.72; 95% CI 1.37 to 16.31). As there was only one trial in each comparison, the issue of random‐effects model did not arise. </p> </section> <section id="CD011646-sec-0111"> <h5 class="title">Health‐related quality of life</h5> <p>None of the trials reported health‐related quality of life at any time point.</p> </section> <section id="CD011646-sec-0112"> <h5 class="title">Liver transplantation</h5> <p>A total of two trials including 444 participants reported liver transplantation (<a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>) (<a href="./references#CD011646-fig-0025" title="">Analysis 2.6</a>). There was no evidence of differences in any of the comparisons. As there was only one trial in each comparison, the issue of random‐effects model did not arise. </p> </section> <section id="CD011646-sec-0113"> <h5 class="title">Decompensated cirrhosis</h5> <p>A total of 11 trials including 2095 participants reported decompensated cirrhosis (<a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0050" title="PaladuguH , SawantP , DalviL , KudalkarJ . Role of pentoxifylline in treatment of severe acute alcoholic hepatitis ‐ a randomized controlled trial. Journal of Gastroenterology and Hepatology2006;21:A459. ">Paladugu 2006</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>) (<a href="./references#CD011646-fig-0026" title="">Analysis 2.7</a>). There was no evidence of any differences in decompensated cirrhosis in any of the comparisons comparing active intervention versus no intervention. The results did not change using the random‐effects model. </p> </section> <section id="CD011646-sec-0114"> <h5 class="title">Cirrhosis</h5> <p>None of the trials reported the proportion of people who developed cirrhosis.</p> </section> <section id="CD011646-sec-0115"> <h5 class="title">Hepatocellular carcinoma</h5> <p>None of the trials reported the proportion of people who developed hepatocellular carcinoma. </p> </section> <section id="CD011646-sec-0116"> <h5 class="title">Any adverse events</h5> <p>A total of four trials including 241 participants reported adverse events (proportion) (<a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>) (<a href="./references#CD011646-fig-0027" title="">Analysis 2.8</a>). The proportion of people with any adverse events was higher in the pentoxifylline group versus the no intervention group (OR 2.21, 95% CI 1.10 to 4.46; 151 participants = 151; 2 trials). There was no evidence of any differences in any adverse events (proportion) in any of the remaining comparisons comparing active intervention versus no intervention. The results did not change using the random‐effects model. </p> <p>A total of 16 trials including 2386 participants reported adverse events (number) (<a href="./references#CD011646-bbs2-0002" title="AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Improved short‐term survival with pentoxifylline treatment in severe acute alcoholic hepatitis. Hepatology1997;26(4 (Pt 2)):250a. AkriviadisE , BotlaR , BriggsW , HanS , ReynoldsT , ShakilO . Pentoxifylline improves short‐term survival in severe acute alcoholic hepatitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:1637‐48. ">Akriviadis 2000</a>; <a href="./references#CD011646-bbs2-0070" title="SpahrL , Rubbia‐BrandtL , FrossardJL , GiostraE , RougemontAL , PuginJ , et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. Journal of Hepatology2002;37:448‐55. ">Spahr 2002</a>; <a href="./references#CD011646-bbs2-0046" title="NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Gastroenterology2004;126(4):A692. NaveauS , Chollet‐MartinS , DharancyS , MathurinP , JouetP , PiquetMA , et al. A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology2004;39(5):1390‐7. ">Naveau 2004</a>; <a href="./references#CD011646-bbs2-0015" title="DeBK , GangopadhyayS , DuttaD , BaksiSD , PaniA , GhoshP . Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World Journal of Gastroenterology2009;15(13):1613‐9. ">De 2009</a>; <a href="./references#CD011646-bbs2-0044" title="MorenoC , LangletP , HitteletA , EvrardS , LasserL , ColleI . Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial. Journal of Hepatology2009;50:S366. MorenoC , LangletP , HitteletA , LasserL , DegreD , EvrardS , et al. Enteral nutrition with or without N‐acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. Journal of Hepatology2010;53(6):1117‐22. ">Moreno 2010</a>; <a href="./references#CD011646-bbs2-0047" title="Nguyen‐KhacE , ThevenotT , PiquetM , BenferhatS , GoriaO , ChatelainD . Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Hepatology2009;50(4 (Suppl)):346a‐7a. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Glucocorticoids plus N‐acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine2011;365:1781‐9. Nguyen‐KhacE , ThevenotT , PiquetMA , BenferhatS , GoriaO , ChatelainD , et al. Treatment of severe acute alcoholic hepatitis (AAH) with corticoids plus N‐acetyl cysteine (C+NAC) versus corticoids alone (C): a multicentre, randomized, controlled trial. Journal of Hepatology2010;52:S38. ">Nguyen‐Khac 2011</a>; <a href="./references#CD011646-bbs2-0025" title="Garrido GarciaJR , SánchezHG , MelchorLA , ElizaldeBCI , SánchezVL . Pentoxifylline versus steroid in short‐term survival in severe acute alcoholic hepatitis. Medicina Interna de México2012;28(3):227‐33. ">Garrido Garcia 2012</a>; <a href="./references#CD011646-bbs2-0067" title="SidhuSS , GoyalO , SinglaP , GuptaD , ChhinaRS , SoodA . A prospective randomised trial to compare the efficacy of corticosteroids plus pentoxifylline versus corticosteroids alone in the treatment of severe alcoholic hepatitis. Journal of Hepatology2010;52:S306‐S. SidhuSS , GoyalO , SinglaP , GuptaD , SoodA , ChhinaRS , et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Digestive Diseases &amp; Sciences2012;57:1664‐71. ">Sidhu 2012a</a>; <a href="./references#CD011646-bbs2-0068" title="SidhuS , SinglaM , BhatiaKL . Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology2006;44(4 (Suppl 1)):373a‐4a. SidhuSS , GoyalO , SinglaM , BhatiaKL , ChhinaRS , SoodA . Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial. Journal of the Association of Physicians of India2012;60:20‐2. ">Sidhu 2012b</a>; <a href="./references#CD011646-bbs2-0037" title="LouvetA , DaoTM , NahonP , DiazE , CarbonellN , BoursierJ , et al. Pentoxifylline does not improve short‐term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. Journal of Hepatology2012;56:S533‐4. MathurinP , LouvetA , DuhamelA , NahonP , CarbonellN , BoursierJ , et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA2013;310:1033‐41. ">Mathurin 2013</a>; <a href="./references#CD011646-bbs2-0016" title="DeB , MandalS , SauD , ManiS , ChatterjeeS , MondalS , et al. Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial. Annals of Medical and Health Sciences Research2014;4(5):810‐6. ">De 2014</a>; <a href="./references#CD011646-bbs2-0052" title="KimDJ , SukKT , ParkSH , TakWY , YimHJ , UmSH , et al. Short‐term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non‐inferiority trial ‐ a preliminary report. Journal of Hepatology2013;58:S219‐20. ParkSH , KimDJ , KimYS , YimHJ , TakWY , LeeHJ , et al. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non‐inferiority, open trial. Journal of Hepatology2014;61:792‐8. ">Park 2014</a>; <a href="./references#CD011646-bbs2-0069" title="SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte colony‐stimulating factor in severe alcoholic hepatitis: a randomized pilot study. American Journal of Gastroenterology2014;109:1417‐23. SinghV , SharmaAK , NarasimhanRL , BhallaA , SharmaN , SharmaR . Granulocyte‐colony stimulating factor (G‐CSF) in alcoholic hepatitis: a randomized controlled trial. Gastroenterology2013;144(5 suppl. 1):S1004. ">Singh 2014</a>; <a href="./references#CD011646-bbs2-0030" title="Higuera‐de la TijeraF , Servin‐CaamanoAI , Cruz‐HerreraJ , Serralde‐ZunigaAE , Abdo‐FrancisJM , Gutierrez‐ReyesG , et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Annals of Hepatology2014;13:343‐52. Higuera‐de la TijeraF , Servin‐CaamanoAI , Serralde‐ZunigaAE , Cruz‐HerreraJ , Perez‐TorresE , Abdo‐FrancisJM , et al. Metadoxine improves the three‐ and six‐month survival rates in patients with severe alcoholic hepatitis. World Journal of Gastroenterology2015;21(16):4975‐85. ">Higuera de la Tijera 2015</a>; <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>; <a href="./references#CD011646-bbs2-0077" title="TkachenkoP , KomkovaI , MaevskayaM , IvashkinV . Prednisolone plus S‐adenosylmethionine in severe alcoholic hepatitis. Journal of Hepatology2016;64(2 suppl. 1):S239. TkachenkoP , MaevskayaM , PavlovA , KomkovaI , PavlovC , IvashkinV . Prednisolone plus S‐adenosil‐L‐methionine in severe alcoholic hepatitis. Hepatology International2016;10(6):983‐7. ">Tkachenko 2016</a>) (<a href="./references#CD011646-fig-0028" title="">Analysis 2.9</a>). There was no evidence of any differences in any adverse events (number) in any of the comparisons comparing active intervention versus no intervention. The results did not change using the random‐effects model. </p> </section> <section id="CD011646-sec-0117"> <h5 class="title">Subgroup analysis and sensitivity analysis</h5> <p>We did not perform any subgroup analysis because all the trials were at high risk of bias; separate data were not available in biopsy‐confirmed alcohol‐related liver disease in many trials, and because of the few trials included in each comparison. We did not perform a sensitivity analysis since the reasons for dropouts were not adequately described in each intervention group to perform a meaningful sensitivity analysis. </p> </section> <section id="CD011646-sec-0118"> <h5 class="title">Reporting bias</h5> <p>As there was no comparison including more than 10 trials, we did not explore reporting bias. </p> </section> <section id="CD011646-sec-0119"> <h5 class="title">Sample size calculations and Trial Sequential Analysis</h5> <p>As shown in <a href="#CD011646-fig-0007">Figure 7</a>, the accrued sample sizes were only small fractions of the diversity‐adjusted required information size (DARIS).The Z‐curve did not cross any of the trial sequential boundaries indicating that there was a high risk of random errors. The Trial Sequential Analysis‐adjusted CIs were as follows. </p> <div class="figure" id="CD011646-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (severe alcoholic hepatitis): glucocorticosteroids versus no intervention and pentoxifylline versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 40.9%), and diversity observed in the analyses (98% and 76%), the accrued sample size (607 participants for glucocorticosteroids versus no intervention and 726 participants for pentoxifylline versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (72,755 participants for glucocorticosteroids versus no intervention and 7148 participants for pentoxifylline versus no intervention). For glucocorticosteroids versus no intervention, the accrued sample size was so small that the trial sequential monitoring boundaries were not drawn. The Z‐curve (blue line) crosses the conventional boundaries (dotted green lines) favouring glucocorticosteroids and pentoxifylline for the two comparisons, but does not cross the conventional boundaries after the large trial (Thursz 2015). The Z‐curve does not cross any of trial sequential monitoring boundaries (dotted red lines) for pentoxifylline versus no intervention. This indicates that there is a high risk of random errors in both these comparisons." data-id="CD011646-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (severe alcoholic hepatitis):</b> glucocorticosteroids versus no intervention and pentoxifylline versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 40.9%), and diversity observed in the analyses (98% and 76%), the accrued sample size (607 participants for glucocorticosteroids versus no intervention and 726 participants for pentoxifylline versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (72,755 participants for glucocorticosteroids versus no intervention and 7148 participants for pentoxifylline versus no intervention). For glucocorticosteroids versus no intervention, the accrued sample size was so small that the trial sequential monitoring boundaries were not drawn. The Z‐curve (blue line) crosses the conventional boundaries (dotted green lines) favouring glucocorticosteroids and pentoxifylline for the two comparisons, but does not cross the conventional boundaries after the large trial (<a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). The Z‐curve does not cross any of trial sequential monitoring boundaries (dotted red lines) for pentoxifylline versus no intervention. This indicates that there is a high risk of random errors in both these comparisons. </p> </div> </div> </div> <p> <ul id="CD011646-list-0026"> <li> <p>Glucocorticosteroids versus no intervention: not estimable (as the accrued sample size was only a small fraction of required information size). </p> </li> <li> <p>Pentoxifylline versus no intervention: 0.60 (95% CI 0.05 to 7.48).</p> </li> </ul> </p> <p>These wide confidence intervals indicate that there is high risk of random error.</p> </section> <section id="CD011646-sec-0120"> <h5 class="title">Quality of the evidence</h5> <p>The quality of the evidence was low or very low for all the outcomes (<a href="./full#CD011646-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD011646-tbl-0007">summary of findings Table 7</a>). The reasons for downgrading include: high risk of bias in trials (downgraded by one level), imprecision (small sample size; downgraded by one level), and imprecision (confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction; downgraded by one level). </p> </section> </section> <section id="CD011646-sec-0121"> <h4 class="title">Alcohol‐related liver diseases (others)</h4> <section id="CD011646-sec-0122"> <h5 class="title">Mortality at maximal follow‐up</h5> <p>A total of 16 trials including 2727 participants reported mortality at maximal follow‐up (<a href="./references#CD011646-bbs2-0022" title="FensterLF . The non efficacy of short‐term anabolic steroid therapy in alcoholic liver disease. Annals of Internal Medicine1966;65:738‐44. ">Fenster 1966</a>; <a href="./references#CD011646-bbs2-0026" title="GeminianiS , MazellaG , AldiniR , BazzoliF , MorselliA M , RossiR , et al. Effect of cycloxilic acid administration on ethanol‐induced hepatic steatosis. Controlled clinical trial. Farmaco ‐ Edizione Pratica1979;34:449‐55. ">Geminiani 1979</a>; <a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0055" title="PierriG , GiorgioA , AmorosoP , FicoP , FinelliL . Epomediol treatment of fatty liver in alcohol abuse. A controlled clinical double‐blind study. Clinica Terapeutica1985;112:527‐35. ">Pierri 1985</a>; <a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0009" title="BoriesP , GuedjJY , MirouzeD , YousfiA , MichelH . Treatment of acute alcoholic hepatitis with prednisolone. 45 patients. Presse Medicale1987;16(16):769‐72. ">Bories 1987</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0017" title="De laMazaMP , PetermannM , BunoutD , HirschS . Effects of long‐term vitamin E supplementation in alcoholic cirrhotics. Journal of the American College of Nutrition1995;14:192‐6. ">De la Maza 1995</a>; <a href="./references#CD011646-bbs2-0024" title="FleigWE , MorganMY , HolzerMA . The ayurvedic medicine LIV.52 in alcoholic cirrhosis of the liver: Results of a prospective, randomised, double‐blind, placebo‐controlled, clinical study. Zeitschrift fur Gastroenterologie1998;36:100. FleigWE , MorganMY , HölzerMA . The ayurvedic drug Liv52 in patients with alcoholic cirrhosis results of a prospective, randomized, doubleblind, placebo‐controlled clinical trial. Journal of Hepatology1997;26(Suppl 1):S127. ">Fleig 1997</a>; <a href="./references#CD011646-bbs2-0010" title="CaballeriaJ . Metadoxine in the treatment of alcoholic fatty liver a randomized multicenter trial. Hepatology1996;24(4 (Pt 2)):444a. CaballeriaJ , ParesA , BruC , MercaderJ , Garcia PlazaA , CaballeriaL , et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double‐blind, placebo‐control trial. Spanish Group for the Study of Alcoholic Fatty Liver. Journal of Hepatology1998;28:54‐60. ">Caballeria 1998</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0053" title="PelletierG , RoulotD , DavionT , MasliahC , CausseX , ObertiF , et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol‐induced cirrhosis and jaundice. Hepatology2003;37:887‐92. ">Pelletier 2003</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>) (<a href="./references#CD011646-fig-0029" title="">Analysis 3.1</a>). The period of follow‐up ranged from one month to 48 months. The risk of mortality at maximal follow‐up was lower in the propylthiouracil group versus the no intervention group (OR 0.45, 95% CI 0.26 to 0.78; 423 participants; 2 trials). The risk of mortality at maximal follow‐up was higher in the ursodeoxycholic acid group versus the no intervention group (OR 2.09, 95% CI 1.12 to 3.90; 226 participants; 1 trial). There was no evidence of difference in any of the remaining comparisons. </p> </section> <section id="CD011646-sec-0123"> <h5 class="title">Early mortality (up to three months)</h5> <section id="CD011646-sec-0124"> <h6 class="title">Thirty‐days mortality</h6> <p>A total of six trials including 580 participants reported 30‐days mortality (<a href="./references#CD011646-bbs2-0026" title="GeminianiS , MazellaG , AldiniR , BazzoliF , MorselliA M , RossiR , et al. Effect of cycloxilic acid administration on ethanol‐induced hepatic steatosis. Controlled clinical trial. Farmaco ‐ Edizione Pratica1979;34:449‐55. ">Geminiani 1979</a>; <a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0055" title="PierriG , GiorgioA , AmorosoP , FicoP , FinelliL . Epomediol treatment of fatty liver in alcohol abuse. A controlled clinical double‐blind study. Clinica Terapeutica1985;112:527‐35. ">Pierri 1985</a>; <a href="./references#CD011646-bbs2-0009" title="BoriesP , GuedjJY , MirouzeD , YousfiA , MichelH . Treatment of acute alcoholic hepatitis with prednisolone. 45 patients. Presse Medicale1987;16(16):769‐72. ">Bories 1987</a>; <a href="./references#CD011646-bbs2-0010" title="CaballeriaJ . Metadoxine in the treatment of alcoholic fatty liver a randomized multicenter trial. Hepatology1996;24(4 (Pt 2)):444a. CaballeriaJ , ParesA , BruC , MercaderJ , Garcia PlazaA , CaballeriaL , et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double‐blind, placebo‐control trial. Spanish Group for the Study of Alcoholic Fatty Liver. Journal of Hepatology1998;28:54‐60. ">Caballeria 1998</a>; <a href="./references#CD011646-bbs2-0053" title="PelletierG , RoulotD , DavionT , MasliahC , CausseX , ObertiF , et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol‐induced cirrhosis and jaundice. Hepatology2003;37:887‐92. ">Pelletier 2003</a>) (<a href="./references#CD011646-fig-0030" title="">Analysis 3.2</a>). There was no evidence of difference in any of the comparisons. There was only one trial included in each comparison. Therefore, random‐effects model was not applicable. </p> </section> <section id="CD011646-sec-0125"> <h6 class="title">Ninety‐days mortality</h6> <p>A total of three trials including 208 participants reported 90‐days mortality (<a href="./references#CD011646-bbs2-0055" title="PierriG , GiorgioA , AmorosoP , FicoP , FinelliL . Epomediol treatment of fatty liver in alcohol abuse. A controlled clinical double‐blind study. Clinica Terapeutica1985;112:527‐35. ">Pierri 1985</a>; <a href="./references#CD011646-bbs2-0009" title="BoriesP , GuedjJY , MirouzeD , YousfiA , MichelH . Treatment of acute alcoholic hepatitis with prednisolone. 45 patients. Presse Medicale1987;16(16):769‐72. ">Bories 1987</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>) (<a href="./references#CD011646-fig-0031" title="">Analysis 3.3</a>). There was no evidence of difference in any of the comparisons. There was only one trial included in each comparison. Therefore, random‐effects model was not applicable. </p> </section> </section> <section id="CD011646-sec-0126"> <h5 class="title">Serious adverse events</h5> <p>Only one trial (37 participants) reported serious adverse events (proportion) (<a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>) (<a href="./references#CD011646-fig-0032" title="">Analysis 3.4</a>). There were no serious adverse events in either SAMe or no intervention groups. None of the trials reported serious adverse events (number). </p> </section> <section id="CD011646-sec-0127"> <h5 class="title">Health‐related quality of life</h5> <p>None of the trials reported health‐related quality of life at any time point.</p> </section> <section id="CD011646-sec-0128"> <h5 class="title">Liver transplantation</h5> <p>Only one trial including 123 participants reported liver transplantation (<a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>) (<a href="./references#CD011646-fig-0033" title="">Analysis 3.5</a>). There was no evidence of difference between SAMe and no intervention (OR 0.32, 95% CI 0.03 to 3.13; 123 participants; 1 trial). </p> </section> <section id="CD011646-sec-0129"> <h5 class="title">Decompensated cirrhosis</h5> <p>A total of three trials including 1182 participants reported decompensated cirrhosis (<a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0053" title="PelletierG , RoulotD , DavionT , MasliahC , CausseX , ObertiF , et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol‐induced cirrhosis and jaundice. Hepatology2003;37:887‐92. ">Pelletier 2003</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>) (<a href="./references#CD011646-fig-0034" title="">Analysis 3.6</a>). There was no evidence of difference in any of the comparisons. There was only one trial included in each comparison. Therefore, random‐effects model was not applicable. </p> </section> <section id="CD011646-sec-0130"> <h5 class="title">Cirrhosis</h5> <p>None of the trials reported the proportion of people who developed cirrhosis.</p> </section> <section id="CD011646-sec-0131"> <h5 class="title">Hepatocellular carcinoma</h5> <p>A total of two trials including 344 participants reported hepatocellular carcinoma (<a href="./references#CD011646-bbs2-0027" title="GluudC . Effect of testosterone treatment in men with alcoholic cirrhosis. Journal of Hepatology1985;1(Suppl 1):S59. The Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double‐blind study. The Copenhagen Study Group for Liver Diseases. Hepatology1986;6(5):807‐13. ">Gluud 1986</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>) (<a href="./references#CD011646-fig-0035" title="">Analysis 3.7</a>). There was no evidence of difference in any of the comparisons. There was only one trial included in each comparison. Therefore, random‐effects model was not applicable. </p> </section> <section id="CD011646-sec-0132"> <h5 class="title">Any adverse events</h5> <p>A total of 18 trials including 2342 participants reported adverse events (proportion) (<a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0021" title="FeherJ , DeakG , MuzesG , LangI , NiederlandV , NekamK , et al. Liver‐protective action of silymarin therapy in chronic alcoholic liver diseases. Orvosi Hetilap1989;130:2723‐7. ">Feher 1989</a>; <a href="./references#CD011646-bbs2-0074" title="TakaseS , MatsudaY , YasuharaM , TakadaA . Effects of malotilate treatment on alcoholic liver disease. Alcohol1989;6(3):219‐22. TakaseS , TakadaA , YasuharaM , SatoH , MatsudaY . Effects of malotilate treatment on the serum markers of hepatic fibrogenesis in liver cirrhosis. Gastroenterologia Japonica1988 Dec;23(6):639‐45. ">Takase 1989</a>; <a href="./references#CD011646-bbs2-0056" title="PlevrisJN , HayesPC , BouchierIAD . Ursodeoxycholic acid in the treatment of alcoholic liver‐disease. European Journal of Gastroenterology &amp; Hepatology1991;3:653‐6. PlevrisJN , JonesAL , DawkesR , HowieAF , BouchierIAD , HayesPC . Ursodeoxycholic acid in the treatment of alcoholic liver disease. Gut1993;34(4):S7. ">Plevris 1991</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0034" title="LottererE , EtzelR . LIV. 52 in patients with alcoholic liver cirrhosis ‐ pilot study of a controlled clinical trial. Forschende Komplementärmedizin1995;2:12‐4. ">Lotterer 1995</a>; <a href="./references#CD011646-bbs2-0020" title="Diaz BelmontA , Dominguez HenkelR , Uribe AnciraF . Parenteral S‐adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases. Anales de Medicina Interna1996;13:9‐15. ">Diaz Belmont 1996</a>; <a href="./references#CD011646-bbs2-0081" title="VelussiM , CernigoiAM , DeMonteA , DapasF , CaffauC , ZilliM . Long‐term (12 months) treatment with an anti‐oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Journal of Hepatology1997;26:871‐9. VelussiM , CernigoiAM , ViezzoliL , DapasF , CaffauC , ZilliM . Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Current Therapeutic Research ‐ Clinical and Experimental1993;53(5):533‐45. ">Velussi 1997</a>; <a href="./references#CD011646-bbs2-0010" title="CaballeriaJ . Metadoxine in the treatment of alcoholic fatty liver a randomized multicenter trial. Hepatology1996;24(4 (Pt 2)):444a. CaballeriaJ , ParesA , BruC , MercaderJ , Garcia PlazaA , CaballeriaL , et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double‐blind, placebo‐control trial. Spanish Group for the Study of Alcoholic Fatty Liver. Journal of Hepatology1998;28:54‐60. ">Caballeria 1998</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0019" title="deSilvaHA , SaparamaduPA , ThabrewMI , PathmeswaranA , FonsekaMM , deSilvaHJ . Liv.52 in alcoholic liver disease: a prospective, controlled trial. Journal of Ethnopharmacology2003;84:47‐50. ">De Silva 2003</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>; <a href="./references#CD011646-bbs2-0032" title="KimMY , BaikSK , JangYO , YeaCJ , WonCS , ByunJW , et al. The beneficial effect of angiotensin‐blocking agent on liver fibrosis in patients with alcoholic liver disease: a randomized controlled trial. Hepatology2009;50:812A‐3A. KimMY , ChoMY , BaikSK , JeongPH , SukKT , JangYO , et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ a randomized open‐label controlled study. Liver International2012;32:977‐87. ">Kim 2012</a>) (<a href="./references#CD011646-fig-0036" title="">Analysis 3.8</a>). There was no evidence of difference in any of the comparisons. Using the random‐effects model, there was no alteration in the results.<br/> <br/> A total of 11 trials including 1965 participants reported adverse events (number) (<a href="./references#CD011646-bbs2-0010" title="CaballeriaJ . Metadoxine in the treatment of alcoholic fatty liver a randomized multicenter trial. Hepatology1996;24(4 (Pt 2)):444a. CaballeriaJ , ParesA , BruC , MercaderJ , Garcia PlazaA , CaballeriaL , et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double‐blind, placebo‐control trial. Spanish Group for the Study of Alcoholic Fatty Liver. Journal of Hepatology1998;28:54‐60. ">Caballeria 1998</a>; <a href="./references#CD011646-bbs2-0014" title="Cortez PintoH , AlexandrinoP , CamiloME , Couveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double‐blind randomized trial. Hepatology2000;32(4 (Pt 2)):423a. Cortez PintoH , AlexandrinoP , SantosPM , AlvesMM , CamiloME , MouraMC . Colchicine in alcoholic cirrhosis ‐ preliminary results of a double‐blind randomized trial. Hepatology1992;16(2 (Pt 2)):229a. Cortez‐PintoH , AlexandrinoP , CamiloME , Gouveia‐OliveiraA , SantosPM , AlvesMM , et al. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. European Journal of Gastroenterology &amp; Hepatology2002;14:377‐81. ">Cortez‐Pinto 2002</a>; <a href="./references#CD011646-bbs2-0023" title="Fernandez‐RodriguezCM , LledoJL , Lopez‐SerranoP , GutierrezML , AlonsoS , Perez‐FernandezMT , et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis‐a randomized double‐blind placebo‐controlled trial. Revista Espanola de Enfermedades Digestivas2008;100:481‐9. Fernandez‐RodriguezCM , LledóJL , Lopez SerranoP , AlonsoS , CerroJ , Sanz‐MayordomoP . Pentoxifylline ameliorates vasodilation and left ventricular function in alcoholic cirrhosis. Journal of Hepatology2005;42(Suppl 2):80. ">Fernandez‐Rodriguez 2008</a>; <a href="./references#CD011646-bbs2-0031" title="KeidingS , BadsbergJH , BeckerU , BentsenKD , BonnevieO , CaballeriaJ , et al. The prognosis of patients with alcoholic liver disease. An international randomized, placebo‐controlled trial on the effect of malotilate on survival. Journal of Hepatology1994;20:454‐60. KeidingS , BendtsenK , BeckerU , BonnevieO , HardtF , JuhlE , et al. Malotilate in alcoholic liver disease a randomized, double‐blind, international trial of the effect of long‐term treatment on survival. Hepatology1990;12(2):419. ">Keiding 1994</a>; <a href="./references#CD011646-bbs2-0038" title="MatoJM , CamaraJ , Fernandez de PazJ , CaballeriaL , CollS , CaballeroA , et al. S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. Journal of Hepatology1999;30:1081‐9. MatoJM , CamaraJ , OrtizP , RodesJ . S‐adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric placebo‐controlled, randomized, double‐blind clinical trial. Hepatology1997;26(4 (Pt 2)):251a. ">Mato 1999</a>; <a href="./references#CD011646-bbs2-0040" title="MediciV , VirataMC , PeersonJM , StablerSP , FrenchSW , GregoryJF3rd , et al. S‐adenosyl‐L‐methionine treatment for alcoholic liver disease: a double‐blinded, randomized, placebo‐controlled trial. Alcoholism, Clinical and Experimental Research2011;35:1960‐5. ">Medici 2011</a>; <a href="./references#CD011646-bbs2-0045" title="MorganTR , NemchauskyB , SchiffE , AnandBS , BloorJ , KidaoJ , et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: Results of a prospective, randomized, placebo‐controlled, multicenter VA trial (CSP 352). Gastroenterology2002;122(4):A641. MorganTR , WeissDG , NemchauskyB , SchiffER , AnandB , SimonF , et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882‐90. ">Morgan 2005</a>; <a href="./references#CD011646-bbs2-0048" title="OrregoH , KalantH , IsraelY , BlakeJ , MedlineA , RankinJG , et al. Effect of short‐term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology1979;76:105‐15. ">Orrego 1979</a>; <a href="./references#CD011646-bbs2-0049" title="OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Lancet1988;1(8590):892. OrregoH , BlakeJE , BlendisLM , ComptonKV , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. New England Journal of Medicine1987;317:1421‐7. OrregoH , BlakeJE , BlendisLM , ComptonKV , VolpeR , IsraelY . Long‐term treatment of alcoholic liver disease with propylthiouracil. Part 2: influence of drop‐out rates and of continued alcohol consumption in a clinical trial. Journal of Hepatology1994;20(3):343‐9. ">Orrego 1987</a>; <a href="./references#CD011646-bbs2-0051" title="ParesA , PlanasR , TorresM , CaballeriaJ , ViverJM , AceroD , et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double‐blind, randomized and multicenter trial. Journal of Hepatology1998;28:615‐21. ">Pares 1998</a>; <a href="./references#CD011646-bbs2-0056" title="PlevrisJN , HayesPC , BouchierIAD . Ursodeoxycholic acid in the treatment of alcoholic liver‐disease. European Journal of Gastroenterology &amp; Hepatology1991;3:653‐6. PlevrisJN , JonesAL , DawkesR , HowieAF , BouchierIAD , HayesPC . Ursodeoxycholic acid in the treatment of alcoholic liver disease. Gut1993;34(4):S7. ">Plevris 1991</a>) (<a href="./references#CD011646-fig-0037" title="">Analysis 3.9</a>). There was no evidence of difference in any of the comparisons. Changing the model from fixed‐effect model to random‐effects model did not alter the conclusions. </p> </section> <section id="CD011646-sec-0133"> <h5 class="title">Subgroup analysis and sensitivity analysis</h5> <p>We did not perform any subgroup analysis because all the trials were at high risk of bias; separate data were not available in biopsy‐confirmed alcohol‐related liver disease in many trials, and because of the few trials included in each comparison. We did not perform a sensitivity analysis because the reasons for dropouts were not adequately described in each intervention group in order to perform a meaningful sensitivity analysis. </p> </section> <section id="CD011646-sec-0134"> <h5 class="title">Reporting bias</h5> <p>Since there was no comparison with more than 10 trials, we did not explore reporting bias. </p> <p>As shown in <a href="#CD011646-fig-0008">Figure 8</a> and <a href="#CD011646-fig-0009">Figure 9</a>, the accrued sample sizes were only small fractions of the diversity‐adjusted required information size (DARIS).The Z‐curve did not cross any of the trial sequential boundaries indicating that there was a high risk of random errors. The Trial Sequential Analysis‐adjusted CIs were as follows. </p> <div class="figure" id="CD011646-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (alcohol‐related disorders (others)): anabolic steroids versus no intervention and antioxidants versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 25.2%), and diversity observed in the analyses (0% in the both the comparisons), the accrued sample size (248 participants for anabolic steroids versus no intervention and 255 participants for antioxidants versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (3428 participants for both comparisons). The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons." data-id="CD011646-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (alcohol‐related disorders (others)):</b> anabolic steroids versus no intervention and antioxidants versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 25.2%), and diversity observed in the analyses (0% in the both the comparisons), the accrued sample size (248 participants for anabolic steroids versus no intervention and 255 participants for antioxidants versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (3428 participants for both comparisons). The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons. </p> </div> </div> </div> <div class="figure" id="CD011646-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (alcohol‐related disorders (others)): colchicine versus no intervention and propylthiouracil versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 25.2%), and diversity observed in the analyses (44% and 0%), the accrued sample size (604 participants for colchicine versus no intervention and 423 participants for propylthiouracil versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (6071 participants for colchicine versus no intervention and 3428 participants for propylthiouracil versus no intervention). For the comparison of colchicine versus no intervention, the Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). For the comparison, propylthiouracil versus no intervention, the Z‐curve crosses the conventional boundaries while it does not cross the trial sequential monitoring boundaries. This indicates that there is a high risk of random errors in both these comparisons." data-id="CD011646-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (alcohol‐related disorders (others)):</b> colchicine versus no intervention and propylthiouracil versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 25.2%), and diversity observed in the analyses (44% and 0%), the accrued sample size (604 participants for colchicine versus no intervention and 423 participants for propylthiouracil versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (6071 participants for colchicine versus no intervention and 3428 participants for propylthiouracil versus no intervention). For the comparison of colchicine versus no intervention, the Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). For the comparison, propylthiouracil versus no intervention, the Z‐curve crosses the conventional boundaries while it does not cross the trial sequential monitoring boundaries. This indicates that there is a high risk of random errors in both these comparisons. </p> </div> </div> </div> <p> <ul id="CD011646-list-0027"> <li> <p>Anabolic steroids versus no intervention: 1.29 (95% CI 0.11 to 15.86).</p> </li> <li> <p>Antioxidants versus no intervention: 1.96 (95% CI 0.12 to 31.91).</p> </li> <li> <p>Colchicine versus no intervention: 1.11 (95% CI 0.30 to 4.15).</p> </li> <li> <p>Propylthiouracil versus no intervention: 0.45 (95% CI 0.05 to 4.13).</p> </li> </ul> </p> <p>These wide confidence intervals indicate that there is high risk of random error.</p> </section> <section id="CD011646-sec-0135"> <h5 class="title">Quality of the evidence</h5> <p>The quality of the evidence was low or very low for all the outcomes (<a href="./full#CD011646-tbl-0008">summary of findings Table 8</a>; <a href="./full#CD011646-tbl-0009">summary of findings Table 9</a>; <a href="./full#CD011646-tbl-0010">summary of findings Table 10</a>; <a href="./full#CD011646-tbl-0011">summary of findings Table 11</a>). The reasons for downgrading include: high risk of bias in trials (downgraded by one level), heterogeneity in some comparisons as evidenced by differences in the effect estimates obtained by fixed‐effect model and random‐effects model (downgraded by one level), imprecision (small sample size; downgraded by one level), and imprecision (confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction; downgraded by one level). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011646-sec-0136" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011646-sec-0136"></div> <section id="CD011646-sec-0137"> <h3 class="title" id="CD011646-sec-0137">Summary of main results</h3> <section id="CD011646-sec-0138"> <h4 class="title">Alcoholic hepatitis</h4> <p>A total of 50 trials (4484 participants with alcoholic hepatitis) were included under this comparison. A total of 48 trials (4335 participants) contributed to one or more outcomes. The type of participants included in the trials appeared to have different severity. Therefore, network meta‐analysis was inappropriate because of the possible violation of transitivity assumption. None of the active interventions reduced mortality at any time point versus no intervention. On the other hand, anti‐tumour necrosis factor (anti‐TNF) may increase the complications and mortality. None of the trials reported health‐related quality of life. There was no improvement in any of the clinical outcomes such as cirrhosis, decompensated cirrhosis, liver transplantation by any active interventions compared with no intervention. None of the trials reported the proportion of participants who developed hepatocellular carcinoma. Overall, there does not appear to be any benefit with any active intervention in participants with alcoholic hepatitis. However, it should be noted that the trials included were at high risk of bias and quality of the evidence was low, as described below. So, there is significant uncertainty in this. </p> </section> <section id="CD011646-sec-0139"> <h4 class="title">Severe acute alcoholic hepatitis</h4> <p>A total of 19 trials (2545 participants with severe alcoholic hepatitis) were included under this comparison. A total of 18 trials (2477 participants) contributed to one or more outcomes. Although the type of participants included in the trials appeared to be similar across comparisons (<a href="./appendices#CD011646-sec-0178">Appendix 4</a>), there was evidence of inconsistency by one or more methods in all the outcomes in which it was possible to assess inconsistency. Therefore, we have presented the results of network meta‐analysis in the appendix and have presented only the main comparisons. As for the participants with alcoholic hepatitis of any severity, there was no evidence of differences indicating any clinical benefit of any active interventions versus no intervention. On the other hand, anti‐TNF may increase the complications. </p> <p>Based on the network meta‐analysis (which we have presented in the appendix because of the uncertainty about the reliability of the results), it appears that granulocyte stimulation factor (GSF) plus pentoxifylline, glucocorticosteroids plus metadoxine, and pentoxifylline plus metadoxine may decrease mortality at maximal follow‐up compared with no intervention. However, it should be noted that these estimates are based on indirect comparisons and were based on single small trials. While these interventions warrant further investigation by direct comparisons in new trials, it is not appropriate to recommend these interventions based on the network meta‐analysis results. </p> </section> <section id="CD011646-sec-0140"> <h4 class="title">Alcohol‐related liver disease (others)</h4> <p>A total of 31 trials (3695 participants with different phases of alcohol‐related liver disease) were included under this comparison. A total of 26 trials (3212 participants) contributed to one or more outcomes. The risk of mortality at maximal follow‐up was lower in the propylthiouracil group versus the no intervention group and higher in the ursodeoxycholic acid group versus the no intervention group. However, the trials which were included in the comparison between propylthiouracil and no intervention were reported in 1979 and 1987. These were small trials of high risk of bias. In addition, the risk of random errors was high as demonstrated by Trial Sequential Analysis. As a result, trials of low risk of bias of sufficient sample size are required before propylthiouracil can be recommended routinely. </p> <p>Health‐related quality of life and the incidence of cirrhosis was not reported in any of the trials. There was no evidence of any clinical benefit in terms of decompensated cirrhosis or liver transplantation. Therefore, there is nothing to suggest that any active intervention improves clinical outcomes in people with any type of alcohol‐related liver disease. </p> </section> </section> <section id="CD011646-sec-0141"> <h3 class="title" id="CD011646-sec-0141">Overall completeness and applicability of evidence</h3> <p>In this review, we have included all the randomised clinical trials on people with alcohol‐related liver disease with and without evidence of alcoholic hepatitis. However, the majority of the trials excluded participants with infection or gastrointestinal bleeding. This is likely to be because of the harmful effect of glucocorticosteroids, which were used in many of the trials either alone or in combination. Therefore, the findings of the review are only applicable in people with alcoholic hepatitis or other forms of alcoholic liver disease who do not have infections or gastrointestinal bleeding. </p> </section> <section id="CD011646-sec-0142"> <h3 class="title" id="CD011646-sec-0142">Quality of the evidence</h3> <p>The overall quality of the evidence was low or very low for all the comparisons. The quality of the evidence was low or very low for all the outcomes. The reasons for downgrading include: high risk of bias in trials (downgraded by one level), imprecision (small sample size; downgraded by one level), and imprecision (confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction; downgraded by one level). </p> </section> <section id="CD011646-sec-0143"> <h3 class="title" id="CD011646-sec-0143">Potential biases in the review process</h3> <p>We selected a range of databases without any language restrictions. We did not rely on the network meta‐analysis results when we suspected the transitivity assumption may not be true or when the evidence was based on small trials of high risk of bias. In addition, we have performed the analysis using the fixed‐effect model and the random‐effects model, and used the more conservative model. We have also assessed the risk of random errors using Trial Sequential Analysis. These are the strengths of the review process. </p> <p>We have excluded studies which compared variations in duration or dose in the different treatments. Hence this review does not provide information on whether one variation is better than other. Another major limitation of the review was the paucity of data. There were few trials included under each comparison. In many comparisons, there was only one trial included under the comparison. This makes it difficult to assess whether the effect estimates are reproducible. This paucity of data decreases the confidence in the results. </p> <p>We only included randomised clinical trials which are known to focus mostly on benefits and do not collect and report harms in a detailed manner. According to our choice of studies (i.e. only randomised clinical trials), we might have missed a large number of studies that address reporting of harms. Accordingly, this review is biased towards benefits ignoring harms. We did not search for interventions and trials registered at regulatory authorities (e.g. FDA (US Food and Drug Administration); EMA (European Medicines Agency), etc). This may have overlooked trials and as such trials usually are unpublished, the lack of inclusion of such trials may make our comparisons look more advantageous than they really are. </p> </section> <section id="CD011646-sec-0144"> <h3 class="title" id="CD011646-sec-0144">Agreements and disagreements with other studies or reviews</h3> <p>We identified one other network meta‐analysis on severe alcoholic hepatitis (<a href="./references#CD011646-bbs2-0169" title="SinghS , MuradMH , ChandarAK , BongiornoCM , SingalAK , AtkinsonSR , et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta‐analysis. Gastroenterology2015;149(4):958‐70.e12. ">Singh 2015</a>). The authors concluded that in patients with severe alcoholic hepatitis, pentoxifylline and corticosteroids (alone and in combination with pentoxifylline or N‐acetyl cysteine) can reduce 30‐day mortality. No intervention decreases risk of mortality between three months and 12 months. Our conclusions differ because we did not rely on the results of the network meta‐analysis of uncertain reliability. </p> <p>Our conclusions also differ from the Cochrane review on propylthiouracil (<a href="./references#CD011646-bbs2-0129" title="FedeG , GermaniG , GluudC , GurusamyKS , BurroughsAK . Propylthiouracil for alcoholic liver disease. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD002800.pub3] ">Fede 2011</a>). This was because we performed a separate analysis of alcoholic hepatitis and other alcoholic liver disease. Our review agrees with the findings of the Cochrane review on pentoxifylline, which concluded that the evidence on the effect of pentoxifylline was inconclusive (<a href="./references#CD011646-bbs2-0180" title="WhitfieldK , RambaldiA , WetterslevJ , GluudC . Pentoxifylline for alcoholic hepatitis. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007339.pub2] ">Whitfield 2009</a>). The findings of our review do not agree with the findings of a systematic review on glucocorticosteroids which concluded that glucocorticosteroids might be effective in people with severe alcoholic hepatitis and that further randomised clinical trials were necessary (<a href="./references#CD011646-bbs2-0157" title="RambaldiA , SaconatoHH , ChristensenE , ThorlundK , WetterslevJ , GluudC . Systematic review: glucocorticosteroids for alcoholic hepatitis‐‐a Cochrane Hepato‐Biliary Group systematic review with meta‐analyses and trial sequential analyses of randomized clinical trials. Alimentary Pharmacology &amp; Therapeutics2008;27(12):1167‐78. ">Rambaldi 2008</a>). A large randomised clinical trial demonstrating no evidence of effect of glucocorticosteroids or pentoxifylline, or their combination on people with severe alcoholic disease was published by <a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>, and whether this trial will change the conclusions of the meta‐analysis by <a href="./references#CD011646-bbs2-0157" title="RambaldiA , SaconatoHH , ChristensenE , ThorlundK , WetterslevJ , GluudC . Systematic review: glucocorticosteroids for alcoholic hepatitis‐‐a Cochrane Hepato‐Biliary Group systematic review with meta‐analyses and trial sequential analyses of randomized clinical trials. Alimentary Pharmacology &amp; Therapeutics2008;27(12):1167‐78. ">Rambaldi 2008</a> or not may become evident when an update of this review is published by Pavlov and colleagues later this year (<a href="./references#CD011646-bbs2-0154" title="PavlovCS , TsochatzisE , CasazzaG , NikolovaD , VolcekE , GluudC . Glucocorticosteroids for people with alcoholic hepatitis. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD001511.pub2] ">Pavlov 2016</a>). </p> <p>We also disagree with EASL (European Association for the Study of Liver) and AASLD (American Association for the Study of Liver Diseases), which recommend glucocorticosteroids in people with severe alcoholic hepatitis and pentoxifylline in people with contraindications to glucocorticosteroids (<a href="./references#CD011646-bbs2-0152" title="O'SheaRS , DasarathyS , McCulloughAJ , Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology2010;51(1):307‐28. ">O'Shea 2010</a>; <a href="./references#CD011646-bbs2-0126" title="European Association for Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. Journal of Hepatology2012;57(2):399‐420. ">EASL 2012</a>). This again may be due to the recent publication of a large trial (of more than 1000 participants) with at least 500 participants included for each pairwise comparison between glucocorticosteroids, pentoxifylline, a combination of the above, and placebo. In this trial, there was no evidence of any benefit of treatment, as opposed to previous small trials, some of which showed benefits and some of which did not show any evidence of benefit of these drugs (<a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). This may also be because of improvement in general medical care for these patients, which means that the treatment effect might have reduced. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011646-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011646-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials." data-id="CD011646-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011646-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis): glucocorticosteroids versus no intervention and pentoxifylline versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (78% and 56%), the accrued sample size (1147 participants for glucocorticosteroids versus no intervention and 881 participants for pentoxifylline versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (10,187 participants for glucocorticosteroids versus no intervention and 5232 participants for pentoxifylline versus no intervention). The Z‐curve (blue line) crosses the conventional boundaries (dotted green lines) favouring glucocorticosteroids and pentoxifylline for the two comparisons, but does not cross the conventional boundaries after the large trial (Thursz 2015). The Z‐curve does not cross any of trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons." data-id="CD011646-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis):</b> glucocorticosteroids versus no intervention and pentoxifylline versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (78% and 56%), the accrued sample size (1147 participants for glucocorticosteroids versus no intervention and 881 participants for pentoxifylline versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (10,187 participants for glucocorticosteroids versus no intervention and 5232 participants for pentoxifylline versus no intervention). The Z‐curve (blue line) crosses the conventional boundaries (dotted green lines) favouring glucocorticosteroids and pentoxifylline for the two comparisons, but does not cross the conventional boundaries after the large trial (<a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). The Z‐curve does not cross any of trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis): colchicine versus no intervention and insulin plus glucagon versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (0% and 52%), the accrued sample size (139 participants for colchicine versus no intervention and 265 participants for insulin plus glucagon versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (2205 participants for colchicine versus no intervention and 4579 participants for insulin plus glucagon versus no intervention). The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons." data-id="CD011646-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis):</b> colchicine versus no intervention and insulin plus glucagon versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (0% and 52%), the accrued sample size (139 participants for colchicine versus no intervention and 265 participants for insulin plus glucagon versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (2205 participants for colchicine versus no intervention and 4579 participants for insulin plus glucagon versus no intervention). The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis): propylthiouracil versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (0%), the accrued sample size (108 participants) was only a small proportion of the diversity‐adjusted required information size (DARIS) (2205 participants); therefore, the trial sequential monitoring boundaries were not drawn.The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines). This indicates that there is a high risk of random errors in this comparison." data-id="CD011646-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (alcoholic hepatitis):</b> propylthiouracil versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 34.8%), and diversity observed in the analyses (0%), the accrued sample size (108 participants) was only a small proportion of the diversity‐adjusted required information size (DARIS) (2205 participants); therefore, the trial sequential monitoring boundaries were not drawn.The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines). This indicates that there is a high risk of random errors in this comparison. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (severe alcoholic hepatitis): glucocorticosteroids versus no intervention and pentoxifylline versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 40.9%), and diversity observed in the analyses (98% and 76%), the accrued sample size (607 participants for glucocorticosteroids versus no intervention and 726 participants for pentoxifylline versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (72,755 participants for glucocorticosteroids versus no intervention and 7148 participants for pentoxifylline versus no intervention). For glucocorticosteroids versus no intervention, the accrued sample size was so small that the trial sequential monitoring boundaries were not drawn. The Z‐curve (blue line) crosses the conventional boundaries (dotted green lines) favouring glucocorticosteroids and pentoxifylline for the two comparisons, but does not cross the conventional boundaries after the large trial (Thursz 2015). The Z‐curve does not cross any of trial sequential monitoring boundaries (dotted red lines) for pentoxifylline versus no intervention. This indicates that there is a high risk of random errors in both these comparisons." data-id="CD011646-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (severe alcoholic hepatitis):</b> glucocorticosteroids versus no intervention and pentoxifylline versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 40.9%), and diversity observed in the analyses (98% and 76%), the accrued sample size (607 participants for glucocorticosteroids versus no intervention and 726 participants for pentoxifylline versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (72,755 participants for glucocorticosteroids versus no intervention and 7148 participants for pentoxifylline versus no intervention). For glucocorticosteroids versus no intervention, the accrued sample size was so small that the trial sequential monitoring boundaries were not drawn. The Z‐curve (blue line) crosses the conventional boundaries (dotted green lines) favouring glucocorticosteroids and pentoxifylline for the two comparisons, but does not cross the conventional boundaries after the large trial (<a href="./references#CD011646-bbs2-0076" title="ForrestE , MellorJ , StantonL , BowersM , RyderP , AustinA , et al. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials2013;14:262. ThurszM , ForrestE , RoderickP , DayC , AustinA , O'GradyJ , et al. The clinical effectiveness and cost‐effectiveness of steroids or pentoxifylline for alcoholic hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. Health Technology Assessment2015;19(102):1‐104. ThurszMR , RichardsonP , AllisonM , AustinA , BowersM , DayCP , et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New England Journal of Medicine2015;372:1619‐28. ">Thursz 2015</a>). The Z‐curve does not cross any of trial sequential monitoring boundaries (dotted red lines) for pentoxifylline versus no intervention. This indicates that there is a high risk of random errors in both these comparisons. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (alcohol‐related disorders (others)): anabolic steroids versus no intervention and antioxidants versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 25.2%), and diversity observed in the analyses (0% in the both the comparisons), the accrued sample size (248 participants for anabolic steroids versus no intervention and 255 participants for antioxidants versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (3428 participants for both comparisons). The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons." data-id="CD011646-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (alcohol‐related disorders (others)):</b> anabolic steroids versus no intervention and antioxidants versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 25.2%), and diversity observed in the analyses (0% in the both the comparisons), the accrued sample size (248 participants for anabolic steroids versus no intervention and 255 participants for antioxidants versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (3428 participants for both comparisons). The Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). This indicates that there is a high risk of random errors in both these comparisons. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of mortality at maximal follow‐up (alcohol‐related disorders (others)): colchicine versus no intervention and propylthiouracil versus no intervention.Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 25.2%), and diversity observed in the analyses (44% and 0%), the accrued sample size (604 participants for colchicine versus no intervention and 423 participants for propylthiouracil versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (6071 participants for colchicine versus no intervention and 3428 participants for propylthiouracil versus no intervention). For the comparison of colchicine versus no intervention, the Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). For the comparison, propylthiouracil versus no intervention, the Z‐curve crosses the conventional boundaries while it does not cross the trial sequential monitoring boundaries. This indicates that there is a high risk of random errors in both these comparisons." data-id="CD011646-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of mortality at maximal follow‐up (alcohol‐related disorders (others)):</b> colchicine versus no intervention and propylthiouracil versus no intervention. </p> <p>Based on an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%, a control group proportion observed in the trials (Pc = 25.2%), and diversity observed in the analyses (44% and 0%), the accrued sample size (604 participants for colchicine versus no intervention and 423 participants for propylthiouracil versus no intervention) was lower than the diversity‐adjusted required information size (DARIS) (6071 participants for colchicine versus no intervention and 3428 participants for propylthiouracil versus no intervention). For the comparison of colchicine versus no intervention, the Z‐curve (blue line) does not cross the conventional boundaries (dotted green lines) or the trial sequential monitoring boundaries (dotted red lines). For the comparison, propylthiouracil versus no intervention, the Z‐curve crosses the conventional boundaries while it does not cross the trial sequential monitoring boundaries. This indicates that there is a high risk of random errors in both these comparisons. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="The network plots showing the comparisons in there were at least two trials. The size of the node (circle) provides a measure of the number of trials in which the particular intervention was included as one of the arms. The thickness of the line provides a measure of the number of direct comparisons between two nodes (interventions). Five outcomes (mortality at maximal follow‐up, 30‐days mortality, 90‐days mortality, decompensated cirrhosis, and adverse events (number) have intervention comparisons in which direct and indirect estimates were available ('closed loops').  Legend: _ = plus; AntiTNF = anti‐TNF (tumour necrosis factor); Control = No active intervention; GSF = granulocyte stimulating factor; NAC = N‐acetyl cysteine; SAMe = S‐adenosyl methionine." data-id="CD011646-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>The network plots showing the comparisons in there were at least two trials. The size of the node (circle) provides a measure of the number of trials in which the particular intervention was included as one of the arms. The thickness of the line provides a measure of the number of direct comparisons between two nodes (interventions). Five outcomes (mortality at maximal follow‐up, 30‐days mortality, 90‐days mortality, decompensated cirrhosis, and adverse events (number) have intervention comparisons in which direct and indirect estimates were available ('closed loops').<br/> Legend: _ = plus; AntiTNF = anti‐TNF (tumour necrosis factor); Control = No active intervention; GSF = granulocyte stimulating factor; NAC = N‐acetyl cysteine; SAMe = S‐adenosyl methionine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="IF (Inconsistency Factor) plots of mortality at maximal follow‐up in which direct and indirect estimates were available. There appears to be inconsistency as the confidence intervals do not overlap 1 for the following loops: no intervention ‐ glucocorticosteroids ‐ pentoxifylline plus glucocorticosteroids (confidence intervals: 0.00 to 0.14) and glucocorticosteroids ‐ pentoxifylline plus glucocorticosteroids ‐ pentoxifylline (0.00 to 0.78)." data-id="CD011646-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>IF (Inconsistency Factor) plots of mortality at maximal follow‐up in which direct and indirect estimates were available. There appears to be inconsistency as the confidence intervals do not overlap 1 for the following loops: no intervention ‐ glucocorticosteroids ‐ pentoxifylline plus glucocorticosteroids (confidence intervals: 0.00 to 0.14) and glucocorticosteroids ‐ pentoxifylline plus glucocorticosteroids ‐ pentoxifylline (0.00 to 0.78). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of mortality at maximal follow‐up (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates are similar. Based on the network meta‐analysis, it appears that GSF plus pentoxifylline, glucocorticosteroids plus metadoxine, and pentoxifylline plus metadoxine decrease mortality at maximal follow‐up compared with no intervention.Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine." data-id="CD011646-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Forest plot of mortality at maximal follow‐up (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates are similar. Based on the network meta‐analysis, it appears that GSF plus pentoxifylline, glucocorticosteroids plus metadoxine, and pentoxifylline plus metadoxine decrease mortality at maximal follow‐up compared with no intervention. </p> <p>Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. None of the interventions seems to be clearly better than others, although GSF plus pentoxifylline appears to be one of the top‐ranking interventions.    Legend: 1: No active intervention; 2: Glucocorticosteroids; 3: Glucocorticosteroids plus anti‐TNF; 4: Glucocorticosteroids plus metadoxine; 5: Glucocorticosteroids plus N‐acetyl cysteine; 6: Glucocorticosteroids plus pentoxifylline; 7: Glucocorticosteroids plus SAMe; 8: GSF plus pentoxifylline; 9: N‐acetyl cysteine; 10: Pentoxifylline; 11: Pentoxifylline plus metadoxine.Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine." data-id="CD011646-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. None of the interventions seems to be clearly better than others, although GSF plus pentoxifylline appears to be one of the top‐ranking interventions.<br/> <br/> Legend: 1: No active intervention; 2: Glucocorticosteroids; 3: Glucocorticosteroids plus anti‐TNF; 4: Glucocorticosteroids plus metadoxine; 5: Glucocorticosteroids plus N‐acetyl cysteine; 6: Glucocorticosteroids plus pentoxifylline; 7: Glucocorticosteroids plus SAMe; 8: GSF plus pentoxifylline; 9: N‐acetyl cysteine; 10: Pentoxifylline; 11: Pentoxifylline plus metadoxine. </p> <p>Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt="IF (Inconsistency Factor) plots of 30‐days mortality in which direct and indirect estimates were available. There appears to be inconsistency for the loop 'no intervention ‐ glucocorticosteroids ‐ pentoxifylline plus glucocorticosteroids' as the confidence intervals do not overlap 1 (confidence intervals: 0.00 to 0.37)." data-id="CD011646-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>IF (Inconsistency Factor) plots of 30‐days mortality in which direct and indirect estimates were available. There appears to be inconsistency for the loop 'no intervention ‐ glucocorticosteroids ‐ pentoxifylline plus glucocorticosteroids' as the confidence intervals do not overlap 1 (confidence intervals: 0.00 to 0.37). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG15.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of 30‐days mortality (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates are similar. Based on the network meta‐analysis, it appears that glucocorticosteroids plus N‐acetyl cysteine and glucocorticosteroids plus metadoxine decrease 30‐days compared with no intervention.Abbreviations: TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine." data-id="CD011646-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Forest plot of 30‐days mortality (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates are similar. Based on the network meta‐analysis, it appears that glucocorticosteroids plus N‐acetyl cysteine and glucocorticosteroids plus metadoxine decrease 30‐days compared with no intervention. </p> <p>Abbreviations: TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG16.png" target="_blank"><b></b></a></p> </div><img alt="The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. None of the interventions seems to be clearly better than others, although glucocorticosteroids plus SAMe, glucocorticosteroids plus metadoxine, and glucocorticosteroids plus N‐acetyl cysteine appear to be the top‐ranking interventions.    Legend: 1: No active intervention; 2: Glucocorticosteroids; 3: Glucocorticosteroids plus anti‐TNF; 4: Glucocorticosteroids plus metadoxine; 5: Glucocorticosteroids plus N‐acetyl cysteine; 6: Glucocorticosteroids plus pentoxifylline; 7: Glucocorticosteroids plus SAMe; 8: N‐acetyl cysteine; 9: Pentoxifylline; 10: Pentoxifylline plus metadoxine.Abbreviations: TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine." data-id="CD011646-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. None of the interventions seems to be clearly better than others, although glucocorticosteroids plus SAMe, glucocorticosteroids plus metadoxine, and glucocorticosteroids plus N‐acetyl cysteine appear to be the top‐ranking interventions.<br/> <br/> Legend: 1: No active intervention; 2: Glucocorticosteroids; 3: Glucocorticosteroids plus anti‐TNF; 4: Glucocorticosteroids plus metadoxine; 5: Glucocorticosteroids plus N‐acetyl cysteine; 6: Glucocorticosteroids plus pentoxifylline; 7: Glucocorticosteroids plus SAMe; 8: N‐acetyl cysteine; 9: Pentoxifylline; 10: Pentoxifylline plus metadoxine. </p> <p>Abbreviations: TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG17.png" target="_blank"><b></b></a></p> </div><img alt="IF (Inconsistency Factor) plots of 90‐days mortality in which direct and indirect estimates were available. There appears to be no evidence of inconsistency in any of the loops as the confidence intervals of all the loops overlap 1." data-id="CD011646-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p>IF (Inconsistency Factor) plots of 90‐days mortality in which direct and indirect estimates were available. There appears to be no evidence of inconsistency in any of the loops as the confidence intervals of all the loops overlap 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG18.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of 90‐days mortality (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates appear different. Based on the random‐effects network meta‐analysis and direct comparison, there is no evidence of differences between any of the comparisons.Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor." data-id="CD011646-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 18</div> <div class="figure-caption"> <p>Forest plot of 90‐days mortality (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates appear different. Based on the random‐effects network meta‐analysis and direct comparison, there is no evidence of differences between any of the comparisons. </p> <p>Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG19.png" target="_blank"><b></b></a></p> </div><img alt="The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. GSF plus pentoxifylline appears to be the top‐ranking intervention.Legend: 1: No active intervention; 2: Glucocorticosteroids; 3: Glucocorticosteroids plus anti‐TNF; 4: Glucocorticosteroids plus metadoxine; 5: Glucocorticosteroids plus N‐acetyl cysteine; 6: Glucocorticosteroids plus pentoxifylline; 7: GSF plus pentoxifylline; 8: Pentoxifylline; 9: Pentoxifylline plus metadoxine.Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor." data-id="CD011646-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 19</div> <div class="figure-caption"> <p>The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. GSF plus pentoxifylline appears to be the top‐ranking intervention. </p> <p>Legend: 1: No active intervention; 2: Glucocorticosteroids; 3: Glucocorticosteroids plus anti‐TNF; 4: Glucocorticosteroids plus metadoxine; 5: Glucocorticosteroids plus N‐acetyl cysteine; 6: Glucocorticosteroids plus pentoxifylline; 7: GSF plus pentoxifylline; 8: Pentoxifylline; 9: Pentoxifylline plus metadoxine. </p> <p>Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG20.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of liver transplantation (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to glucocorticosteroids are provided. Since there was only one trial for each comparison, random‐effects model is not applicable for direct comparisons. The direct estimates and network meta‐analysis estimates appear similar. There is no evidence of differences between any of the comparisons.Abbreviations: TNF = tumour necrosis factor." data-id="CD011646-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 20</div> <div class="figure-caption"> <p>Forest plot of liver transplantation (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to glucocorticosteroids are provided. Since there was only one trial for each comparison, random‐effects model is not applicable for direct comparisons. The direct estimates and network meta‐analysis estimates appear similar. There is no evidence of differences between any of the comparisons. </p> <p>Abbreviations: TNF = tumour necrosis factor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG21.png" target="_blank"><b></b></a></p> </div><img alt="The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. Glucocorticosteroids plus pentoxifylline appears to be the top‐ranking intervention.Legend: 1: Glucocorticosteroids; 2: Glucocorticosteroids plus N‐acetyl cysteine; 3: Glucocorticosteroids plus pentoxifylline" data-id="CD011646-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 21</div> <div class="figure-caption"> <p>The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. Glucocorticosteroids plus pentoxifylline appears to be the top‐ranking intervention. </p> <p>Legend: 1: Glucocorticosteroids; 2: Glucocorticosteroids plus N‐acetyl cysteine; 3: Glucocorticosteroids plus pentoxifylline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG22.png" target="_blank"><b></b></a></p> </div><img alt="IF (Inconsistency Factor) plots of decompensated cirrhosis in which direct and indirect estimates were available. There appears to be inconsistency in several loops as the confidence intervals do not overlap 1. The loops in which the confidence intervals do not overlap 1 are: no intervention ‐ glucocorticosteroids ‐ pentoxifylline plus glucocorticosteroids (confidence intervals: 0.32 to 0.88), glucocorticosteroids ‐ pentoxifylline ‐ metadoxine plus pentoxifylline (0.00 to 0.16), and glucocorticosteroids ‐ metadoxine plus glucocorticosteroids ‐ pentoxifylline (0.00 to 0.17)." data-id="CD011646-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 22</div> <div class="figure-caption"> <p>IF (Inconsistency Factor) plots of decompensated cirrhosis in which direct and indirect estimates were available. There appears to be inconsistency in several loops as the confidence intervals do not overlap 1. The loops in which the confidence intervals do not overlap 1 are: no intervention ‐ glucocorticosteroids ‐ pentoxifylline plus glucocorticosteroids (confidence intervals: 0.32 to 0.88), glucocorticosteroids ‐ pentoxifylline ‐ metadoxine plus pentoxifylline (0.00 to 0.16), and glucocorticosteroids ‐ metadoxine plus glucocorticosteroids ‐ pentoxifylline (0.00 to 0.17). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG23.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of decompensated cirrhosis (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates appear similar. Glucocorticosteroids plus metadoxine appears to have a lower decompensated cirrhosis rate than no intervention. There was no evidence of any differences in any other interventions versus no intervention in the random‐effects model.Abbreviations: TNF = tumour necrosis factor." data-id="CD011646-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 23</div> <div class="figure-caption"> <p>Forest plot of decompensated cirrhosis (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates appear similar. Glucocorticosteroids plus metadoxine appears to have a lower decompensated cirrhosis rate than no intervention. There was no evidence of any differences in any other interventions versus no intervention in the random‐effects model. </p> <p>Abbreviations: TNF = tumour necrosis factor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG24.png" target="_blank"><b></b></a></p> </div><img alt="The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. Glucocorticosteroids plus metadoxine appears to be the top‐ranking intervention.Legend: 1: No active intervention; 2: Glucocorticosteroids; 3: Glucocorticosteroids plus anti‐TNF; 4: Glucocorticosteroids plus metadoxine; 5: Glucocorticosteroids plus N‐acetyl cysteine; 6: Glucocorticosteroids plus pentoxifylline; 7: Pentoxifylline; 8: Pentoxifylline plus metadoxine.Abbreviations: TNF = tumour necrosis factor." data-id="CD011646-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 24</div> <div class="figure-caption"> <p>The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. Glucocorticosteroids plus metadoxine appears to be the top‐ranking intervention. </p> <p>Legend: 1: No active intervention; 2: Glucocorticosteroids; 3: Glucocorticosteroids plus anti‐TNF; 4: Glucocorticosteroids plus metadoxine; 5: Glucocorticosteroids plus N‐acetyl cysteine; 6: Glucocorticosteroids plus pentoxifylline; 7: Pentoxifylline; 8: Pentoxifylline plus metadoxine. </p> <p>Abbreviations: TNF = tumour necrosis factor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG25.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of adverse events (proportion) (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates appear similar. There was no evidence of any differences in any other interventions versus no intervention using the random‐effects model.Abbreviations: GSF = granulocyte stimulating factor." data-id="CD011646-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 25</div> <div class="figure-caption"> <p>Forest plot of adverse events (proportion) (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates appear similar. There was no evidence of any differences in any other interventions versus no intervention using the random‐effects model. </p> <p>Abbreviations: GSF = granulocyte stimulating factor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG26.png" target="_blank"><b></b></a></p> </div><img alt="The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. No active intervention appears to be the top‐ranking intervention, while GSF plus pentoxifylline appears to be the worst‐ranking intervention.Legend: 1: No active intervention; 2: GSF plus pentoxifylline; 3: N‐acetyl cysteine 4: Pentoxifylline.Abbreviations: GSF = granulocyte stimulating factor." data-id="CD011646-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 26</div> <div class="figure-caption"> <p>The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. No active intervention appears to be the top‐ranking intervention, while GSF plus pentoxifylline appears to be the worst‐ranking intervention. </p> <p>Legend: 1: No active intervention; 2: GSF plus pentoxifylline; 3: N‐acetyl cysteine 4: Pentoxifylline. </p> <p>Abbreviations: GSF = granulocyte stimulating factor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG27.png" target="_blank"><b></b></a></p> </div><img alt="IF (Inconsistency Factor) plots of adverse events (number) in which direct and indirect estimates were available. There appears to be inconsistency in several loops as the confidence intervals do not overlap 1. The loops in which the confidence intervals did not overlap 1 are: no intervention ‐ pentoxifylline ‐ pentoxifylline plus glucocorticosteroids (confidence intervals: 0.44 to 0.74), no intervention ‐ glucocorticosteroids ‐ pentoxifylline plus glucocorticosteroids (confidence intervals: 0.38 to 0.64), no intervention ‐ glucocorticosteroids ‐ pentoxifylline (0.00 to 0.68), glucocorticosteroids ‐ pentoxifylline‐ metadoxine plus pentoxifylline (0.00 to 0.39), and glucocorticosteroids ‐ metadoxine plus glucocorticosteroids ‐ pentoxifylline (0.00 to 0.39)." data-id="CD011646-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 27</div> <div class="figure-caption"> <p>IF (Inconsistency Factor) plots of adverse events (number) in which direct and indirect estimates were available. There appears to be inconsistency in several loops as the confidence intervals do not overlap 1. The loops in which the confidence intervals did not overlap 1 are: no intervention ‐ pentoxifylline ‐ pentoxifylline plus glucocorticosteroids (confidence intervals: 0.44 to 0.74), no intervention ‐ glucocorticosteroids ‐ pentoxifylline plus glucocorticosteroids (confidence intervals: 0.38 to 0.64), no intervention ‐ glucocorticosteroids ‐ pentoxifylline (0.00 to 0.68), glucocorticosteroids ‐ pentoxifylline‐ metadoxine plus pentoxifylline (0.00 to 0.39), and glucocorticosteroids ‐ metadoxine plus glucocorticosteroids ‐ pentoxifylline (0.00 to 0.39). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG28.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of adverse events (number) (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates are similar. Based on the network meta‐analysis, it appears that glucocorticosteroids, pentoxifylline, and pentoxifylline plus glucocorticosteroids have more adverse events compared with no intervention.Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine." data-id="CD011646-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 28</div> <div class="figure-caption"> <p>Forest plot of adverse events (number) (network meta‐analysis estimates and direct comparisons when available): Both fixed‐effect model and random‐effects model for other interventions compared to no intervention are provided. The direct estimates and network meta‐analysis estimates are similar. Based on the network meta‐analysis, it appears that glucocorticosteroids, pentoxifylline, and pentoxifylline plus glucocorticosteroids have more adverse events compared with no intervention. </p> <p>Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-AFig-FIG29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-AFig-FIG29.png" target="_blank"><b></b></a></p> </div><img alt="The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. None of the interventions seems to be clearly better than others, although GSF plus pentoxifylline appears to be the worst‐ranking intervention.    Legend: 1: No active intervention; 2: Glucocorticosteroids; 3: Glucocorticosteroids plus anti‐TNF; 4: Glucocorticosteroids plus metadoxine; 5: Glucocorticosteroids plus N‐acetyl cysteine; 6: Glucocorticosteroids plus pentoxifylline; 7: Glucocorticosteroids plus SAMe; 8: GSF plus pentoxifylline; 9: N‐acetyl cysteine; 10: Pentoxifylline; 11: Pentoxifylline plus metadoxine.Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine." data-id="CD011646-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 29</div> <div class="figure-caption"> <p>The top figure shows the surface area under the curve constructed on the basis of the ranking probabilities. The bottom figure shows the probability of each intervention being best, second best, third best, and so on. None of the interventions seems to be clearly better than others, although GSF plus pentoxifylline appears to be the worst‐ranking intervention.<br/> <br/> Legend: 1: No active intervention; 2: Glucocorticosteroids; 3: Glucocorticosteroids plus anti‐TNF; 4: Glucocorticosteroids plus metadoxine; 5: Glucocorticosteroids plus N‐acetyl cysteine; 6: Glucocorticosteroids plus pentoxifylline; 7: Glucocorticosteroids plus SAMe; 8: GSF plus pentoxifylline; 9: N‐acetyl cysteine; 10: Pentoxifylline; 11: Pentoxifylline plus metadoxine. </p> <p>Abbreviations: GSF = granulocyte stimulating factor; TNF = tumour necrosis factor; SAMe = S‐adenosyl methionine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/appendices#CD011646-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-AFig-FIG29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alcoholic hepatitis (all), Outcome 1 Mortality at maximal follow‐up." data-id="CD011646-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Alcoholic hepatitis (all), Outcome 1 Mortality at maximal follow‐up.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alcoholic hepatitis (all), Outcome 2 Mortality (30‐days)." data-id="CD011646-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Alcoholic hepatitis (all), Outcome 2 Mortality (30‐days).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alcoholic hepatitis (all), Outcome 3 Mortality (90‐days)." data-id="CD011646-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Alcoholic hepatitis (all), Outcome 3 Mortality (90‐days).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alcoholic hepatitis (all), Outcome 4 Serious adverse events (proportion)." data-id="CD011646-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Alcoholic hepatitis (all), Outcome 4 Serious adverse events (proportion).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alcoholic hepatitis (all), Outcome 5 Serious adverse events (number)." data-id="CD011646-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Alcoholic hepatitis (all), Outcome 5 Serious adverse events (number).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alcoholic hepatitis (all), Outcome 6 Liver transplantation." data-id="CD011646-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Alcoholic hepatitis (all), Outcome 6 Liver transplantation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alcoholic hepatitis (all), Outcome 7 Decompensated cirrhosis." data-id="CD011646-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Alcoholic hepatitis (all), Outcome 7 Decompensated cirrhosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alcoholic hepatitis (all), Outcome 8 Cirrhosis." data-id="CD011646-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Alcoholic hepatitis (all), Outcome 8 Cirrhosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alcoholic hepatitis (all), Outcome 9 Adverse events (proportion)." data-id="CD011646-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Alcoholic hepatitis (all), Outcome 9 Adverse events (proportion).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Alcoholic hepatitis (all), Outcome 10 Adverse events (number)." data-id="CD011646-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Alcoholic hepatitis (all), Outcome 10 Adverse events (number).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Severe alcoholic hepatitis, Outcome 1 Mortality at maximal follow‐up." data-id="CD011646-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Severe alcoholic hepatitis, Outcome 1 Mortality at maximal follow‐up.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Severe alcoholic hepatitis, Outcome 2 Mortality (30 days)." data-id="CD011646-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Severe alcoholic hepatitis, Outcome 2 Mortality (30 days).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Severe alcoholic hepatitis, Outcome 3 Mortality (90 days)." data-id="CD011646-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Severe alcoholic hepatitis, Outcome 3 Mortality (90 days).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Severe alcoholic hepatitis, Outcome 4 Serious adverse events (proportion)." data-id="CD011646-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Severe alcoholic hepatitis, Outcome 4 Serious adverse events (proportion).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Severe alcoholic hepatitis, Outcome 5 Serious adverse events (number)." data-id="CD011646-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Severe alcoholic hepatitis, Outcome 5 Serious adverse events (number).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Severe alcoholic hepatitis, Outcome 6 Liver transplantation." data-id="CD011646-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Severe alcoholic hepatitis, Outcome 6 Liver transplantation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Severe alcoholic hepatitis, Outcome 7 Decompensated cirrhosis." data-id="CD011646-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Severe alcoholic hepatitis, Outcome 7 Decompensated cirrhosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Severe alcoholic hepatitis, Outcome 8 Adverse events (proportion)." data-id="CD011646-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Severe alcoholic hepatitis, Outcome 8 Adverse events (proportion).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Severe alcoholic hepatitis, Outcome 9 Adverse events (number)." data-id="CD011646-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Severe alcoholic hepatitis, Outcome 9 Adverse events (number).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alcohol‐related liver disease (others), Outcome 1 Mortality at maximal follow‐up." data-id="CD011646-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Alcohol‐related liver disease (others), Outcome 1 Mortality at maximal follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alcohol‐related liver disease (others), Outcome 2 Mortality (30 days)." data-id="CD011646-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Alcohol‐related liver disease (others), Outcome 2 Mortality (30 days).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alcohol‐related liver disease (others), Outcome 3 Mortality (90 days)." data-id="CD011646-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Alcohol‐related liver disease (others), Outcome 3 Mortality (90 days).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alcohol‐related liver disease (others), Outcome 4 Serious adverse events (proportion)." data-id="CD011646-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Alcohol‐related liver disease (others), Outcome 4 Serious adverse events (proportion). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alcohol‐related liver disease (others), Outcome 5 Liver transplantation." data-id="CD011646-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Alcohol‐related liver disease (others), Outcome 5 Liver transplantation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alcohol‐related liver disease (others), Outcome 6 Decompensated cirrhosis." data-id="CD011646-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Alcohol‐related liver disease (others), Outcome 6 Decompensated cirrhosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alcohol‐related liver disease (others), Outcome 7 Hepatocellular carcinoma." data-id="CD011646-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Alcohol‐related liver disease (others), Outcome 7 Hepatocellular carcinoma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alcohol‐related liver disease (others), Outcome 8 Adverse events (proportion)." data-id="CD011646-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Alcohol‐related liver disease (others), Outcome 8 Adverse events (proportion).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011646-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/urn:x-wiley:14651858:media:CD011646:CD011646-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_t/tCD011646-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alcohol‐related liver disease (others), Outcome 9 Adverse events (number)." data-id="CD011646-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Alcohol‐related liver disease (others), Outcome 9 Adverse events (number).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/media/CDSR/CD011646/image_n/nCD011646-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Glucocorticosteroids compared with no intervention for alcoholic hepatitis (all severity)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Glucocorticosteroids compared with no intervention for alcoholic hepatitis (all severity)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with alcoholic hepatitis (all severity) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> glucocorticosteroids </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Glucocorticosteroids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>353 per 1000</b> <br/> (301 to 409) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.85</b> <br/> (0.67 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1147</b> <br/> (12 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>391 per 1000</b> <br/> (313 to 472) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.00</b> <br/> (0.71 to 1.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>672</b> <br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>390 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>467 per 1000</b> <br/> (385 to 552) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.37</b> <br/> (0.98 to 1.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>546</b> </p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded by one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded by one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded by one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Glucocorticosteroids compared with no intervention for alcoholic hepatitis (all severity)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Pentoxifylline compared with no intervention for alcoholic hepatitis (all severity)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pentoxifylline compared with no intervention for alcoholic hepatitis (all severity)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with alcoholic hepatitis (all severity) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> pentoxifylline </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pentoxifylline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>331 per 1000</b> <br/> (271 to 396) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.77</b> <br/> (0.58 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>881</b> <br/> (6 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>431 per 1000</b> <br/> (342 to 528) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.18</b> <br/> (0.81 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>545</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>390 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>406 per 1000</b><br/> (327 to 491) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.07</b><br/> (0.76 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>545</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Pentoxifylline compared with no intervention for alcoholic hepatitis (all severity)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Colchicine compared with no intervention for alcoholic hepatitis (all severity)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Colchicine compared with no intervention for alcoholic hepatitis (all severity)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with alcoholic hepatitis (all severity) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> colchicine </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Colchicine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 3 to 4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>86 per 1000</b> <br/> (32 to 206) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.31</b> <br/> (0.47 to 3.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>139</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>185 per 1000</b><br/> (9 to 853) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 3.18</b><br/> (0.13 to 81.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Colchicine compared with no intervention for alcoholic hepatitis (all severity)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Insulin plus glucagon compared with no intervention for alcoholic hepatitis (all severity)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Insulin plus glucagon compared with no intervention for alcoholic hepatitis (all severity)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with alcoholic hepatitis (all severity) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> insulin plus glucagon </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Insulin plus glucagon</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>423 per 1000</b> <br/> (307 to 550) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.14</b> <br/> (0.69 to 1.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>265</b> <br/> (5 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>623 per 1000</b> <br/> (371 to 821) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 2.57</b> <br/> (0.92 to 7.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Insulin plus glucagon compared with no intervention for alcoholic hepatitis (all severity)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Propylthiouracil compared with no intervention for alcoholic hepatitis (all severity)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Propylthiouracil compared with no intervention for alcoholic hepatitis (all severity)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with alcoholic hepatitis (all severity) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> propylthiouracil </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Propylthiouracil</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>427 per 1000</b> <br/> (243 to 636) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.16</b> <br/> (0.50 to 2.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>108</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Propylthiouracil compared with no intervention for alcoholic hepatitis (all severity)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Glucocorticosteroids compared with no intervention for severe alcoholic hepatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Glucocorticosteroids compared with no intervention for severe alcoholic hepatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with severe alcoholic hepatitis </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> glucocorticosteroids </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Glucocorticosteroids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 2 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>409 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>378 per 1000</b><br/> (304 to 456) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.88</b> <br/> (0.63 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>607</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>272 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>274 per 1000</b> <br/> (210 to 348) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.01</b> <br/> (0.71 to 1.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>607</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>390 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>467 per 1000</b> <br/> (385 to 552) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.37</b> <br/> (0.98 to 1.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>546</b> </p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Glucocorticosteroids compared with no intervention for severe alcoholic hepatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Pentoxifylline compared with no intervention for severe alcoholic hepatitis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pentoxifylline compared with no intervention for severe alcoholic hepatitis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with severe alcoholic hepatitis </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> pentoxifylline </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pentoxifylline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>409 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>356 per 1000</b> <br/> (290 to 425) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.80</b> <br/> (0.59 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>726</b> <br/> (4 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>272 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>306 per 1000</b> <br/> (232 to 394) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.18</b> <br/> (0.81 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>545</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>390 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>406 per 1000</b> <br/> (327 to 491) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.07</b> <br/> (0.76 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>545</b> <br/> (1 trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Pentoxifylline compared with no intervention for severe alcoholic hepatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Anabolic steroids compared with no intervention for alcohol‐related disorders (others)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Anabolic steroids compared with no intervention for alcohol‐related disorders (others)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol‐related disorders (others) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> anabolic steroids </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anabolic steroids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 6 to 28 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>252 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>303 per 1000</b> <br/> (191 to 446) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.29</b> <br/> (0.70 to 2.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>248</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Anabolic steroids compared with no intervention for alcohol‐related disorders (others)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Antioxidants compared with no intervention for alcohol‐related disorders (others)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Antioxidants compared with no intervention for alcohol‐related disorders (others)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol‐related disorders (others) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> antioxidants </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Antioxidants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>252 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>398 per 1000</b> <br/> (250 to 567) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.96</b> <br/> (0.99 to 3.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>255</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3,4</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Antioxidants compared with no intervention for alcohol‐related disorders (others)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Colchicine compared with no intervention for alcohol‐related disorders (others)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Colchicine compared with no intervention for alcohol‐related disorders (others)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol‐related disorders (others) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> colchicine </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Colchicine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 41 to 48 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>252 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>272 per 1000</b><br/> (212 to 340) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.11</b><br/> (0.80 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>604</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Colchicine compared with no intervention for alcohol‐related disorders (others)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011646-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Propylthiouracil compared with no intervention for alcohol‐related disorders (others)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Propylthiouracil compared with no intervention for alcohol‐related disorders (others)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> alcohol‐related disorders (others) </p> <p><b>Settings:</b> secondary or tertiary care </p> <p><b>Intervention:</b> propylthiouracil </p> <p><b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No intervention</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Propylthiouracil</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality at maximal follow‐up</b> </p> <p>Follow‐up: 1 to 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>252 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>132 per 1000</b><br/> (81 to 208) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.45</b><br/> (0.26 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>423</b> <br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Early mortality (mortality up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (proportion)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events (number)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>None of the trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: trial(s) were at high risk of bias (downgraded one level) </p> <p><sup>2</sup>Imprecision: small sample size (downgraded one level) </p> <p><sup>3</sup>Imprecision: Confidence intervals overlapped a clinically significant increase or reduction and clinically insignificant increase or reduction (downgraded one level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Propylthiouracil compared with no intervention for alcohol‐related disorders (others)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/full#CD011646-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011646-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alcoholic hepatitis (all)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at maximal follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Amlodipine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.22, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Anabolic steroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.43, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Antioxidants versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.19, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Anti‐TNF versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.64 [1.31, 16.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Colchicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.47, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.67, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.64, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Insulin plus glucagon versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.69, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 N‐acetyl cysteine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.34, 4.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 N‐acetyl cysteine plus antioxidants versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.44, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 Penicillamine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.15, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.58, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13 Propylthiouracil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.50, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14 Silymarin versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15 Anabolic steroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.36, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16 Antioxidants versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.63, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.67, 8.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.04, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.32, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.67, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21 SAMe plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.06, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22 GSF versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.05, 20.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24 Metadoxine plus pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.06, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25 Metadoxine plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.08, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26 Metadoxine plus pentoxifylline versus metadoxine plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.55, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.63, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28 Rifaximin plus UDCA plus glucocorticosteroids versus UDCA plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.20, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29 GSF plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30 Metadoxine plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.12, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality (30‐days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Amlodipine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.22, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Anti‐TNF versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.8 [0.50, 6.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Colchicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.36, 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.34, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.46, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Insulin plus glucagon versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.46, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 N‐acetyl cysteine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.46, 9.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.33, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Propylthiouracil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.50, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Antioxidants versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.93, 4.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.74 [0.73, 30.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.11, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.62, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15 SAMe plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16 GSF versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.05, 20.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.57, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18 Metadoxine plus pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.16, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19 Metadoxine plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.12, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20 Metadoxine plus pentoxifylline versus metadoxine plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.53, 4.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.25, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22 Rifaximin plus UDCA plus glucocorticosteroids versus UDCA plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.05, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23 Metadoxine plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.18, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality (90‐days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Antioxidants versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.14, 8.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Colchicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [0.13, 81.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.71, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.64, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Insulin plus glucagon versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.92, 7.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.81, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Silymarin versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.13, 23.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.04, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.29, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.56, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 Metadoxine plus pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.08, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 Metadoxine plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.55, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15 Metadoxine plus pentoxifylline versus metadoxine plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.12, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.53, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17 GSF plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18 Metadoxine plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.06, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events (proportion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Anti‐TNF versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events (number) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Anti‐TNF versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Liver transplantation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Insulin plus glucagon versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Decompensated cirrhosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Anti‐TNF versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.45, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Colchicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.56, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.70, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.63, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.55, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Propylthiouracil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.47, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.24, 8.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.36, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.46, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.57, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.73, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.12 Metadoxine plus pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.49, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.13 Metadoxine plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.37, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.14 Metadoxine plus pentoxifylline versus metadoxine plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.81, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.15 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.59, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.16 Metadoxine plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.50, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Cirrhosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.19, 9.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events (proportion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Amlodipine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.12, 7.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Anti‐TNF versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.25 [0.99, 10.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Colchicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [1.80, 8.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Insulin plus glucagon versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.75, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 N‐acetyl cysteine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.51, 6.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 N‐acetyl cysteine plus antioxidants versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.10, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 Propylthiouracil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.36, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.10 Silymarin versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.11 Antioxidants versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.29 [2.14, 18.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.12 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.44 [1.33, 14.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.13 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.85, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.14 Rifaximin plus UDCA plus glucocorticosteroids versus UDCA plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.04, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.15 GSF plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.97 [0.73, 269.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events (number) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Amlodipine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.13, 6.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Anti‐TNF versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [1.05, 4.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Colchicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.86, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.10, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.85, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 Insulin plus glucagon versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.81, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 N‐acetyl cysteine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.52, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8 N‐acetyl cysteine plus antioxidants versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.9 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.92, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.10 Propylthiouracil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.62, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.11 Antioxidants versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.79, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.12 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.77, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.13 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.44, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.14 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.15 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.78, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.16 SAMe plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.35, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.17 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.75, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.18 Metadoxine plus pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.54, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.19 Metadoxine plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.47, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.20 Metadoxine plus pentoxifylline versus metadoxine plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.83, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.21 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.78, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.22 Rifaximin plus UDCA plus glucocorticosteroids versus UDCA plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.06, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.23 GSF plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.00 [0.61, 198.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.24 Metadoxine plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.57, 1.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alcoholic hepatitis (all)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011646-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Severe alcoholic hepatitis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at maximal follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.63, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.64, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 N‐acetyl cysteine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.34, 4.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.59, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.67, 8.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.04, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.32, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.67, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 SAMe plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.06, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 Metadoxine plus pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.06, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12 Metadoxine plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.11, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13 Metadoxine plus pentoxifylline versus metadoxine plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.55, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.63, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15 GSF plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16 Metadoxine plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.12, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality (30 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.45, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.46, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 N‐acetyl cysteine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [0.46, 9.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.64, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.81 [0.75, 30.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.11, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.62, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 SAMe plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.82, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Metadoxine plus pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.16, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Metadoxine plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.12, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13 Metadoxine plus pentoxifylline versus metadoxine plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.53, 4.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.45, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15 Metadoxine plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.18, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality (90 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.71, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.64, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.81, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.13, 23.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.04, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.29, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.56, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Metadoxine plus pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.06, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Metadoxine plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.08, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 Metadoxine plus pentoxifylline versus metadoxine plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.55, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.53, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 GSF plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 Metadoxine plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.12, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events (proportion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events (number) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Liver transplantation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Decompensated cirrhosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.64, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.63, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.55, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.24, 8.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.36, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.46, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.57, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.73, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9 Metadoxine plus pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.49, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10 Metadoxine plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.37, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11 Metadoxine plus pentoxifylline versus metadoxine plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.81, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.12 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.59, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.13 Metadoxine plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.50, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events (proportion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 N‐acetyl cysteine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.51, 6.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.10, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.44 [1.33, 14.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.85, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 GSF plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.97 [0.73, 269.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events (number) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.98, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Pentoxifylline plus glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.85, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 N‐acetyl cysteine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.52, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.01, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Anti‐TNF plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.77, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 Metadoxine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.44, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 N‐acetyl cysteine plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Pentoxifylline plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.86, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 SAMe plus glucocorticosteroids versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.35, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.10 Pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.75, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.11 Metadoxine plus pentoxifylline versus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.54, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.12 Metadoxine plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.47, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.13 Metadoxine plus pentoxifylline versus metadoxine plus glucocorticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.83, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.14 Pentoxifylline plus glucocorticosteroids versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.78, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.15 GSF plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.00 [0.61, 198.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.16 Metadoxine plus pentoxifylline versus pentoxifylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.57, 1.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Severe alcoholic hepatitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011646-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Alcohol‐related liver disease (others)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality at maximal follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Anabolic steroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.70, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Antioxidants versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.99, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Colchicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.80, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Cycloxilic acid versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Epomediol versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.15, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Malotilate versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.52, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Metadoxine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 Propylthiouracil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.26, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 SAMe versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.21, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 Silymarin versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.46, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12 Ursodeoxycholic acid versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.12, 3.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality (30 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Cycloxilic acid versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Epomediol versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Metadoxine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Propylthiouracil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Ursodeoxycholic acid versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality (90 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Epomediol versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Glucocorticosteroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 SAMe versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serious adverse events (proportion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 SAMe versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Liver transplantation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 SAMe versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Decompensated cirrhosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Colchicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Malotilate versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Ursodeoxycholic acid versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hepatocellular carcinoma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Anabolic steroids versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 SAMe versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events (proportion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Antioxidants versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Colchicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.66, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Malotilate versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.45, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Metadoxine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.96 [0.12, 73.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.86 [0.75, 82.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Propylthiouracil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.73, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 SAMe versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [0.65, 5.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 Silymarin versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.48, 5.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 Ursodeoxycholic acid versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 7.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 Candesartan plus ursodeoxycholic acid versus ursodeoxycholic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events (number) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Colchicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.75, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Malotilate versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.48, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Metadoxine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [0.12, 71.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Pentoxifylline versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.86, 56.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Propylthiouracil versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.58, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 SAMe versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.69, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 Silymarin versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.48, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Ursodeoxycholic acid versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 7.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Alcohol‐related liver disease (others)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011646.pub2/references#CD011646-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011646.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011646-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011646-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD011646-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011646-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011646\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011646\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011646\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011646\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011646\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011646.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011646.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011646.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011646.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011646.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729407008"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011646.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729407012"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011646.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edc1b0c20f4a4',t:'MTc0MDcyOTQwNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 